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It has recently been suggested that b-dystroglycan localises to the nucleus in a range 
of cell types. At the nucleus it is thought that b-dystroglycan plays a role in 
maintaining nuclear morphology and regulating structural nuclear proteins lamin B1 
and emerin in mouse C2C12 myoblasts. It is hypothesised that b-dystroglycan is 
involved in regulating the mechanical properties of nuclei through interactions with 
lamin B1 and emerin or by adding additional support to the Linker of Nucleoskeleton 
and Cytoskeleton complex. This hypothesis was investigated using CRISPR/Cas9 
disruption of the dystroglycan gene (DAG1) in human myoblast cells. In this DAG1 
disrupted cell line, the previous reports of abnormal nuclear shape were not 
observed, however, it was found that both nuclear and cell size was greater in DAG1 
disrupted cells. This increase in size was also rescued by the addition of exogenous 
dystroglycan. The increase in size was not due to a senescence phenotype as 
previously suggested, however, the reason for an increase in size has yet to be fully 
understood.  
 
As with nuclear shape, the previously reported abnormal levels and localisation of 
lamin B1 and emerin in DAG1 disrupted C2C12 cells were not observed in the human 
myoblasts. Further, following analysis of nuclear mechanical properties of DAG1 
disrupted and control cells using atomic force microscopy it was found that there was 
no difference in nuclear mechanics at a whole cell level. However, when nuclei were 
isolated from the whole cell environment, the DAG1 disrupted nuclei were less stiff 
than control nuclei. 
 
The results described here suggest that disruption of the DAG1 gene has little effect 
on nuclear shape, regulation of nuclear proteins or nuclear mechanics. This suggests 
previously published results from C2C12 mouse myoblasts are not universal across 
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1.1.1 DAG1 Gene and Biosynthesis 
 
The human DAG1 gene is 2685 base-pairs (excluding introns) and is located on 
chromosome 3 at band p21. The gene consists of three exons and two introns, the 
smaller intron is located 5’ of the ATG region while the larger intron is 3’ of the ATG 
region (Figure 1.1) (Gee et al., 1993; Ibraghimov-Beskrovnaya et al., 1993; Smalheiser 
and Schwartz, 1987). The gene organisation is highly conserved across the metazoan 
phyla with the large intron 3’ of the ATG region conserved across the whole phyla. 
The small intron 5’ of the ATG region is conserved except in cnidaria, placozoa or 
porifera (Brancaccio and Adams, 2017).  
 
The DAG1 gene is transcribed into a single mRNA which encodes the dystroglycan 
(DG) precursor protein. DAG1 is ubiquitously expressed in human adult and foetal 
tissue (Ibraghimov-Beskrovnaya et al., 1993). In addition to the ubiquitous 
expression in human tissue, DAG1 is highly conserved in vertebrates and somewhat 
conserved in invertebrates (Table 1.1). Despite a lack of sequence similarity the 
general domain structure of the protein is conserved across the metazoan phyla 
(Adams and Brancaccio, 2015). As the majority of studies involving DG use either 
human or mouse cell lines or mouse models, further reference to DG will discuss 
mammalian DG unless otherwise stated and the human numbering system will be 
used.  
 
Table 1.1 List of species DG has been identified in and the protein and DNA similarity to human DG. 







H. sapiens 1605 DAG1 100 100 
P. troglodytes 460372 DAG1 99.4 99.6 
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M. mulatta 706179 DAG1 97.7 98.0 
C. lupus 476623 DAG1 95.2 88.8 
M. musculus 13138 Dag1 93.5 87.0 
B. taurus 281439 DAG1 93.2 87.8 
R. norvegicus 114489 Dag1 92.9 86.0 
G. gallus 100049058 DAG1 77.2 73.0 
X. tropicalis 549272 dag1 69.9 66.9 
X. laevis Xenbase Gene ID: 
XB-GENE-
1015774 
dag1 67.3  
D. rerio 286829 dag1 64.8 63.3 
Invertebrates 
D. melanogaster  UniPort: Q8STB9 Dg 32.8  
C. elegans UniPort: Q22629 dgn-1 23.72  
 
The translation of the DAG1 mRNA produces a 97kDa precursor protein which 
consists of a signal peptide (aa 1-29), a-DG subunit (aa 30-653) and a b-subunit (aa 
654-895) (Figure 1.1b). The cleavage of the precursor protein into the a- and b-
subunits occurs between Gly653 and Ser654 and occurs upon translocation to the 
endoplasmic reticulum (ER) (Akhavan et al., 2008; Deyst et al., 1995; Esapa et al., 
2003; Holt et al., 2000). The cleavage event is the result of an autoproteolytic SEA 
(sea urchin, enterokinase, agrin) domain identified in DG.  SEA domains have been 
mostly characterised in mucin proteins such as MUC1 (Macao et al., 2006). Although 
the exact mechanism of cleavage has not been described for DG, it has been 
determined that the cleavage occurs between Gly653 and Ser654 located in the loop 
connecting sheets b2 and b3 of the SEA domain (Akhavan et al., 2008). The cleavage 
site of MUC1 is also located between a Gly and Ser on the connecting loop of b2 and 
b3 and the cleavage is facilitated by conformational strain within the loop region 
(Macao et al., 2006). It is highly likely that DG autoproteolysis occurs via the same 
mechanism. Interestingly, one study suggests that the inhibition of the proteasome 
via lactacystin prevents cleavage of the DG precursor, however, this has not been 
tested in other members of the SEA domain family (Esapa et al., 2003).  
 18 
 
Figure 1.1 Schematic of DAG1 gene and DG protein. (a) schematic of the DAG1 gene. (b) Schematic of the DG 
protein. 
 
Following the cleavage of precursor DG into the a- and b-subunits within the ER, the 
two subunits are translocated to the plasma membrane (PM) via the secretory 
pathway. During this translocation both subunits are subject to post-translational 
modifications, specifically glycosylation (Barresi and Campbell, 2006). Glycosylation 
is not required for cleavage of the DG precursor (Holt et al., 2000) and DG targeting 
to the PM was not dependent on precursor cleavage (Esapa et al., 2003). Post-
translational modifications will be discussed in detail in the following sections 
however, there is contradicting evidence as to whether glycosylation is essential for 
localisation of DG to the PM. Holt (2000) and colleagues found that upon treatment 
with tunicamycin, an inhibitor of N-linked glycosylation, there was aberrant b-DG 
localisation. Without treatment b-DG localised to the PM and following tunicamycin 
treatment b-DG showed perinuclear localisation. However, this study did not address 
the contribution of O-linked glycosylation. On the other hand, Esapa (2003) and 
colleagues showed that inhibiting both N- and O-linked glycosylation did not prevent 
the targeting of a-DG to the PM. This would appear to disagree with data from Holt’s 
(2000) study, however, both studies are looking at the localisation of the two 
different subunits. Taken together these two studies suggest abnormal glycosylation 
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The structure of a-DG was first investigated in 1995 with the use of electron 
microscopy (EM). Brancaccio and colleagues used isolated a-DG from chicken cardiac 
muscle and were able to determine that a-DG had a dumbbell shape. The N- and C-
terminus of a-DG formed globular domains separated by an elongated disordered 
region termed the mucin-like region (Brancaccio et al., 1995). Based on sequence 
analysis the mucin region contained more than 40 Ser/Thr residues and a high 
number of Pro residues (Brancaccio et al., 1995). Due to the highly disordered mucin-
like region it has so-far not been possible to generate any high-resolution structural 
information of full-length a-DG. The globular N-terminus of human and murine a-DG 
has been determined to a high resolution using X-ray crystallography (Bozic et al., 
2004; Bozzi et al., 2015; Covaceuszach et al., 2017a, 2017b). However, no structure 
has been determined for the central mucin domain or the globular C-terminal 
domain.  
 
1.1.2.2 Glycosylation of a-Dystroglycan 
 
As discussed above a-DG is post-translationally cleaved from the DAG1 precursor 
protein, a-DG then goes through extensive glycosylation before reaching the PM. 
Glycans that are associated with glycoproteins such as a-DG can be divided into two 
groups depending on the amino acids they link to. Glycans that are linked to 
asparagine residues are termed N-glycans while glycans linked to either a serine or 
threonine residue are termed O-glycans. For N-linked glycans a N-acetylglucosamine 
(GlcNAc) moiety is linked to the Asn residue via an aspartylglycosylamine linkage. 
Classically for O-linked glycans, a N-acetylgalactosamine (GalNAc) moiety is linked to 
the Ser or Thr residue via the hydroxyl group. In addition to the Ser/Thr-GalNAc there 
are alternative types of O-glycosylation such as O-mannosylation which is found 
extensively in a-DG (Nilsson et al., 2010; Stalnaker et al., 2010). 
 
The extent of a-DG glycosylation was originally determined by SDS-PAGE. The 
predicted Mw of a-DG is ~74kDa however the observed Mw is significantly higher than 
that with a mass of between 100-156kDa in kidney, 120kDa in brain, peripheral nerve 
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and smooth muscle, 140kDa in cardiac muscle, 150kDa in lung tissue, 156kDa in 
epithelia and skeletal muscle and 190kDa in Torpedo electric organ (Barresi and 
Campbell, 2006; Martin, 2003). In addition to differences between tissues there are 
also differences within tissues at different developmental stages (Leschziner et al., 
2000). This disparity between apparent Mw and predicted Mw is due to the extensive 
glycosylation of a-DG which appears to be tissue specific. It was initially confirmed 
that a-DG contains N-linked glycans. However, when a-DG was treated with N-
glycosidase F which specifically removes N-glycans, the apparent Mw only decreased 
by 4kDa, suggesting the majority of glycosylation is the O-linked form (Ervasti and 
Campbell, 1991). Further investigation of a-DG revealed that a high proportion of O-
glycans were O-mannosyl glycans (Chiba et al., 1997; Sasaki et al., 1998).  
 
a-DG consists of three main types of O-glycans which have been designated Core 
M1, M2 and M3 (Figure 1.2). These three core structures all consist of Ser/Thr linked 
mannose and have similarities in their biosynthesis. The structure of Core M1 
consists of a GlcNAc linked to the mannose, Core M2 is branched with two GlcNAc 
moieties linked to the mannose and Core M3 consists of GlcNAc and a 
phosphorylated mannose (Yoshida-Moriguchi et al., 2013). For all of these core O-
glycan scaffolds, additional sugar moieties can be added (Meng et al., 2018).  
 
In addition to O-mannosyl links there is also extensive O-GalNAc glycosylation of a-
DG, however, the exact mechanisms of this have not been as extensively studied as 
O-mannosylation. A large number of the potential glycosylation sites of a-DG have 
been identified (Table 1.2) while three studies have looked at the types of a-DG O-
linked glycosylation in skeletal muscle of rabbit (Stalnaker et al., 2010), mouse 
(Harrison et al., 2012) and human (Nilsson et al., 2010). These studies agree that the 
type of glycosylation (O-mannosyl and O-GalNAcsyl) is not residue specific, both 
types have been detected using mass spectrometry (MS) at all identified O-
glycosylation sites apart from Thr367 and Thr369 which have only identified O-Man-
linked glycans (Nilsson et al., 2010). This suggests that the type of glycosylation does 




Figure 1.2 Structure of Core M1, M2 and M3 O-glycans associated with a-DG. (a) Structure of core M1, (b) core 
M2, (c) core M3, (c) extended core M3. 
 
Table 1.2 List of possible glycosylation sites of a-DG. Confirmed glycosylation sites are indicated by “Yes” with 
the reference for the study that identified it. (1) Hara et al., 2011; Yagi et al., 2013, (2) Nilsson et al., 2010, (3) 
Yoshida-moriguchi et al., 2010, (4) Stanlnaker et al 2010. 








T317 Yes (1) T423 No 
T319 Yes (1) T424 No 
T322 No S430 Yes (4) 
T328 No T431 No 
T329 No T436 No 
S336 No S438 No 
T341 No T439 No 






































































S344 No T442 No 
T351 No T443 No 
T353 No T444 No 
T367 Yes (2) T445 No 
T369 Yes (2) T446 Yes (4) 
T372 Yes (2) T450 Yes (4) 
T379 No T455 Yes (2) 
T381 Yes (3) T463 Yes (4) 
T388 Yes (3) T464 Yes (4) 
S391 Yes (4) S467 No 
T395 Yes (4) T469 Yes (4) 
T396 No T473 Yes (4) 
T404 No S475 Yes (4) 
T406 No T478 Yes (4) 
T414 No T482 No 
T418 No T483 Yes (4) 
T421 No T484 Yes (4) 
T422 No S485 No 
 
1.1.2.3 Interactions of a- Dystroglycan 
 
The known primary-binding partners of a-DG consist almost entirely of proteins with 
laminin globular (LG) domains. The LG domain was originally identified in laminins 
and the term comes from the five tandem domains, with repeat cystine residues, 
found at the C-terminus of all laminin a chains and each domain is generally 
separated by short linker sequences (Beck et al., 1990; Timpl et al., 2000). In addition 
to laminins a number of other proteins within the extracellular matrix (ECM) also 




Laminins consist of three peptide chains termed a, b and g with the LG domains being 
found on in the a-chain (Figure 1.3). In humans there are 5 types of laminin; laminin-
1, laminin-2, laminin-3, laminin-4 and laminin-5 and a-DG is capable of binding all 
except laminin-3 but with varying affinities (Table 1.3) (McDearmon et al., 2006; Pall 
et al., 1996; Smirnov et al., 2002; Talts et al., 2000).  
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Table 1.3. Table of the binding affinities for a-DG and different types of laminin. References: (1) Pall et al., 
1996, (2) Smirnov et al., 2002, (3) Talts et al., 2000, (4) McDearmon et al., 2006. 
a-DG Tissue Laminin-1 Laminin-2 Laminin-4 Laminin-5 
Skeletal Muscle 8nM (1) 8-18nM (1,2) 400nM (3)  
Central Nervous 
System 
20nM (4)  60-80nM (4) 80-1000nM 
(4) 
 
In the late 1990’s and early 2000’s there was conflicting research as to how a-DG 
binds to and interacts with laminin. Initially, Ervasti and Campbell (1993) 
demonstrated that following treatment with N-glycanase a-DG retained laminin 
binding, suggesting N-glycosylation is not required for laminin binding. A number of 
studies have also shown that neither the N- or C- terminal of a-DG are capable of 
laminin binding (Brancaccio et al., 1997; Sciandra et al., 2001; Di Stasio et al., 1999). 
Taken together, these studies would suggest that the interaction between a-DG and 
laminin occurs in the highly glycosylated mucin region. Reports confirm this and 
suggest that the interaction is dependent upon glycosylation (Michele et al., 2002). 
However, in 2004 Bozic and colleagues provided data from solid-phase binding 
assays that suggested the N-terminal fragment (aa28-313) and just the N-terminal 
IG-like domain (aa28-168) was capable of binding murine laminin-1 (Bozic et al., 
2004). This would suggest that the glycosylation was not required for binding, 
however, no data was provided to indicate binding affinities, so it is not known 
whether this binding is physiologically relevant. Overall, this early data would suggest 
that a-DG interacts with laminin via the mucin-like region and is dependent upon 
glycosylation.  
 
In addition to glycosylation, it has also been shown that the interaction between a-
DG and laminins requires Ca2+ ion binding and the essential amino acids required for 
laminin binding are positioned close to the Ca2+ ion (Timpl et al., 2000). It has been 
demonstrated that Ca2+ binding to LG4 of the a-chain of laminin-2 but not LG5 was 
required for efficient binding between laminin and a-DG (Wizemann et al., 2003).  A 
1.4Å structure has more recently been determined for the LG4 domain from the a-
chain of laminin-2 in complex with the polysaccharide that is both generated by 
LARGE and present upon a-DG. This structure shows that a Xyl-GlcA disaccharide, 
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also termed matriglycan, straddles the Ca2+ ion (Briggs et al., 2016). This study 
confirms both the requirement for Ca2+ binding and the presence of the glycans, in 
particular LARGE generated matriglycan.  
 
It is clear that the interaction between a-DG and laminins is dependent upon the 
glycosylation state of a-DG and the coordination of a stabilising Ca2+ ion, but there is 
a final feature of the LG domains that contribute to the relative binding affinities of 
different laminins. This additional feature is the presence of tandem LG domain 
repeats. However, the presence of these tandem repeats does not guarantee a-DG 
binding. For laminin-1 there are two sets of repeats; LG1-3 and LG3-4. LG1-3 does 
not bind a-DG whereas LG4-5 binds with high affinity. It is also worth noting that LG4 
is capable of binding with high affinity without LG5 but LG5 cannot bind in the 
absence of LG4 (Durbeej et al., 2001). Laminin-2-5 all have the LG1-3 repeats but only 
in laminin-2 and laminin-4 is there evidence of binding at these regions. Additionally, 
all laminins (1-5) have the LG4-5 tandem repeats and all except laminin-3 (no a-DG 
binding) have some degree of a-DG binding. Taken together this suggest that the 
tandem LG repeats are important for a-DG binding but not essential. 
 
1.1.2.3.2 Other LG Domain Containing Proteins 
 
As discussed above the matriglycan component of a-DG is required for the binding 
of the LG domains of laminin and this interaction is stabilised by Ca2+ ions. 
Additionally, there are a number of other ECM proteins that contain LG domains and 
are capable of binding glycosylated a-DG (Figure 1.3). These ECM proteins include; 
agrin (Bowe et al., 1994; Campanelll et al., 1994; Gee et al., 1994) where LG1 and LG2 
are required for binding while LG3 shows very weak binding (Gesemann et al., 1996; 
Stetefeld et al., 2004); Perlecan (Friedrich et al., 1999; Talts et al., 1999) which binds 
glycosylated a-DG with the three LG domains and all three are required for tightest 
binding (Friedrich et al., 1999); Pikachurin consists of three LG domains but only LG2 
and LG3 are required for high affinity binding to glycosylated a-DG (Kanagawa et al., 
2010); Neurexin is also capable of binding glycosylated a-DG (Sugita et al., 2001), 
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neurexin contains six LG domains but both LG2 and LG6 are capable of binding a-DG 
in an isolated manner and does not depend on a tandem array of LG domains 
(Sheckler et al., 2006); Finally, Slit2 is capable of binding glycosylated a-DG but only 
consists of a single LG domain (Wright et al., 2012). 
 
 
1.1.2.3.3 Non-LG Domain Interactions 
 
In addition to the LG domain containing proteins there are also a small number of a-
DG interactors that do not rely on the classical LG domain interaction. Biglycan is a 
Laminin a1
N CNTR EGF-L LN-IV EGF-L LN-IV EGF-L LNa D1 LNa D2Coil LG1 LG2 LG3 LG4 LG5
Agrin
N CNTR Kazal Domain LN-IVEGF-L SEA LG1 LG2 LG3EGF-L EGF-L EGF-L
Perlecan
N CSEA IG-L LN-IVEGF-L LG1 LG2 LG3EGF-L EGF-L EGF-LLN-IV EGF-L LN-IV IG-LEGF-L
Pikachurin
N CFibronectin Type III Domain LG1 LG2 LG3EGF-L EGF-LEGF-L
Neurexin a1
N CLG1 LG2 LG3EGF-L EGF-L LG4 LG5 EGF-L LG6 Neurexin Domain
Slit2
N CNTR Leu- and Cys-rich repeats LG1 EGF-LEGF-L Cys knot
Laminin IV domain (LN-IV)
Epidermal Growth Factor-Like (EGF-L)
Laminin Globular Domain (LG)
Figure 1.3 Schematic of the interacting partners of a-DG containing laminin globular domains. 
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small sulphate proteoglycan that interacts with a-DG despite containing no LG 
domain, the interaction also does not depend on a-DG glycosylation. The interaction 
between a-DG and biglycan occurs via a-DGs C-terminal domain (Bowe et al., 2000). 
Possibly the most important interaction a-DG makes is with the transmembrane 
(TM) domain protein b-DG which anchors it to the membrane. The interaction 
between a- and b-DG occurs via the C-terminal region of a-DG and the extracellular 
N-terminal region of b-DG, this interaction is non-covalent and has a Kd between 1-
10µM (Ervasti and Campbell, 1991; Sciandra et al., 2001; Di Stasio et al., 1999). 
 
In addition to the beneficial interactions that a-DG makes with laminin, agrin, 
perlecan, pikachurin, neurexin, Slit2, biglycan and b-DG, it is also the receptor for 
viral and bacterial pathogens. a-DG acts as a receptor for the causative agent of 
leprosy, Mycobacterium laprae, this interaction requires laminina2 as a cofactor 
(Rambukkana et al., 1998). Additionally, a-DG is the receptor for old world arena 
viruses such as lymphocytic chorionic meningitis virus (LCMV) and Lassa fever virus 
(LFV), these viruses bind directly to a-DG via the Gp1 viral protein. Neither LCMV nor 
LFV are able to bind recombinant a-DG which suggests that glycosylation is required 






The b component of DAG1 consists of 242 amino acids (654-895 of the precursor 
protein, human numbering) and has a predicted Mw of 26.6kDa. On SDS-PAGE it 
migrates with an apparent Mw of ~43kDa, this disparity is possibly due to 
glycosylation, relatively high basic amino acid content (particularly lysine), poly 
proline regions, the fact it is a TM protein or a combination of all of these factors. b-
DG consists of an extracellular N-terminal region, a TM region and a cytoplasmic C-




The structure of the extracellular N-terminal region of b-DG has been the most 
studied region. Di Stasio (1999) and colleagues produced an N-terminal recombinant 
fragment of murine b-DG consisting of amino acids 654-750 (equivalent to 652-748 
in humans) (Di Stasio et al., 1999). Using circular dichroism, they determined that the 
fragment consisted of relatively few secondary structural elements and that at least 
the extreme N-terminal region of the fragment was flexible. This was later expanded 
upon, again using the 654-750 murine b-DG fragment and was investigated using 
circular dichroism, Fourier-transform inferred spectroscopy and the secondary 
structure prediction method GOR. They identified an a-helix between positions 674-
684 and a b-sheet between positions 702-726. They also identified a smaller b-sheet 
and a few b-turns but the majority of the fragment could not be assigned secondary 






























































Figure 1.4 Schematic of b-DG. (a) Domain organisation and important residues and regions within those 
domains. (b) Schematic indicating the location of key binding sites and the proteins that interact at each binding 
site. 
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disordered (Boffi et al., 2001). The high probability that the N-terminal b-DG 
fragment is disordered makes it difficult to crystallise which is one possible reason 
that a crystal structure has not been determined.   
 
In addition to a disordered N-terminal region, b-DG also consists of a TM and an 
intracellular C-terminal domain. b-DG is a type 1 TM protein owing to the single pass 
TM domain with an extracellular N-terminus and an intracellular C-terminus (Ott and 
Lingappa, 2002). There have been no structural studies of the C-terminus of b-DG 
and this is likely due to the high level of flexibility within this region. The C-terminus 
is highly enriched for proline residues and consists of 120 residues. Within the C-
terminus in the juxtamembrane region is a nuclear localisation signal (NLS) at 
position 776-782 (Lara-Chacón et al., 2010) and a number of protein binding motifs 
that will be discussed in detail below. 
 
1.1.3.2 Post-Translational Modifications 
 
b-DG is not subject to the high levels of glycosylation characteristic of a-DG however, 
there are some post-translational modifications that play an important functional 
role. The modifications of b-DG include glycosylation, phosphorylation, 




The glycosylation of b-DG was first determined in 1991, it was found that when b-DG 
was treated with N-glycosidase F there was a reduction in mass of 2kDa, suggesting 
the presence of N-linked glycans (Ervasti and Campbell, 1991). It was later suggested, 
based on the primary structure of mouse b-DG, that an N-glycosylation consensus 
motif in the N-terminus at Asn661 was present as were three O-glycosylation sites at 
Ser725, Ser728 and Ser729 however, neither Ser725 or Ser729 are conserved in other 





At least two types of phosphorylation have been identified experimentally in b-DG, 
phosphorylation of threonine at position 790 (Bian et al., 2014; Zhou et al., 2013) and 
tyrosine phosphorylation at position 892 which is located within the important PPxY 
binding motif (James et al., 2000; Sotgia et al., 2001). The functional relevance of the 
Thr790 is not known but Y892 has been studied extensively. The phosphorylation of Y892 
is regulated by the binding of extracellular ligands to a-DG, namely, laminin and agrin 
(James et al., 2000; Sotgia et al., 2003). The binding of laminin or agrin results in the 
phosphorylation of Y892 by the Src kinase and Src-family kinases (Sotgia et al., 2003). 
The tyrosine phosphorylation has two important effects i) it results in the 
internalisation of b-DG for degradation or for localisation to intracellular 
compartments (Lara-Chacón et al., 2010; Sotgia et al., 2003) and ii) it acts as a 
molecular switch in order to regulate the binding partners of b-GD (Bozzi et al., 2009; 
Ilsley et al., 2001). 
 
1.1.3.2.3 Protein Cleavage 
 
As described in section 1.1.3.1, b-DG is identified as a ~43kDa protein by SDS-PAGE, 
however, two other species of b-DG have been identified according to their 
migration on SDS-PAGE at Mw ~30kDa and 26kDa (Figure 1.4). All three of these 
fragments are identified by the monoclonal antibody MANDAG2 which is specific for 
the extreme C-terminus region of b-DG (Leocadio et al., 2016; Yamada et al., 2001).  
 
The 30kDa fragment has been identified in peripheral nerve, kidney, lung and smooth 
muscle but was apparently absent in skeletal muscle, cardiac muscle and brain 
(Yamada et al., 2001). In this same study they determined that the 30kDa fragment 
was the result of matrix metalloproteinase (MMP) activity which proteolytically 
cleaved the extracellular N-terminal of b-DG (Yamada et al., 2001). Using inhibitor 
and knockout assays it was determined that the MMPs responsible for the cleavage 
of b-DG are the gelatinases, also known as MMP-2 and MMP-9 (Agrawal et al., 2006; 
 30 
Zhong et al., 2006). One of the MMP-9 cleavage sites is between His715 and Leu716 
which results in the release of a peptide consisting of 61 amino acids (Bozzi et al., 
2009). Cleavage sites for MMP-2 and additional sites of MMP-9 have yet to be 
identified.  
 
Further cleavage of the 30kDa fragment has been described based on the 
identification of a 26kDa fragment. The generation of this fragment was dependent 
upon cell density in LNCaP prostate cancer cells and it was suggested that high cell 
density increased cleavage of the 30kDa fragment into the 26kDa fragment (Leocadio 
et al., 2016). The functional protease involved in this cleavage is g-secretase which 
cleaves b-DG at the juxtamembrane region releasing the cytoplasmic C-terminal 
domain (Leocadio et al., 2016). It has also been shown that g-secretase plays a similar 
role in a number of other type 1 membrane proteins (Hemming et al., 2008). 
Recombinant b-DG cytoplasmic domain also migrates at 26kDa on SDS-Page despite 




b-DG has a plethora of binding partners, with the exception of a-DG binding the N-
terminal region (Sciandra et al., 2001; Di Stasio et al., 1999), all known interactions 
occur in the cytoplasmic C-terminal region. The C-terminal region is packed with 
potential binding sites (Figure 1.4), including binding sites for WW domain containing 
proteins, Src-homology 3 (SH3) domain containing proteins and Src-homology 2 
(SH2) domain containing proteins. All of these binding sites are in close proximity and 
often overlap which requires intricate regulation to ensure effective signal 
transduction and cytoskeletal organisation. The juxtamembrane region of C-terminal 
b-DG is involved in a number of protein interactions.  
 
1.1.3.3.1 Proteins Containing WW Domains 
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The WW domain, so named after two tryptophan residues separated by 20-21 amino 
acids (Bork and Sudol, 1994) is a key binding domain that interacts with b-DG, via the 
PPxY binding motif. Recently the PPxY-WW interaction has been shown to also 
include PY motifs in addition to the classical PPxY motif (Lin et al., 2019). The most 
well studied PPxY (or PY) binding motif is found at the extreme C-terminus of b-DG 
(Figure 1.4a) and consists of the PPPY (889-892) sequence in human b-DG but there 
is also PPEY at position 828-831 and APPY at 860-863. There are multiple proteins 
that interact with b-DG via a WW-PPxY interaction; dystrophin (Jung et al., 1995), 
utrophin (James et al., 2000), caveolin-3 (Sotgia et al., 2000), YAP (Morikawa et al., 
2017), KIBRA (Lin et al., 2019), MAGI-2 (Sumita et al., 2007), MAGI-3 (Lin et al., 2019), 
neuroligin-2 (Sumita et al., 2007) and WWP1 (Cho et al., 2018) (Figure 1.4b). 
 
Dystrophin is the most well characterised of the WW domain proteins known to 
interact with b-DG. Dystrophin is found almost exclusively in muscle and plays an 
essential role in connecting the extracellular matrix with the intracellular 
cytoskeleton via the dystrophin-associated protein complex (DAPC) which will be 
discussed in detail below. The WW domain of dystrophin is located in the C-terminus 
within a cystine-rich domain (Bork and Sudol, 1994) and the crystal structure of C-
terminal dystrophin in complex with the b-DG binding site has been solved to 1.9Å 
(Huang et al., 2000). Based on the structural analysis it was found that the WW 
domain of dystrophin embeds within an adjacent EF-hand-like domain and b-DG 
binds to the surface produced from the WW domain and EF-hand domain (Huang et 
al., 2000). In addition to the presence of the EF-hand domain the interaction between 
the WW domain of dystrophin and the PPPY domain of b-DG is stabilised by Ca2+ ions 
(Ervasti and Campbell, 1991). The regulation of the interaction between dystrophin 
and b-DG occurs via phosphorylation of Y892 (discussed above), this phosphorylation 
event prevents the binding of dystrophin (Ilsley et al., 2001). 
 
Utrophin is both a structural and functional paralogue of dystrophin and is found in 
muscle and non-muscle cells. As with dystrophin, utrophin consists of a WW domain 
in the C-terminus and requires the presence of an EF-hand domain to stabilise the 
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interaction. Additionally, the phosphorylation of Y892 negatively regulates the 
utrophin-b-DG interaction as phosphorylation resulted in loss of utrophin binding in 
co-immunoprecipitation (Co-IP) assays (James et al., 2000).  
 
In the early 2000’s the protein caveolin-3 was identified as WW domain containing 
protein that interacts with b-DG (Sotgia et al., 2000). Caveolin-3 is a muscle specific 
protein that associates with small invaginations of the PM known as caveolae. A 
number of other caveolin proteins also contain WW domains including caveolin-2 but 
based on Co-IP assays there is no interaction between b-DG C-terminal fragment or 
caveolin-2 (Sotgia et al., 2000). This study also suggests that caveolin-3 and 
dystrophin compete for the b-DG PPPY binding site. However, interestingly the 
interaction between caveolin-3 and b-DG is not regulated by tyrosine 
phosphorylation. This was tested with phosphorylation at both Y892 and Y886 and 
binding was unaffected by either (Sotgia et al., 2000).  
 
The Hippo pathway, identified in Drosophila, is involved in regulating organ size and 
responding to mechanical stimuli. This pathway relies on WW domain and PPxY motif 
containing proteins. Recently, b-DG has been identified as a binding partner for the 
WW domain containing proteins KIBRA and YAP. These play opposing roles in the 
Hippo pathway with KIBRA inhibiting the pathway while YAP, a transcriptional 
cofactor, is a downstream effector of the pathway. YAP was initially identified as a b-
DG binding protein in 2017 where it was shown to be involved in murine 
cardiomyocyte proliferation (Morikawa et al., 2017). More recently, a mass spec 
analysis of DG in Drosophila identified Yki (YAP homologue) and Kbr (KIBRA 
homologue) as interaction partners of b-DG (Yatsenko et al., 2020). Perhaps the most 
compelling evidence is the detailed structural analysis of the interaction between 
KIBRA and the C-terminal binding region of b-DG (Lin et al., 2019). In this paper they 
determined that highest affinity binding between WW domain and PY motifs occur 
when both tandem WW domain and tandem PY motifs are only separated by a short 
linker sequence. KIBRA and b-DG fit this category and bind with an Kd of ~96nM. The 
authors did not asses binding between YAP and b-DG but did find that the two WW 
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domains found in YAP were separated by a much longer linker sequence suggesting 
a lower affinity between b-DG and YAP compared with b-DG and KIBRA (Lin et al., 
2019). 
 
In the case of MAGI-2 and neuroligin-2, MAGI2 is a synaptic scaffold molecule while 
neuroligin-2 is a post-synaptic protein involved in the maturation of GABAergic 
synapses. Both proteins were identified in rat hippocampal neurones where they 
were demonstrated to interact with b-DG (Sumita et al., 2007). Interestingly, their 
binding was not restricted to the PPPY motif at position 889-892, they were also able 
to bind to the PPEY and APPY sequences located N-terminally of the C-terminal motif 
(Sumita et al., 2007). As with MAGI-2, MAGI-3 is a scaffold protein and contains 
tandem WW domains. These tandem WW domains allow binding with b-DG with a 
Kd of 2.7µM (Lin et al., 2019).  
 
The WW domain proteins discussed thus far are either structural proteins, in the case 
of dystrophin, utrophin, caveolin-3, MAGI-2/3 and neuroligin-2, or involved in signal 
transduction, in the case of KIBRA and YAP. WWP1 on the other hand is a protein 
that itself regulates levels of b-DG (Cho et al., 2018). It is a member of the NEDD4 E3 
ubiquitin ligase family which ubiquitinates proteins targeting them for subsequent 
degradation. Cho and colleagues found that WWP1 interacts with b-DG via the WW 
domains. Both dystrophin and utrophin compete for the binding site and decrease 
binding of WWP1. The mutation of Y831 or Y892 in b-DG resulted in decreased 
interaction, suggesting WWP1 is able to bind to either of the PY motifs. In this study 
they also investigated other members of the NEDD4 family which are also WW 
domain containing proteins, they found that WWP2, Itch, Smurf1/2, NEDD4 and 
NEDD4L all resulted in decreased levels of b-DG but a direct interaction was not 
investigated (Cho et al., 2018). Conversely, it was found that NEDD4L doesn’t interact 
with b-DG in SPOT assays, direct biochemical interactions, immunoprecipitation or 
immunofluorescence assays (Piggott, 2014). 
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1.1.3.3.2 Proteins Containing SH3 Domains 
 
Many proteins identified as b-DG binding proteins contain a SH3 domain, SH3 domain 
containing proteins are generally involved in cell signalling resulting in the regulation 
of the cytoskeleton. SH3 domain proteins bind proline-rich regions. The SH3 domain 
proteins that interact with b-DG include Grb2 (Yang et al., 1995), Tks5 (Thompson et 
al., 2008) and vinexin (Thompson et al., 2010a) (Figure 1.4b).  
 
Grb2 is an important protein involved in signalling, by linking receptor tyrosine 
kinases with small GTP binding proteins that are involved in cytoskeletal organisation 
induced by growth factors. The b-DG-Grb2 interaction was identified in 1995. It was 
identified in both brain tissue (Cavaldesi et al., 1999) and skeletal muscle and was 
confirmed in vitro with a GST-fusion protein interaction assay and in vivo with a Co-
IP assay from rabbit skeletal muscle and brain tissue (Yang et al., 1995). The 
interaction between b-DG and Grb2 occurs between the extreme C-terminus of b-
DG and the SH3 domains of Grb2 but the N-terminal SH3 domain binds b-DG with a 
higher affinity than the C-terminal SH3 domain. The Kd of the interaction between 
the 20 amino acids at the C-terminus of b-DG and Grb2 was in the nanomolar range 
(between 240-280nM) (Russo et al., 2000). The binding site on b-DG was identified 
as the PxxP motif that overlaps with the PPxY motif involved in WW domain binding. 
Additionally, the binding of Grb2 was found to be inhibited by binding of dystrophin 
to b-DG (Russo et al., 2000).  
 
The SH3 domain protein Tks5 was identified as a b-DG interaction partner using a 
phage display library (Kärkkäinen et al., 2006). This interaction was then verified 
using a combination of Co-IP and GST pulldown assays and co-localisation was 
determined using immunofluorescence microscopy (Thompson et al., 2008). Tks5 
plays a key role in actin bundling and regulation of podosomes, which are involved in 
cell motility and extracellular matrix degradation. The Tks5-b-DG interaction is 
dependent upon phosphorylation of b-DG as the interaction requires 
phosphorylation to facilitate the interaction (Thompson et al., 2008). Other than the 
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original research by Thompson and colleagues there has been no further research 
into this interaction, thus the exact sites of interaction have yet to be described.  
 
Vinexin is a vinculin binding partner and is localised to focal adhesions, as with Tks5, 
vinexin was identified via a SH3 phage display library and was then validated using 
GST-SH3 domain affinity column, Co-IP and SPOT arrays (Thompson et al., 2010a). 
The specific vinexin-b-DG interaction occurs between the 3rd SH3 domain of vinexin 
and the proline-rich SH3 binding motif PYVP at position 891-894 which overlaps with 
the WW binding domain motif PPPY. The cytoskeletal protein vinculin was also 
associated with the b-DG-vinexin complex however, there was no direct interaction 
detected between b-DG and vinculin suggesting the b-DG-vinexin-vinculin complex 
is stabilised by vinexin binding both b-DG and vinculin (Thompson et al., 2010a). 
 
1.1.3.3.3 Proteins Containing SH2 Domains 
 
SH2 domain proteins, as with SH3 domain proteins are generally involved in signalling 
pathways. SH2 domains are capable of binding phosphorylated tyrosine residues 
which generally have a proline or leucine residue at the +3 position from the 
phosphotyrosine. There are a number of these sites present on the cytoplasmic 
domain of b-DG with the most prominent of these being the YVPP sequence (892-
895) which overlaps with the PPPY binding motif. As discussed above, Src kinase is 
responsible for the phosphorylation of tyrosine residues on b-DG and this 
phosphorylation event is responsible for switching the PPPYVPP (889-895) from a 
WW domain binding motif to a SH2 binding motif (Sotgia et al., 2001, 2003). In order 
to investigate SH2 domain proteins that bind b-DG Sotgia and colleagues (2001) 
carried out GST-tagged pulldown experiments and probed for a number of both 
catalytic and adaptor SH2 containing proteins. From this screen they identified five 
proteins that bound in a phosphotyrosine-dependent manner, these included; c-Src, 
Fyn, Csk, NCK1 and SHC1 (Sotgia et al., 2001). C-Src, Fyn and Csk are all tyrosine 
protein kinases whereas NCK1 and SHC1 are both scaffold proteins but all SH2 
domains identified are involved in signal transduction with many displaying overlap 
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between pathways that involve other b-DG binding proteins such as Grb2 and MAPK 
(Ahmed and Prigent, 2017; Chaki and Rivera, 2013). The binding of all five SH2 
domain proteins were dependent upon phosphorylation of C-terminal b-DG and 
more specifically they required the PPxY motif at the extreme C-terminus (Sotgia et 
al., 2001). 
 
1.1.3.3.4 Proteins Binding the Juxtamembrane Region of b-Dystroglycan 
 
The juxtamembrane region of b-DG refers to the region immediately following the 
TM domain and consists of a cluster enriched for the basic amino acids Arg and Lys. 
This region is located at the opposite end of the cytoplasmic domain to the WW, SH2 
and SH3 binding motifs. As with the binding motifs discussed above, the 
juxtamembrane region is capable of binding both signalling and structural proteins, 
in particular; MEK2, ERK (Spence et al., 2004a), rapsyn (Cartaud et al., 1998) and ezrin 
(Spence et al., 2004b) (Figure 1.4b).  
 
Mitogen-activated protein kinase kinase 2 (MEK2) and extracellular signal regulated 
kinase (ERK) are both involved in the Ras-Raf-MEK-ERK kinase cascade pathway 
which is involved in regulating proliferation, differentiation, migration, senescence 
and apoptosis and is mis-regulated in a number of diseases including cancers (Sun et 
al., 2015). It was determined by yeast-two-hybrid and pulldown assays that the b-DG 
interacts with both MEK2 and phosphorylated (activated) ERK1 (Spence et al., 
2004a). The exact site of b-DG-ERK1/MEK2 interaction has been predicted but not 
experimentally determined, ERK1 and MAK2 bind small clusters of basic residues 
(Tanoue et al., 2000) which are present in the juxtamembrane region of b-DG, 
additionally the juxtamembrane region has a predicted MAPK binding site (Gouw et 
al., 2018).  
 
Receptor associated protein at synapse (rapsyn) is a scaffold protein localised to the 
neuromuscular junction (NMJ) where it plays an essential role in clustering and 
anchoring the acetylcholine receptor (AChR) (Gautam et al., 1995). The interaction 
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between b-DG and rapsyn was investigated in the in Torpedo electric organ where 
there is a high concentration of AChR. Using a combination of affinity 
chromatography and ligand blot assays it was determined that the fragment 
consisting of just the juxtamembrane region of b-DG was necessary for binding of 
rapsyn (Cartaud et al., 1998). 
 
Ezrin is a protein involved in the linking of TM proteins with the actin cytoskeleton 
via an actin binding domain. The direct interaction between b-DG and ezrin was 
determined using a combination of GST pulldown and Co-IP assays (Spence et al., 
2004b). The juxtamembrane binding site was identified by mutating the RKKRK basic 
sequence to AAAAA which resulted in loss of b-DG-ezrin interaction and also resulted 
in loss of actin-rich surface protrusions within cultured cells (Spence et al., 2004b). 
This interaction is likely to be important for maintaining the connection between the 
extracellular matrix and the cytoskeleton.  
 
1.1.3.3.5 Interacting Partners with Unknown Binding Sites 
 
As evidenced above, b-DG is capable of interacting with a large number of proteins 
at both the extreme C-terminus of the cytoplasmic domain and at the 
juxtamembrane region. However, there are some proteins that have been 
demonstrated to be b-DG interacting partners, but the specific site of interaction has 
yet to be determined. These include actin (Chen et al., 2003), plectin (Rezniczek et 
al., 2007), integrinb1, tubulin, talin (Cerecedo et al., 2008), myosin IIA (Buisson et al., 
2014) and plakoglobin (Eid Mutlak et al., 2020) (Figure 1.4b).  
 
1.1.4 The Role of Dystroglycan at the Plasma Membrane 
 
1.1.4.1 Components of the Dystrophin/Utrophin Associated Protein Complex 
 
The DAPC, and the dystrophin glycoprotein complex (DGC) are interchangeable 
terms describing the PM complex that has dystrophin at its centre, additionally the 
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complex containing utrophin is termed the utrophin associated protein complex 
(UAPC). Based on personal preference the term DAPC (or UAPC) will be used 
henceforth. The DAPC contains multiple components, some of which form their own 
subcomplexes but broadly the core components can be separated into three groups 
(i) the extracellular component (ii) the membrane components, and (iii) the 
cytoplasmic components. There is only a single extracellular component of the DAPC 
and that is a-DG which interacts with extracellular proteins including laminin, 
perlecan and agrin and is non-covalently bonded to b-DG (see section 1.1.2.3). The 
membrane proteins associated with the DAPC are b-DG, sarcoglycans and sarcospan 
while the cytoplasmic proteins include dystrophin, dystrobrevins and syntrophins 
(Figure 1.5).  
 
 
Figure 1.5 Schematic of the components and organisation of the DAPC. Dystroglycan 
forms the central component of the DAPC. a-DG interacts with the ECM proteins and is 
anchored to the membrane through interactions with b-DG. b-DG then directly 
interacts with dystrophin which is the key protein in interacting and organising the 
cytoskeleton. Figure was made using BioRender. 
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1.1.4.1.1 Membrane Components 
 
The structure and interacting partners of b-DG have been discussed in detail in 
section 1.1.3. Additionally, b-DG is the predominant TM protein involved in 
anchoring the DAPC/UAPC at the PM as it provides the direct connection between 
the extracellular a-DG and the cytoplasmic dystrophin (Ervasti and Campbell, 1991; 
Ibraghimov-Beskrovnaya et al., 1992).  
 
In addition to b-DG the sarcoglycans and sarcospan make up the membrane 
components of the DAPC/UAPC. The sarcoglycans, which are single pass TM proteins, 
form a heterotetrameric complex (Chan et al., 1998) where a-, b-, g- and 𝛿-
sarcoglycan form the main complex in skeletal muscle but both ε- and ζ-sarcoglycan 
are found in the smooth muscle and replace the a- and g-sarcoglycans respectively 
(Imamura et al., 2005; Wheeler et al., 2002). Sarcospan is an additional component 
of the sarcoglycan complex and consists of four TM regions (Crosbie et al., 1997) and 
is required for stabilising interactions within the DAPC (Crosbie et al., 1999; Yoshida 
et al., 2000). 
 
1.1.4.1.2 Dystrophin and Utrophin 
 
Dystrophin is the central cytoplasmic component and the namesake for the DAPC. It 
is anchored to the PM, and the rest of the DAPC, in part by the interaction with b-DG 
as discussed in section 1.1.3.3. Dystrophin is encoded by the DMD gene which is 
controlled by three upstream promoters; the brain (Boyce et al., 1991), the muscle 
(Chelly et al., 1990) and the Purkinji (Holder et al., 1996) promoters which allow 
tissue specific expression. These promoters result in the expression of full-length 
dystrophin which is termed Dp427. In addition to upstream promoters there are four 
internal promoters which result in the expression of shorter isoforms of dystrophin 
including; Dp260, Dp140, Dp116 and Dp71, the smallest isoform Dp40 is the result of 
alternative splicing of the Dp71 transcript (D’souza et al., 1995; Górecki et al., 1992). 
The different isoforms are expressed in different tissues with Dp260 expressed in the 
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retina (D’souza et al., 1995), Dp140 expressed in both the brain and the kidney (Lidov 
et al., 1995), Dp116 expressed in the Schwann cells of peripheral nerves (Byers et al., 
1993) and Dp71 is the most abundant of all the isoforms and most uniformly 
expressed but found at highest levels in the neurones and glia within the brain (Blake 
et al., 1992). 
 
The full-length Dp427 contains four main domains: a C-terminal region which consists 
of a-helical coiled-coils (Blake et al., 1995a) which is only found in dystrophin and 
related proteins (Tinsley et al., 1992); Adjacent to the C-terminal region is the cystine-
rich domain containing the WW binding domain that interacts with b-DG (Bork and 
Sudol, 1994); The region next to the WW binding domain consists of a long flexible 
central rod domain made up of spectrin-like repeats and contains more than 2800 
amino acids arranged in triple helical repeats (Koenig and Kunkel, 1990); The final 
region is the N-terminus which contains two calponin homology (CH) regions which 
are responsible for binding actin filaments, this N-terminal domain is also referred to 
as actin binding domain 1 (ABD1) (Way et al., 1992) (Figure 1.6). The smaller 
dystrophin isoforms are lacking the N-terminal region and parts, or all, of the central 
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Figure 1.6 Schematic depicting the domain organisation of different dystrophin isoforms and utrophin. 
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Dystrophin plays the essential role of binding actin filaments as part of the DAPC. The 
DAPC is capable of binding 24 actin monomers per dystrophin molecule. This is due 
to both ABD1 found in the N-terminus but also a second ABD identified in the central 
rod domain (Rybakova et al., 1996). It was found that multiple spectrin repeats were 
rich in basic residues which facilitates the interaction with actin filaments  (Amann et 
al., 1998; Rybakova et al., 2000). Investigation into the binding affinities of the 
isolated ABDs within dystrophin had a binding affinity in the µM range while full 
length dystrophin had a binding affinity in the nM range suggesting the whole protein 
is required for high affinity binding of actin (Rybakova and Ervasti, 1997). In addition 
to actin binding, the DAPC was also shown to decrease the rate of actin 
depolymerisation, thus stabilising the actin filament. The interaction between 
dystrophin and actin filaments was similar to that observed between the DAPC and 
actin suggesting that dystrophin is the key protein for the DAPC-actin interaction 
despite other members of the complex having proposed actin binding abilities 
(Rybakova et al., 1996).  
 
In addition to actin binding, dystrophin also plays a role in binding other cytoskeletal 
elements and linking them to the DAPC. Dystrophin is capable of interacting with the 
cytolinker protein plectin which is involved in linking together actin filaments, 
microtubules and intermediate filaments. The interaction between dystrophin and 
plectin occurs via the cystine-rich domain adjacent to the C-terminal domain 
(Rezniczek et al., 2007). The intermediate filament synemin has also been suggested 
to interact with dystrophin in vitro, in particular the interaction requires the central 
rod region and the interaction site overlaps the actin binding site (Bhosle et al., 2006). 
A direct interaction between dystrophin and the intermediate filament cytokeratin 
19 has been identified, this interaction involves the N-terminal ABD1 (Stone et al., 
2005, 2007). There is also indirect evidence suggesting that dystrophin is involved in 
microtubule interactions as the WW domain of dystrophin co-sediments with 
microtubules and when dystrophin is absent in mice the microtubule lattice is less 
organised than control mice (Prins et al., 2009). Taken together, these studies 
suggest that dystrophin not only binds actin but is able to interact both directly and 
indirectly with other members of the cytoskeleton. However, these interactions 
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appear to occur in regions responsible for actin binding suggesting different 
cytoskeletal components compete for dystrophin interaction sites.  
 
Dystrophin is capable of interacting with cytoskeletal proteins and other proteins 
within the DAPC, but it has also been reported that dystrophin is capable of binding 
membrane phospholipids. It was found that dystrophin lacking ABD1 was still capable 
of localising to the PM (Corrado et al., 1996), as was a construct lacking the WW 
domain required for b-DG interaction (Gardner et al., 2006). This suggests the b-DG-
dystrophin interaction is not essential for localising dystrophin to the PM. 
Dystrophin’s ability to localise to the PM is in part due to the direct interaction with 
membrane phospholipids that contain phosphatidylserine and phosphatidylcholine 
(DeWolf et al., 1997). Tryptophan residues were identified as important for the 
dystrophin-lipid interaction (Le Rumeur et al., 2003, 2007) while the coiled-coil 
region that includes repeat 1-3 strongly binds lipids and result in conformational 
changes in dystrophin which affects the binding of actin (Legardinier et al., 2008; 
Mias-Lucquin et al., 2020; Dos Santos Morais et al., 2018). 
 
Utrophin is a homolog of dystrophin with highly conserved structural organisation. 
As with dystrophin, the transcript responsible for producing utrophin is controlled by 
a number of promoter sequences both upstream and within the gene (Burton et al., 
1999; Dennis et al., 1996) and there is also evidence suggesting shorter isoforms of 
utrophin are produced (Blake et al., 1995b; Lumeng et al., 1999; Wilson et al., 1999). 
The full length utrophin protein consists of the same domains as dystrophin including 
the C-terminal a-helical coiled coils, an adjacent cystine-rich region involved in 
binding b-DG, a central rod domain consisting of spectrin-like repeats and an N-
terminal ABD (Blake et al., 1992; Khurana et al., 1990; Love et al., 1991) (Figure 1.6).  
 
As with dystrophin, utrophin is capable of binding other DAPC/UAPC proteins 
including b-DG which is discussed above (James et al., 2000), sarcoglycans 
(Matsumura et al., 1992), a-dsytrobrevin-1 (Peters et al., 1998) and syntrophins 
(Kramarcy et al., 1994; Peters et al., 1997a). The C-terminal ABD domain of utrophin 
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is very similar to the ABD of dystrophin (Keep et al., 1999a, 1999b; Moores et al., 
2000) and binds with high affinity to actin filaments (Winder et al., 1995). However, 
utrophin does not appear to have the ABD2 present in the central rod domain of 
dystrophin, it lacks the basic repeat region present in dystrophin (Amann et al., 
1999). Despite this, utrophin is still capable of binding actin with high affinity and 
with a ratio of 14 actin monomers for every 1 utrophin molecule (Rybakova et al., 
2002). The interactions between dystrophin and cytolinker plectin and the 
intermediate filament synemin are also found in utrophin (Bhosle et al., 2006; 
Rezniczek et al., 2007). However, the indirect interaction between dystrophin and 
microtubules was not observed for utrophin (Belanto et al., 2014). 
 
1.1.4.1.3 Additional Cytoplasmic Components 
 
The two key cytoplasmic components of the DAPC/UAPC other than 
dystrophin/utrophin are dystrobrevin and syntrophin. There are two types of 
dystrobrevins; a- and b-dystrobrevins which are encoded by the DTNA and DTNB 
genes respectively (Blake et al., 1996; Peters et al., 1997b). Both a- and b-
dystrobrevins have homology with the cystine-rich C-terminal region of dystrophin 
which contains the WW domain (Ambrose et al., 1997; Blake et al., 2002; Loh et al., 
1998). Dystrobrevins are capable of binding DAPC/UAPC components dystrophin 
(Butler et al., 1992; Sadoulet-Puccio et al., 1997; Suzuki et al., 1992), utrophin 
(Nawrotzki et al., 1998), sarcoglycans (Yoshida et al., 2000) and syntrophins (Dwyer 
and Froehner, 1995), in addition to cytoskeletal components synemin (Mizuno et al., 
2001), syncoilin (Newey et al., 2001; Poon et al., 2002), desmin (Sandoval et al., 
1983), a-actinin (Bellin et al., 1999) and vinculin (Bellin et al., 2001). 
 
The syntrophin family consists of a-, b- and g-syntrophins and each of these are 
expressed in different tissues (Adams et al., 1993; Ahn et al., 1996; Peters et al., 
1997a; Piluso et al., 2000). The syntrophins contain a PDZ binding domain as well as 
a domain unique to syntrophins termed SU domain. As with dystrobrevins, 
syntrophins are capable of binding DAPC/UAPC components including dystrophin, 
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utrophin (Ahn and Kunkel, 1995; Suzuki et al., 1995) and dystrobrevin (Dwyer and 
Froehner, 1995; Newey et al., 2000) while also able to interact directly with the actin 
cytoskeleton (Iwata et al., 2004).  
 
1.1.4.2 Functions of the DAPC/UAPC 
 
1.1.4.2.1 Mechanical Support of the Sarcolemma 
 
As discussed above dystrophin and the DAPC are localised at the sarcolemma 
(Zubrzycka-Gaarn et al., 1988) where it makes up, along with integrins, the costamere 
which links the basal lamina to the sarcomere within the muscle fibre (Porter et al., 
1992; Straub et al., 1992). This physical connection occurs via the basal lamina 
components interacting with a-DG, a-DG in turn binding b-DG and associating with 
the sarcoglycan-sarcospan subcomplex, the b-DG-sarcoglycan-sarcospan TM 
complex interacts with dystrophin, dystrobrevin and syntrophins which in turn 
interact with the cytoskeleton linking the whole complex with the sarcomere. (Figure 
1.5) The loss of the central dystrophin molecule results in the general loss of the 
DAPC components and reduces this linkage. The mdx mouse model lacks the 
dystrophin gene and many muscle specific phenotypes have been described 
including reduced force generation (Consolino and Brooks, 2004; Dellorusso et al., 
2001), increased permeability to membrane impermeable dyes following force 
generation (Petrof et al., 1993), increased release of creatine kinase (Bulfield et al., 
1984), increased centrally nucleated fibres (Coulton et al., 1988) which is an indicator 
of muscle fibre regeneration and increased muscle fibre necrosis (Matsuda et al., 
1995) compared with control mice. Together this data suggests that the loss of DAPC 
at the sarcolemma results in muscle damage which emphasises the role the DAPC 
plays in maintaining muscle membrane integrity. 
 
1.1.4.2.2 Non-mechanical Roles of DAPC/UAPC 
 
 45 
The DAPC/UAPC is known to play an essential role in synaptic formation and 
organisation, particularly in the NMJ. The NMJ is a specific synapse that is formed 
between the neurone and the muscle. The role of the DAPC/UAPC at the NMJ 
involves the binding of agrin to a-DG, this binding event results in the localisation of 
the DAPC/UAPC to the NMJ in addition to the rapsyn-dependent clustering of 
DAPC/UAPC with AChR (Gautam et al., 1995; Rybakova et al., 2002).  
 
A great deal of research has gone into understanding the interactions and the 
functional role of DAPC/UAPC and membrane channels; including ion channels and 
aquaporins (AQP). It is apparent that the interaction between the DAPC/UAPC and 
these channels is predominantly mediated through the syntrophins, and particularly 
via their PDZ domains. The DAPC/UAPC has been shown to interact with voltage-
gated channels such as Nav1.5 (Gavillet et al., 2006); non-voltage-gated ion channels 
such as TRPC1 (Vandebrouck et al., 2006) and TRPC4 (Sabourin et al., 2009); inward-
rectifier potassium channels such as Kir4.1 (Connors et al., 2004); and aquaporins, 
specifically AQP4 (Amiry-Moghaddam et al., 2003; Neely et al., 2001). 
 
1.1.5 Dystroglycan and Disease 
 
1.1.5.1 Muscular Dystrophy  
 
Muscular dystrophies (MD) are characterised generally by muscle weakness and 
wasting and can include ocular or mental abnormalities. The most common type of 
childhood MD is Duchenne MD and is caused by a lack of dystrophin resulting in loss 
of the DAPC (Ervasti et al., 1990). As well as dystrophin, mutations in other 
DAPC/UAPC components can also lead to various types of MDs (Duclos et al., 1998). 
However, here we focus on MDs caused by mutations in DG or mutations in proteins 
involved in the regulation and post-translational modifications of DG – together 





Based on the Online Mendelian Inheritance in Man (OMIM) categorisation of 
diseases, muscular dystrophy dystroglycanopathies (MDDG) can be separated into 
three classes; (A) congenital MD (CMD) with brain/eye abnormalities, (B) CMD with 
mild brain abnormalities and (C) limb-girdle MD (LGMD) with A being the most and 
C being the least severe. The cause of MDDGs is predominantly hypoglycosylation of 
a-DG which reduces the ligand binding affinity and destabilises the ECM-
cytoskeleton link. They can also be classified as 1°, 2° and 3° dystroglycanopathies, 
depending on whether mutations affect dystroglycan itself, genes involved in the 
glycosylation of dystroglycan or genes involved in the metabolic pathways supplying 
precursors for the glycosylation enzymes. 
 
One of the most severe forms of MDDG is Walker-Warburg syndrome (WWS) which 
is a CMD and often results in death before the age of 1 year old. There has been one 
recorded example of WWS being caused by a mutation in DAG1. This mutation was 
a deletion of a cytosine at position 743 identified in 5 patients within a family, the 
deletion resulted in an absence of both a- and b-DG subunits (Riemersma et al., 
2015). Other mutations have been identified in a number of enzymes involved in a-
DG glycosylation (see section 1.1.2.2) including; POMT1 (Beltrán-Valero de Bernabé 
et al., 2002), POMT2 (Van Reeuwijk et al., 2005), fukutin (Beltrán-Valero de Bernabé 
et al., 2003), FKRP (Beltran-Valero de Bernabé et al., 2004), LARGE (van Reeuwijk et 
al., 2007), POMGNT2, POMK (Jae et al., 2013) and B3GALNT2 (Al Dhaibani et al., 
2018). WWS is clearly a heterogenous disease based on the number of gene 
mutations associated, however, it has been shown that the relationship between 
disease severity and a-DG glycosylation is also heterogenous. Patients with 
mutations in POMT1, POMT2 or POMGNT1 have good correlation between a-DG 
glycosylation and disease severity whereas patients with mutations in fukutin or 
FKRP have no significant relationship between a-DG glycosylation and disease 
severity (Jimenez-Mallebrera et al., 2009). However, generally patients with WWS 
have reduced levels of a-DG glycosylation (Beltrán-Valero de Bernabé et al., 2002). 
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Muscle-eye-brain (MEB) disease, as with WWS, is a severe CMD but with additional 
ocular defects or symptoms of epilepsy and lissencephaly. Patients life expectancy 
varies between 10-30 years (Santavuori et al., 1989). As with WWS there has only 
been one documented account of a mutation in DAG1 resulting in MEB disease (Geis 
et al., 2013). The mutation (c.2006G>T) is a missense mutation that results in a 
phenylalanine replacing a cystine at position 669 which is located within the b-DG 
subunit (Geis et al., 2013). This mutation has been investigated at the cellular level 
using the equivalent mutation in murine DG. Signorino and colleagues found that the 
mutation resulted in accumulation of the uncleaved precursor protein in the ER 
(Signorino et al., 2017). MEB disease is also a heterogenous disease as mutations 
have been identified in the a-DG processing enzymes; POMT2 (Mercuri et al., 2006), 
FKRP (Beltran-Valero de Bernabé et al., 2004) and POMGNT2 (Yoshida et al., 2001). 
These mutations result in the hypoglycosylation of a-DG (Kano et al., 2002).  
 
Fukuyama-type congenital muscular dystrophy (FCMD) is found almost exclusively in 
Japanese patients and is classified as an autosomal recessive disorder that can result 
in muscle, neuronal and eye abnormalities (Toda et al., 2000). The gene involved in 
this type of CMD is almost exclusively fukutin with the majority of patients having a 
3kb insertion into the 3’ untranslated region resulting in reduced mRNA stability and 
reduced protein levels (Kobayashi et al., 1998). As with other CMDs described above, 
FCMD results in a decrease in glycosylation of a-DG (Hayashi et al., 2001). 
 
LGMD is less severe than the other MDs discussed here but is still characterised by 
muscle weakness and sometimes associated with cardiomyopathy and mental 
insufficiency (eg LGMD2I). The disease onset ranges from adolescence to adulthood 
(Brockington et al., 2001). Two separate mutations in DAG1 have been found in 
patients with LGMD. In 2011 Hara and colleagues identified a missense mutation 
resulting in the substitution of a threonine residue for a methionine at position 192 
located in the a-DG subunit (Hara et al., 2011). The mutation was identified in a 
woman with LGMD who displayed some cognitive impairment. They further 
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characterised the mutation by investigating the equivalent mutation in a murine 
model and found the mutation prevents LARGE binding, thus inhibiting a-DG 
glycosylation (Hara et al., 2011). The second DAG1 mutation was identified more 
recently in 2018 by Dai and colleagues. They identified a homozygous missense 
mutation in a 64 year old Chinese male who suffered from mild LGMD. The mutation 
(c.2326C>T) results in the substitution of arginine for cystine at position 776. This 
substitution is within the NLS signal region of b-DG, however based on 
immunoblotting evidence the mutation significantly reduced levels of a-DG (Dai et 
al., 2018). In addition to mutations in DAG1, mutations have also been identified in 
FKRP (Brockington et al., 2001) and POMK (Strang-Karlsson et al., 2018). In LGMD 
patients instead of a complete absence of DG there appears to be a reduction in 
molecular mass suggesting glycosylation is reduced (Brown et al., 2004). 
 
In addition to those discussed above, two additional DAG1 mutations have been 
identified in a 7 year old male patient. However, he shows very mild MD phenotype 
with no evidence of muscle weakness or wastage. There is immunohistological 
evidence including few regenerating fibres and mild fibrosis that are suggestive of a 
MD phenotype. Both mutations, V74I and D111N, are located within the N-terminus 
of a-DG and resulted in reduced a-DG glycosylation. The reduced glycosylation 
phenotype was tested in DAG1 knockout cell lines and neither of the mutant forms 
rescued the phenotype but both resulted in regular expression and localisation of b-




The interactions between cells and the ECM are important when it comes to the 
progression of many cancer types, a loss or reduction in connectivity can result in 
tumour cell metastasis. With DG playing a key role in connecting cells with the ECM 
it is logical to assume that a reduction of DG or impaired function would lead to 
increased tumour metastasis. DG was first implicated in having a role in cancer as 
early as 1993 when it was determined that the DAG1 gene was mapped to a genomic 
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region suggested to be involved in tumour suppression (Ibraghimov-Beskrovnaya et 
al., 1993). Since then, a number of reports have focused on the expression and 
localisation of DG in many cancer cell types. High-grade primary prostate and breast 
cancers showed reduced levels of DG (Henry et al., 2001). Sgambato and colleagues 
also looked at breast cancers and colon cancers and found that levels of DG were 
reduced compared to control tissue. Interestingly, they find that the mRNA levels are 
unaffected but protein levels are decreased suggesting an increase in protein 
degradation, they also suggest that levels of DG negatively correlate with tumour 
grade and stage (Sgambato et al., 2003).  
 
The above studies have looked at DG as a whole, while some studies have decided to 
focus on either a- or b-DG. Sgambato and colleagues looked at the levels of a-DG in 
cervical, vulval and squamous tumours. They found in normal control cells more than 
80% were a-DG positive while this decreased depending on grade and invasiveness 
with only 2.6% of invasive cervical tumours being a-DG positive (Sgambato et al., 
2006). Shen et al (2012) investigated the expression of a-DG in gastric cancer and 
found that levels of DG decreased during tumour progression. They also found that 
a-DG expression correlated with patient survival, however, b-DG expression did not 
(Shen et al., 2012). In addition to a-DG protein levels, Shimojo et al (2011) 
investigated levels of a-DG glycosylation in prostate cancer. They argue that it is in 
fact a reduction in glycosylation which results in a decrease in laminin binding that 
correlates with increased tumour stage rather than a decrease in a-DG protein levels 
(Shimojo et al., 2011). Taken together, this data suggests that both a-DG protein 
levels and glycosylation states play a role in the progression of various types of 
cancer.  
 
b-DG has also been investigated for its role in various cancer cell types – some studies 
have focused on the relative protein levels while others have focused on various 
post-translational modifications. When levels of b-DG in oesophageal tumours were 
compared with healthy tissue it was found that the protein levels were decreased in 
the tumour cells however, the levels of mRNA were unchanged suggesting increased 
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degradation (Parberry-Clark et al., 2011) This was also observed in oral cancers with 
MMPs being implicated as the mechanism for b-DG degradation (Jing et al., 2004). 
Additionally, in a large scale study it was found that b-DG expression in oesophageal 
and colorectal adenocarcinomas, uretic transitional cell carcinoma and breast cancer 
was reduced or absent (Cross et al., 2008) while it was found in prostate cancer that 
b-DG expression was decreased and then re-expressed following metastasis 
(Mathew et al., 2013). 
 
As well as altered levels of b-DG in multiple cancer types there have been a number 
of reports of increased b-DG cleavage in cancer cells. The 30kDa fragment (discussed 
in section 1.1.3.2.3) was found to be expressed at higher levels in human breast 
cancer cell lines compared with controls. However, when they investigated a number 
of cancer cell lines some only had the 30kDa fragment, some had both the 43kDa and 
30kDa fragment and some simply had the 43kDa fragment (Losasso et al., 2000). 
Building on this, Cross et al (2008) found one prostate cancer cell line (PC3) had just 
the 43kDa fragment while another prostate cancer cell line (DU145) had both the 
30kDa and 43kDa fragments suggesting the differential cleavage of b-DG is not a 
universal sign of cancer. Additionally, Mitchell et al (2013) looked at the prostate cell 
line LNCaP and found that the cleavage events were cell density dependent. Work 
from the Winder lab suggest that the cleavage of b-DG in various cancer cells results 
in the localisation of the 30kDa fragment to the nucleus, however, the role the b-DG 
fragments may play in the nucleus of cancer cells has yet to be investigated (Mathew 
et al., 2013; Mitchell et al., 2013). 
 
1.2 Nuclear Dystroglycan 
 
1.2.1 Dystrophin Associated Protein Complex in the Nucleus 
 
Components of the DAPC were identified as nuclear, following the discovery of 
isoforms of Dp71 that appeared to preferentially localise to the nucleus of C2C12 
myoblasts and N1E-115 neuroblastoma cell lines (González et al., 2000). The two 
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isoforms were initially termed Dp71f and Dp71d; Dp71f was spliced at exon 78 while 
Dp71d was not (Aleman et al., 2001). Both isoforms were found in the nucleus but to 
varying degrees. The allocations of Dp71f and Dp71d were further divided into sub-
groups (Aragón et al., 2016) but we will discuss them in terms of Dp71f and Dp71d 
below. The nuclear localisation of Dp71 was further investigated by Marquez and 
colleagues in a study of PC12 neuronal cells. They found that during differentiation 
of PC12 cells the Dp71f was localised throughout the cell while Dp71d was localised 
almost exclusively to the nucleus (Marquez et al., 2003). In addition to the 
predominantly cytoplasmic localisation of Dp71f and nuclear localisation of Dp71d 
identified in C2C12, N1E-115 (González et al., 2000) and PC12 (Marquez et al., 2003) 
cells, this localisation difference is also observed in HeLa (Fuentes-Mera et al., 2006), 
a variety of mammary epithelial (Oppizzi et al., 2008), hippocampal neurone 
(Rodríguez-Munoz et al., 2015) and HEK293 (Nishida et al., 2016) cell lines. The 
nuclear import of Dp71d is not dependent upon a classical NLS but is instead 
dependent upon a ZZ domain, specifically ZZ-4 and requires Zn2+ to facilitate the 
import. Importin a2 and b1 were identified as the key importins required for nuclear 
localisation while CRM1 was required for nuclear export (Suárez-Sánchez et al., 
2014).  
 
While it is evident that Dp71, particularly Dp71d, localises to the nucleus of multiple 
cell types there is still limited understanding as to the physiological function of this 
localisation. Multiple studies have investigated the localisation of other DAPC 
components in order to determine whether Dp71 functions as part of a nuclear DAPC 
or if it has an independent nuclear function. To this end it was found that b-DG, b-
sarcoglycan, a/b-dystrobrevin, a/b-syntrophin and nNOS were identified in the 
nucleus of HeLa cells and found to form a nuclear DAPC complex (Fuentes-Mera et 
al., 2006); b-DG, a/b-dystrobrevin and a/b-syntrophin formed a DAPC in the nucleus 
of PC12 cells while a-, b- and 𝛿-sarcoglycan were not identified in the nucleus 
(Villarreal-Silva et al., 2010); b-DG, a/b-dystrobrevin and a/b-syntrophin also 
associate to form a nuclear DAPC in hippocampal neurones (Rodríguez-Munoz et al., 
2015). Additionally, the nuclear DAPC components were analysed in C2C12 
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myoblasts and C2C12 myotubes where it was found that a nuclear DAPC was present 
in both myoblasts and myotubes despite a lack of Dp71 expression in myotubes 
(Gonzalez-Ramirez et al., 2008). Taken together this evidence would suggest that 
nuclear Dp71 is associated with a nuclear DAPC in a range of cell lines and that the 
association of a nuclear DAPC does not explicitly require Dp71. 
 
In addition to determining whether Dp71 is associated with a nuclear DAPC a number 
of other studies have focused on understanding the role of Dp71 in the nucleus by 
studying the localisation within the nucleus, protein interactions and the 
consequences of perturbing Dp71 expression. In determining the localisation of Dp71 
within the nucleus Fuentes-Mera and colleagues used a high salt extraction method 
on HeLa cells to isolate the nuclear matrix which consists of the structural nuclear 
lamins, in addition to other proteins. Using this method they identified that Dp71, b-
DG and b-dystrobrevin associated with the nuclear matrix and also identified 
interactions between Dp71 and lamin B1 (Fuentes-Mera et al., 2006). In addition to 
HeLa cells, this interaction between Dp71 and lamin B1 was also implied in PC12 cells 
where Dp71 and lamin B1 were found to colocalise (Rodríguez-Muñoz et al., 2008; 
Villarreal-Silva et al., 2011). In addition to the interaction between Dp71 and lamin 
B1, Suarez-Sanchez and colleagues identified an interaction between Dp71 and the 
nuclear envelope (NE) protein emerin using Co-IP assays. Taken together this 
evidence would suggest that Dp71 localises just inside the NE where it associates 
with the nuclear lamina protein lamin B1 and the NE protein emerin.  
 
A number of studies have investigated the physiological effects of perturbing Dp71 
expression, an important point here is that the methods used resulted in the 
depletion of all Dp71 isoforms not just the predominantly nuclear Dp71d isoform. It 
was found that upon depletion of Dp71 in PC12 cells there was a decrease in total 
levels of b-DG, a/b-dystrobrevin and ε-sarcoglycan while levels of a1-syntrophin 
were unaffected but the localisation shifted to mostly nuclear (Villarreal-Silva et al., 
2010). When Dp71 depleted cells were compared with suitable controls they were 
found to have decreased cell proliferation but no difference in cell death. The 
depletion of Dp71 results in an increased number of cells in G0/G1 with delayed 
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G0/G1 to S phase transition. The Dp71 depleted cells also have a decrease in the 
levels of lamin B1 and no effect on levels of emerin or lamin A/C (Villarreal-Silva et 
al., 2011). Additionally, there is weak evidence suggesting that emerin may be 
mislocalised in Dp71 depleted cells (Suárez-Sánchez et al., 2014; Villarreal-Silva et al., 
2011). As the depletion of Dp71 results in the depletion of other nuclear DAPC 
components including b-DG it is important to determine whether the decrease in 
Dp71 is responsible for these observable phenotypes, or if it is the subsequent 
depletion of another DAPC component. 
 
1.2.2 Nuclear Import and Export of b-dystroglycan 
 
As described above, b-DG is translocated to the nucleus either independently or as 
part of a nuclear DAPC. However, a number of studies have aimed to understand the 
precise nuclear translocation pathway of b-DG. The initial study into the nuclear 
translocation of b-DG identified a bipartite NLS in the juxtamembrane position that 
consists of the sequences 776RKKRKGK782 and 793KK794 (Oppizzi et al., 2008). The 
mutation of these sequences resulted in a predominant cytoplasmic localisation. It 
was also identified that the nuclear translocation of b-DG was independent of 
glycosylation and precursor protein cleavage (Oppizzi et al., 2008). The presence and 
function of the NLS was also confirmed by Lara-Chacon and colleagues but they 
suggest only the 776RKKRKGK782 sequence was required and not the 793KK794 (Lara-
Chacón et al., 2010), this was also confirmed using mutational analysis. In this study 
they went a few steps further in identifying the import pathway by confirming the 
NLS sequence was able to translocate a tetra-GFP construct to the nucleus suggesting 
the sequence is solely responsible for nuclear translocation and is not dependent 
upon the rest of the b-DG protein. Through sequential mutational experiments they 
determined that the R779 and K780 were the key residues responsible for nuclear 
import. Additionally, it was determined that nuclear import was dependent upon 
nuclear pore complex (NPC) function and Ran activity and is mediated by an 
interaction between the NLS of b-DG and importin a/b with a KD of <1nM (Lara-
Chacón et al., 2010). 
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The importin a/b interaction with the NLS of b-DG was confirmed by another group 
who also found that the cytoskeletal organisation protein ezrin bound to the NLS of 
b-DG. However, when constitutively active ezrin was used there was an increase in 
nuclear localisation of b-DG while inactive ezrin resulted in cytoplasmic accumulation 
(Vásquez-Limeta et al., 2014). Mutation of the ezrin NLS did not inhibit nuclear 
accumulation of b-DG however, the deletion of the actin binding domain of ezrin did, 
suggesting that cytoskeletal organisation may play a role in the translocation of b-DG 
to the nucleus, this was validated by cytoskeletal disruption using cytochalasin B 
(Vásquez-Limeta et al., 2014).   
 
In order to determine whether the nuclear pool of b-DG was being internalised at 
the PM or was simply transported to the nucleus following post-translational 
modifications, non-permeable biotinylation experiments were carried out (Gracida-
Jiménez et al., 2017; Vásquez-Limeta et al., 2014). It was found that the nuclear b-
DG was in part generated from the PM. In an elegant set of experiments, it was 
successfully shown that b-DG had to pass from the ER to the Golgi before it is 
transported to the nucleus. It is also shown that the PM pool of b-DG then goes 
through clathrin-mediated endocytosis where it then enters the ER. The protein 
Sec61b is then required, through direct interactions, to export b-DG from the ER into 
the cytoplasm where it can then interact with Impa/b and be transported through 
the NPC into the nucleus (Gracida-Jiménez et al., 2017). Ultimately, the model for the 
translocation of b-DG to the nucleus is a retrograde one where it has to be 
transported to the PM where it is then internalised, incorporated into the ER and 
then released to the cytoplasm where it can ultimately enter the nucleus through the 




Figure 1.7 Schematic illustrating the trafficking of b-DG from the PM to the NE via the ER. Nuclear translocation 
of b-DG involves the retrograde trafficking from the PM to the NE. b-DG is post-translationally modified in the ER 
and then transported to the PM. At the PM b-DG is internalised and either transported to the NE or degraded. b-
DG transport into the nucleus requires a NLS and interacts directly with importin a/b. 
  
It has been established previously that phosphorylated b-DG, specifically 
phosphorylation at Y892, results in the increased internalisation of b-DG (Lipscomb 
et al., 2016; Sotgia et al., 2001). Thus, it stands to reason that phosphorylation may 
play a role in the nuclear translocation. However, there are conflicting results in the 
literature. In one study a phosphatase inhibitor is used to increase levels of 
phosphorylated b-DG and found an increased nuclear accumulation (Lara-Chacón et 
al., 2010). Furthermore, they used a mutant which replaced the Y892 with a 
phenylalanine which cannot be phosphorylated and somewhat surprisingly also 
found nuclear accumulation (Lara-Chacón et al., 2010). One experiment suggests 
unphosphorylated b-DG results in nuclear accumulation while the other suggests 
phosphorylation of b-DG results in nuclear accumulation. Additional evidence is 
found in the form of using a c-Src inhibitor, as c-Src is one of the kinases responsible 
for b-DG phosphorylation, inhibition of c-Src results in decreased phosphorylation of 
b-DG. This decrease in phosphorylation results in a decrease in nuclear b-DG 
suggesting phosphorylation may be required for nuclear translocation to the nucleus 
(Gracida-Jiménez et al., 2017). Taken together, these three experiments suggest a 
slightly different explanation than either author suggested. It would seem that while 





Y892 site and may be one, or a combination of other phosphorylation sites 
responsible for this regulation.  
 
There are some similarities between the nuclear import of Dp71 (see section 1.2.1) 
and b-DG, primarily the interaction between the protein and Impa/b which 
facilitates the translocation through the NPC. Additionally, there are some 
similarities between the nuclear export of Dp71 and b-DG, namely the interaction 
with the nuclear exporter CRM1 (Suárez-Sánchez et al., 2014; Vélez-Aguilera et al., 
2018). Nuclear accumulation of b-DG occurs when cells are treated with leptomycin 
B (LMB) which specifically inhibits CRM1. A direct interaction between b-DG and 
CRM1 was also demonstrated using multiple pull-down assays. This interaction 
occurs between the nuclear export signal (NES) of b-DG and CRM1. The NES is located 
within the transmembrane region consisting of 763ILLIAGIIAM772 where 763ILL765 were 
determined to be the key hydrophobic residues - based on mutation experiments. 
Given the NES is located within the transmembrane region it was also shown that 
nucleoplasmic b-DG had a much higher turnover rate than the PM pool (Vélez-
Aguilera et al., 2018). 
 
1.2.3 Role of b-dystroglycan in the Nucleus  
 
1.2.3.1 Nuclear Structure and Nuclear Protein Interactions 
 
It is clear that b-DG is present in the nucleus and that it localises to the NE via the TM 
domain. Given that the NE is a double membrane it needs to be determined whether 
b-DG resides in both the outer nuclear membrane (ONM) and the inner nuclear 
membrane (INM) or if it is actually restricted to one of these. Using immuno-electron 
microscopy, it was determined that nuclear b-DG localises to just the INM and wasn’t 
found at the ONM. Interestingly, when the soluble nuclear proteins were removed 
by an extraction buffer b-DG remained and appeared to be associated with the 
nucleoskeleton (Martínez-Vieyra et al., 2013). Additionally, nuclear b-DG has been 
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identified in the nucleoplasm and at the nucleoli (Azuara-Medina et al., 2019; 
Martínez-Vieyra et al., 2013). 
 
The nucleoskeleton, as the name implies, makes up the structural component of the 
nucleus and is responsible for the overall shape and integrity of the nucleus in 
addition to being responsible for the mechanical properties. The key components of 
the nucleoskeleton are the lamins, lamins are type V intermediate filaments and are 
divided into A and B types. Both types form a meshwork of oligomers just below the 
NE where they are anchored to both the NE and the chromatin via protein 
interactions (Nmezi et al., 2019; Ranade et al., 2019; Shimi et al., 2015). As b-DG is 
an INM protein it is suggested that it may be involved in anchoring the lamins to the 
NE thereby ensuring the shape and integrity of the nucleus. It has been shown that 
when DG is perturbed, either by specific knockdown (KD) of b-DG or by knockout 
(KO) of the DAG1 gene, there is a resultant disruption to the nuclear shape. In the KD 
experiment there was a significantly higher proportion of nuclei determined 
abnormal, this included nuclei that had irregular shape, nuclear blebbing or was 
either double or half the size of the control nuclei (Martínez-Vieyra et al., 2013). This 
result was confirmed in the KO experiments; a significantly higher proportion of 
abnormal nuclei in the KO condition compared with the control were observed – 
abnormal was defined as fissured, kidney shaped or blebbed (Gómez-Monsiváis et 
al., 2020). An additional study of DG KO cells confirmed these observations, they 
found that a significantly higher proportion of KO nuclei have nuclear blebs (8% and 
10% for the KO samples and just 4% for the control), KO nuclei also have a 
significantly lower nuclear circularity compared with the controls and have a 
significantly larger nuclear area (Jimenez-Gutierrez et al., 2020). These experiments 
were all carried out in mouse C2C12 myoblasts. Taken together these perturbation 
experiments strongly suggest b-DG plays a role in the maintenance of nuclear shape 
and integrity in C2C12 myoblasts. 
 
As it is clear that b-DG is localised to various regions within the nucleus it is important 
to understand its various interacting partners in order to understand its function. 
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Using a combination immunofluorescence microscopy and classical biochemical 
techniques a number of binding partners have been identified. A direct interaction 
has been determined between b-DG and p80-coilin which is a protein associated with 
Cajal bodies within the nucleus (Martínez-Vieyra et al., 2013). Additional interactions 
have been identified between b-DG and a number of nucleoli proteins including 
Nopp140 (Martínez-Vieyra et al., 2013), upstream binding factor (UBF) and B23 
(Azuara-Medina et al., 2019). However, no direct interaction could be detected 
between b-DG and RNA polymerase I or SC35 a marker protein for splicing speckles. 
Additionally, no interaction could be confirmed between b-DG and the nuclear pore 
complex proteins Nup62 or Tpr. As b-DG was extracted as part of the insoluble 
nucleoskeleton it would be expected that it interacts with at least one component of 
the nuclear lamina. b-DG has been shown in multiple assays that it interacts directly 
with lamin A/C and lamin B1 (Martínez-Vieyra et al., 2013). In addition to the nuclear 
lamina, b-DG has been shown to interact directly with the INM protein emerin which 
also plays a role in connecting the nuclear lamina to the INM (Gómez-Monsiváis et 
al., 2020; Martínez-Vieyra et al., 2013). 
 
1.2.3.2 Regulation and Localisation of Emerin and Lamin B1 
 
1.2.3.2.1 Lamin B1 
 
As discussed above lamin B1 was identified as an interacting partner of Dp71 as well 
as b-DG. More recent studies have also confirmed the interaction between b-DG and 
lamin B1 and have also investigated how perturbing b-DG (or DG) affects the 
regulation and localisation of lamin B1. When investigating the effects on lamin B1 
following b-DG (or DG) perturbation either by KD, KO or use of a NES mutant resulting 
in excessive nuclear accumulation, it is reported that the overall protein levels of 
lamin B1 are reduced compared with controls (Gómez-Monsiváis et al., 2020; 
Martínez-Vieyra et al., 2013; Vélez-Aguilera et al., 2018). Despite the reduction in 
protein levels the mRNA transcript levels are unaffected suggesting that a lack of b-
DG may reduce the stability of lamin B1 resulting in faster turnover. This was indeed 
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confirmed in the NES mutant study where accumulation of nuclear b-DG resulted in 
accelerated protein turnover via the nuclear proteosome (Vélez-Aguilera et al., 
2018).  
 
The DG perturbation studies described have also identified mislocalisation of lamin 
B1 and some phenotypes associated with lamin B1. When b-DG was specifically 
knocked down it was found that lamin B1 was mislocalised from the nucleus and 
formed distinct aggregates surrounding the nucleus (Martínez-Vieyra et al., 2013). 
This same abnormal staining was observed upon nuclear accumulation of b-DG via 
the NES mutant (Vélez-Aguilera et al., 2018). These two studies taken together 
suggest that it isn’t just a decrease in b-DG levels responsible for maintaining correct 
lamin B1 localisation but also an increase which implies that the nuclear levels of b-
DG are finely tuned and disruption of this results in inappropriate localisation of 
lamin B1.  
 
It is important to note that despite lamin A/C being implicated as a binding partner 
of b-DG there is no evidence that reducing or eliminating b-DG results in a decrease 
in levels of lamin A/C or any abnormal localisation. However, it does appear that the 
nuclear accumulation of b-DG results in a decrease in total levels of lamin A/C but 
has no effect on mRNA levels or the protein localisation (Martínez-Vieyra et al., 2013; 




As with lamin B1, emerin has been identified as a binding partner for b-DG in multiple 
studies and the mechanism of that interaction has been further elucidated. The 
interaction between the two NE proteins is facilitated primarily through their TM 
domains but additional regions – particularly the C-terminus of emerin – are required 
for tighter binding. The key residues within the TM domains, Met770 and Thr751 for 
b-DG and Ala238 and Phe236 for emerin were determined by computer modelling 
but are yet to be confirmed through mutagenesis assays. The dissociation constant 
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for the interaction between full-length b-DG and full-length emerin is 3.32nM as 
determined by surface plasmon resonance implying a very strong interaction 
(Gómez-Monsiváis et al., 2020).   
 
Multiple studies have investigated the effects on emerin caused by perturbing b-DG 
(or DG) and the results are similar to those observed for lamin B1. The KD, KO or 
nuclear accumulation of b-DG (or DG) resulted in a decrease in overall emerin levels 
with no effect on the mRNA levels (Gómez-Monsiváis et al., 2020; Martínez-Vieyra et 
al., 2013; Vélez-Aguilera et al., 2018). The turnover of emerin was also shown to be 
increased in DG KO cells suggesting a decrease in protein stability as observed for 
lamin B1. Interestingly, in Emery-Dreifuss muscular dystrophy (EDMD) patient 
samples lacking emerin there was a decrease in levels of b-DG and NE staining 
suggesting the regulation and localisation may be reciprocal (Gómez-Monsiváis et al., 
2020). 
 
As with lamin B1, the localisation of emerin was disrupted in b-DG (or DG) perturbed 
cells. These cells displayed an emerin staining pattern similar to lamin B1 upon DG 
perturbation with aggregates forming both within and around the nucleus and a 
distinct loss of the NE ring staining (Martínez-Vieyra et al., 2013; Vélez-Aguilera et al., 
2018).  
 
Emerin is required for a number of processes within the nucleus and essential for 
correct cell functioning. These include the maintenance of the centrosome 
(Salpingidou et al., 2007) and regulating b-catenin activity which is an intracellular 
signal transducer involved in the Wnt signalling pathway (Markiewicz et al., 2006). 
These processes were investigated in b-DG (or DG) perturbed cells; when b-DG was 
knocked down there was an increase in the average distance between nucleus and 
centrosome to a similar extent as observed in emerin-null cells; a significantly higher 
proportion of KD cells with multiple centrosomes (17%) compared with the control 
(2%) was also observed (Martínez-Vieyra et al., 2013). A similar increase in nuclear-
centrosome distance was observed in both DG KO cells and cells expressing the b-DG 
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NES mutant resulting in nuclear accumulation (Gómez-Monsiváis et al., 2020; Vélez-
Aguilera et al., 2018). In addition to centrosomal organisation emerin plays a role in 
the regulation of b-catenin. Upon nuclear accumulation of b-DG there was a 2-fold 
increase in b-catenin activity compared with the controls (Vélez-Aguilera et al., 
2018). However, this was not investigated in either the DG KO or the b-DG KD. 
Additionally, it hasn’t been confirmed that the increased nucleus-centrosome 
phenotype is due to the mislocalisation of emerin or whether b-DG may play a more 
direct role.   
 
1.2.3.3 Nucleoli Organisation and rRNA Transcription 
 
As nucleoli organisation has been attributed, in part, to lamin B1 (Martin et al., 2009); 
the evidence suggesting localisation of b-DG to the nucleoli and a direct interaction 
determined between b-DG and Nopp140 it would appear that b-DG may be playing 
some functional role at the nucleoli. This functional role has been hinted at in b-DG 
KD cells and DG KO cells where there was a decrease in average size of nucleoli 
compared with the relevant control (Jimenez-Gutierrez et al., 2020; Martínez-Vieyra 
et al., 2013). Additionally, when b-DG accumulates in the nucleus due to mutation of 
the NES it was determined that the nucleoli of these cells where both smaller in size 
and decreased in number (Vélez-Aguilera et al., 2018). 
 
More recently, a more detailed investigation into the role of b-DG at the nucleolus 
has been carried out which suggests b-DG may play a role in regulating transcription 
of rRNA (Azuara-Medina et al., 2019). In this study they identified a 30kDa fragment 
of b-DG which strongly localised to the nucleoli and increased in proportion relative 
to full-length b-DG following nucleoli stress. This fragment consists of the 
cytoplasmic domain of b-DG without the TM domain which they term the 
intracellular domain (ICD). Using multiple biochemical assays, they determined that 
both full-length b-DG and the ICD interact directly with nucleoli protein UBF and to a 
lesser extent B23. These interactions also demonstrated a preference for the ICD 
over full-length b-DG. They then investigated the effect of knocking down b-DG on 
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these proteins and found reduced levels of the nucleoli proteins UBF, B23 and 
fibrillarin despite no direct interaction between fibrillarin and b-DG. Additionally, 
overexpression of a GFP-b-DG ICD construct also resulted in mislocalisation of UBF 
but not B23 and results in a decrease in RNA polymerase I activity. Most interestingly, 
they suggest that KD of b-DG resulted in the nucleoli becoming larger and the total 
number decreasing compared with the control (Azuara-Medina et al., 2019). This is 
a direct contradiction of their previous results suggesting b-DG KD cells had smaller 
nucleoli (Martínez-Vieyra et al., 2013). These experiments were done in the same cell 
line (C2C12 mouse myoblasts) but with different RNAi molecules. The disparity 
between these two experiments calls into question the validity of these results. 
Despite this the authors further investigate the role of b-DG ICD at the nucleoli. They 
find KD of b-DG results in a decrease in levels of pre-rRNA 18S and an increase in 28S 
and further determine an interaction between b-DG and the promoter region of the 
rRNA. In this study they were unable to identify a nucleoli localisation or DNA binding 
sequence within the b-DG sequence suggesting that DNA binding is via interactions 
with other DNA binding proteins. Taken together, these experiments demonstrate a 
direct interaction between b-DG and nucleoli proteins with KD of b-DG resulting in 
decreased 18S and increased 28S rRNA expression while overexpression of GFP-b-
DG-ICD resulted in increased 18S and decreased 28S rRNA expression suggesting b-
DG plays a regulatory role in rRNA expression (Azuara-Medina et al., 2019). 
 
1.2.3.4 Cellular Senescence 
 
In two recent studies, it was noted that overexpression and the nuclear accumulation 
of b-DG in cells resulted in a decreased growth rate compared with controls (Azuara-
Medina et al., 2019; Vélez-Aguilera et al., 2018). These results have recently been 
further expanded with evidence from DG KO cells which provides evidence for a 
decreased growth rate in cells lacking DG (Jimenez-Gutierrez et al., 2020). The 
decreased growth rate was investigated further to understand what caused this 
phenotype. It was found that a higher proportion of KO cells were in G0/G1 phase 
compared with the controls (Jimenez-Gutierrez et al., 2020), this was also observed 
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in the NES mutant (Vélez-Aguilera et al., 2018). Cell cycle progress at G0/G1 phase is 
indicative of senescent cells and it was found, following a b-galactosidase senescence 
assay that 20-25% of DG KO cells were senescent compared with just 5% for wild type 
(WT) cells. This senescence phenotype was also confirmed using other senescence 
markers including an increase in nuclear and cell size, a decrease in heterochromatin 
as determined by H3K9me3 intensity and decrease in average nucleoli area. 
Additionally, cells were treated with the senescence inducing molecule sodium 
butyrate. Treatment for 10 days induced senescence in almost 100% of WT cells but 
after 5 days of treatment 60-70% of KO cells were senescent compared with just 30% 
of WT. These data suggest the DG KO cells are already primed for a senescence 
phenotype and become senescent more readily. In order to determine what causes 
the senescence they investigated the mitotic process and levels of DNA damage. 
During mitosis there were significantly more mitotic abnormalities in DG KO cells 
compared with control – this included multipolar mitotic spindles and 
multidirectional alignment of chromosomes. This data would be in agreement with 
the increased number of centrosomes observed in KD and NES mutant cells 
described above. Following cell treatment with thymidine to release the cell cycle 
into S phase they found an increase in DNA damage, DNA damage response, the 
proportion of cells with nuclear blebs and telomere shortening in DG KO cells 
compared with WT cells. Taken together these data suggest that errors during 
mitosis as caused by multipolar spindles and multidirectional chromosome alignment 
lead to increased DNA damage which results in increased DNA damage induced 
senescence (Jimenez-Gutierrez et al., 2020).  
 
1.3 Project Hypothesis 
 
Dystroglycan plays a central role in maintaining a mechanical link between the 
extracellular matrix and the cytoskeleton with b-DG being the key anchor for the 
whole DAPC. In mouse C2C12 myoblast cells, b-DG localises to the nucleus where it 
is suggested to interact with a range of nuclear proteins including components of the 
nucleoskeleton. Disruption of DG in this cell line results in abnormal localisation and 
levels of structural nuclear proteins lamin B1 and emerin. 
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Based on the results described in mouse C2C12 myoblasts, one aim of this project 
was to investigate if the same observations are made in human myoblast cell lines. 
Additionally, a potential disruption of structural proteins lamin B1 and emerin would 
be expected to result in a change in the mechanical properties of the nucleus. 
Therefore, the overall aim of this project was to understand whether disrupting DG 
in a human myoblast cell line affects the mechanical properties of nuclei. This was 
investigated using a combination of biochemical and microscopy techniques 




2 Materials and Methods 
 
2.1 Bacteria and Molecular Biology 
 
2.1.1 Bacterial Growth 
 
Escherichia coli (DH5a) were grown in 5ml 2xYT liquid bacterial growth media (16g 
Tryptone, 10g Yeast extract and 5g NaCl made up to 1L with dH2O) at 37°C in a 
shaking incubator overnight. 
 
In order to generate competent bacteria 1ml of the overnight culture was transferred 
to 100ml of 2xYT and placed in the shaking incubator at 37°C. Cells were incubated 
until they reached an OD600 of between 0.4-0.6 AU, this was determined using a 
spectrophotometer (7315 spectrophotometer, Jenway). When the culture had 
reached the required density, the culture was centrifuged (Sigma 1-15K) at 700x g for 
10 minutes at 4°C in order to pellet the cells. The supernatant was discarded, and the 
cell pellet was resuspended in 10ml of ice cold CaCl2 at a final concentration of 
100mM and incubated at 4°C for 2 hours. The cell suspension was then centrifuged 
at 700x g at 4°C for 10 minutes in order to pellet the cells. The supernatant was 
discarded, and the pellet was resuspended in 2ml of 100mM CaCl2 and 15% glycerol. 
The cell suspension was then aliquoted into 100ml aliquots and flash frozen using 
liquid nitrogen. They were then stored at -80°C until they were used.  
 
2.1.2 Transformation of Competent Bacteria 
 
The competent DH5a cells described in section 2.1.1 were used for transformation. 
The cells were thawed on ice and then incubated on ice for a further 10 minutes. The 
plasmid DNA (100-200ng) was added to the competent cells and incubated on ice for 
30 minutes. Following the 30 minute incubation the bacterial cells were heat shocked 
at 42°C for 30 seconds and then returned to the ice for 2 minutes. Following heat 
shock, 500ml of non-selective 2xYT was added and the cell suspension was incubated 
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at 37°C for 1 hour in the shaking incubator to allow recovery. The bacterial 
suspension was then centrifuged at 3000x g for 2 minutes to pellet the cells. The cell 
pellet was then resuspended in 100ml of 2xYT and plated on agar plates containing 
selection antibiotic. The plates were incubated at 37°C overnight.  
 
2.1.3 Bacterial Glycerol Stocks 
 
Transformed bacterial stocks were produced by selecting a colony from the agar 
plate and culturing it in 5ml 2xYT with the appropriate antibiotic. The culture was 
incubated overnight at 37°C in the shaking incubator. 750ml of the overnight culture 
was then added to 750ml of 50% glycerol and stored at -80°C.  
 
2.1.4 Plasmid Purification 
 
Plasmid purification was achieved using mini- or maxiprep kits (Qiagen) for either 
small- or large-scale purifications. The plasmids were purified from transformed E. 
coli cells. The purification was carried out as per the manufacturer’s instructions. The 
cells were lysed using an alkaline lysis solution. The DNA was then bound to an anion 
exchange membrane (miniprep) or resin (maxiprep) and a salt wash was used to 
remove any impurities. The DNA was then eluted from the membrane or resin and 
subjected to isopropanol precipitation to concentrate and desalt the DNA. The 
concentrated DNA was then dissolved in sterile dH2O and the concentration was 
determined using the NanoDrop Lite (Thermo Fisher Scentific, UK). The DNA solution 
was then stored at -20°C until use.  
 
2.1.5 DNA Sequencing 
 
DNA sequencing was carried out by MRC PPU DNA sequencing and services and 




2.2 Cell Culture 
 
2.2.1 Growth of Cells 
 
Human myoblast (Table 2.1) (Mamchaoui et al., 2011; Santos-Zas et al., 2017) cell 
lines were maintained in Skeletal Muscle Cell Growth Media (PromoCell). Cells were 
grown to 70-80% confluency, determined on an inverted microscope (CETI) at 10x 
magnification. They were grown at 37°C and 5% CO2 in a humidified environment. 
Cells were passaged using trypsin-EDTA (0.05% trypsin, 0.5mM EDTA, pH 7.4). 
Following dissociation of cells, media was added and centrifuged at 100x g (11030 
rotor, Sigma) for 3 minutes. Cells were resuspended in media and plated at the 
required density in plastic culture flasks (Greiner Bio-one). 
 
Table 2.1 List of cells used. 
Cell Type Original clone number Referred to in text 
Human Myoblast KM155  WT 
gRNA Control Clone 1.B8 Control 
DAG1 Knockout Clone 1.B6 DAG1 KO A 
DAG1 Knockout Clone OG DAG1 KO B 
DAG1 Knockout  Clone 2.D8 DAG1 KO C 
DAG1 Knockout Clone 1.G4 DAG1 KO D 
DAG1 Knockout Clone 1.G7 DAG1 KO E 
 
 
2.2.2 Cell Counting 
 
20µl of cell suspension was added to 20µl 0.4% Trypan Blue (Lonza, US) and 20µl of 
this mixture added to the haemocytometer. The haemocytometer is etched with 4 x 
1mm2 squares, the number of cells in each square was counted, cells that had taken 
up Trypan Blue were not counted. This was done using a 10x magnification on an 
inverted microscope (CETI). Each mm2 contains 100nl of liquid so to calculate the 
number of cells per ml the average number of cells must be multiplied by 104. The 








2.2.3 Cell Seeding Based on Confluency 
 
Cell seeding based on confluency was used for cell density experiments. The initial 
cell density was determined using an inverted microscope (CETI) at 10x 
magnification. The area of the flask or dish that was being seeded was divided by the 
area of the initial flask to give a scaling value. The cells were centrifuged at 100x g 
(11030 rotor, Sigma) for 3 minutes and the pellet was resuspended in 10ml of media. 
The scaling value is the same as the volume of cell suspension in ml to get the same 
confluency as the initial flask, the correct confluency for each experiment was then 
calculated based on this.  
 
2.2.4 Cell Synchronisation with Thymidine Block 
 
As described by Jimenez-Gutierrez et al (2020). Cells were grown to 20-30% 
confluency as determined by an inverted microscope (CETI) at 10x magnification. 
Cells were treated with 2mM thymidine (Sigma-Aldrich) and cultured at 37°C, 5% CO2 
for 18 hours. Thymidine was then removed and replaced with fresh media and 
cultured for 9 hours. 2mM thymidine was then added and incubated for 18 hours. 
Cells were then either harvested for experiments and analysis or fresh media was 
added and harvested at indicated time points. 
 
2.2.5 Cell Synchronisation with Serum Starvation 
 
The system was similar to that outlined by Dreesen et al. (2013) and Villarreal-Silva 
et al. (2011). Cells were seeded at the required density and grown for 24 hours at 
37°C, 5% CO2 using Skeletal Muscle Cell Growth Media (PromoCell) with supplements 
added. Cells were then washed twice with 1 x phosphate buffered saline (PBS; 
137mM NaCl, 10mM phosphate, 2.7mM KCl, pH 7.4) and Skeletal Muscle Cell Growth 
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Media (PromoCell) without supplements (serum free) was added and cells were 
incubated at 37°C, 5% CO2 for 24 hours. Following serum starvation for 24 hours cells 
were washed twice with 1x PBS and fully supplemented media was added. Cells were 
then harvested either immediately or at the indicated time points.  
 
2.2.6 Lipofectamine 2000 Cell Transfection 
 
Transfecting DNA into myoblast cell lines used Lipofectamine 2000 and was carried 
out as per the manufacturer’s instructions. Cells were seeded and grown to a high 
density (>80%) in antibiotic free cell growth media. Plasmid DNA (1-5µg) was added 
to 100µl low-serum media and 2µl (per well of a 12 well dish) lipofectamine 2000 
was added to 100µl low-serum media and incubated at room temperature for 5 
minutes. 100µl of lipofectamine and media mixture was added to 100µl of DNA and 
media mixture and incubated for 20 minutes at room temperature. Following 
incubation, the 200µl of lipofectamine, DNA and media mixture was added to each 
well containing cells. The cells were then incubated at 37°C and 5% CO2 for 6 hours 
before changing media. Cells were then grown for a further 18 hours to allow protein 





2.3 Atomic Force Microscopy 
 
2.3.1 Whole Cell Sample Preparation 
 
Cells were seeded at 60% confluency in 40 x 11 mm petri dishes (TPP®) and incubated 
at 37°C, 5% CO2 for 24 hours before measurements. For cell synchronisation 
experiments cells were seeded at 40% confluency and incubated at 37°C, 5% CO2 for 
24 hours. For synchronisation, serum free media was then added and incubated as 
above for 24 hours, regular media was added prior to measurements, the sample 
was measured within an hour of synchronisation release.  
 
2.3.2 Trichostatin A Treatment 
 
Cells were seeded at 40% confluency and incubated at 37°C, 5% CO2 for 24 hours. 
Cells were then washed and 300nM of Trichostatin A (TSA; Cell Guidance Systems, 
UK) in serum free media was added to the sample. Cells were incubated at 37°C, 5% 
CO2 for 24 hours. Prior to measurement the cells were washed with 1 x PBS and 
300nM of TSA in normal media was added to the sample. The sample was then 
measured within an hour of synchronisation release (Hobson et al., 2020).  
 
2.3.3 Cytochalasin D Treatment 
 
Cells were seeded at 40% confluency and incubated at 37°C, 5% CO2 for 24 hours. 
Cells were then washed and 500nM of Cytochalasin D (CytoD; Thermo Fisher 
Scientific, UK) in serum free media was added to the sample. Cells were incubated at 
37°C, 5% CO2 for 24 hours. Prior to measurement the cells were washed with 1 x PBS 
and 500nM of CytoD in normal media was added to the sample. The sample was then 
measured within an hour of synchronisation release.  
 
2.3.4 Poly-L-Lysine Coating of Dishes 
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0.01% Poly-L-lysine solution with molecular weight 150,000-300,000 Da (Sigma-
Aldrich) was added to the petri dish and incubated at room temperature for 30 
minutes. Poly-L-lysine solution was then removed, the petri dish was then washed 
twice with sterile H2O. The dish was then left at room temperature for at least 1 hour 
to dry to ensure complete coating of the surface.  
 
2.3.5 Nuclear Sample Preparation 
 
This protocol was adapted from the cell fractionation protocol described in Martínez-
Vieyra et al. (2013). Cells grown to 80% confluency in T175 flask were washed twice 
in ice-cold 1x PBS and scraped into 2ml of ice-cold 1x PBS. Cells were then centrifuged 
at 3,500x g at 4°C for 15 minutes (Sigma 1-15K). The pellet was then resuspended in 
0.5ml fractionation TM buffer (10mM Tris-HCl pH 8.0, 2mM MgCl2 0.5mM PMSF, 1x 
protease inhibitor cocktail (Roche)) and incubated on ice for 10 minutes. 0.5ml of 2% 
Triton X-100 (Sigma-Aldrich) in PBS was then added to the cell suspension and 
incubated on ice for 10 minutes. The cell suspension was then transferred to a 
Dounce homogeniser (Wheaton) and the cells were homogenised with between 18-
26 strokes, the membrane integrity was monitored using an inverted microscope 
(CETI) at 10x magnification. The cell suspension was then centrifuged at 3,500x g at 
4°C for 15 minutes. The supernatant containing the non-nuclear fraction was saved 
for further analysis. The pellet contained the nuclear fraction and was resuspended 
in 0.5ml of fractionation buffer I (0.32M sucrose, 3mM CaCl2, 0.1mM EDTA, 10mM 
Tris-HCl pH 8.0, 1mM DTT, 0.5mM PMSF and 0.5% NP-40).  0.5ml of fractionation 
buffer II (2M sucrose, 0.1mM EDTA, 10mM Tris-HCl pH 8.0, 1mM DTT and 0.5mM 
PMSF) was then added to the nuclear suspension and pipetted to ensure thorough 
mixing. In an ultra-centrifuge tube (Beckman) 1ml of fractionation buffer II was 
added and the nuclear suspension was laid on top with 3ml of fractionation buffer I 
being laid on top of the nuclear suspension. This produces a sucrose gradient which 
was then centrifuged at 80,000 rpm using the MLA-80 rotor at 4°C for 1 hour. The 
supernatant was then removed, the pellet was resuspended in 4ml PBS, this was then 
added to the poly-L-lysine (Sigma) coated 40 x 11 mm petri dishes (TPP®) and left to 
attach for at least 30 minutes. After at least 30 minutes the PBS was removed and 
 72 
fresh PBS was added, PBS was then removed and cell growth media was added ready 
for measurements. 
 
2.3.6 AFM Cantilever Preparation 
 
Tipless MLCT-O10 AFM probes (Bruker) were used, all triangular cantilevers (A,C,D,E 
and F) were removed using tweezers while the rectangular cantilever was retained 
(spring constant between 0.020-0.025N/m, length between 195-205mm, width 
between 15-25mm). The cantilever was then mounted on the AFM (Nanowizard III, 
JPK Instruments). Microscope slides were cleaned using Piranha solution (80% (v/v) 
H2SO4, 20% (v/v) H2O2) for at least 1 hour, washed with isopropanol and allowed to 
dry. The UV-curing adhesive (Norland Optical Adhesive 81, Norland) was added to 
the microscope slide and spread using a scalpel blade, the 5µm diameter polystyrene 
spheres (Sigma) were added to the slide above the adhesive and the slide was then 
placed on the microscope (Nikon A1). Using the manual height adjustment, the 
cantilever was lowered to contact the adhesive and retracted, followed by lowering 
to remove excess adhesive and then again to pick up the sphere. The cantilever was 
then removed from the mount and the adhesive was cured using UV for at least 5 
minutes.  
 
2.3.7 Whole Cell Data Acquisition 
 
Data was acquired using the JPK Nanowizard III with either modified tipless MLCT-
010 (described in section 2.4.6) with a nominal spring constant of 0.02N/m or MLCT-
SPH-5UM (Bruker) with a nominal spring constant of 0.03N/m. The JPK Nanowizard 
was mounted on a Nikon A1 inverted microscope. Prior to measurements the 
cantilever was calibrated using the thermal vibration method to determine the spring 
constant. Prior to measuring the cells, the sensitivity of the cantilever in the cell 
growth media at 37°C was determined using the contact-based method. Using a 40x 
magnification on the optical microscope a single cell was identified and either the 
area over the nucleus or an area of the cytoplasm was measured with an approach 
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speed of 5µm/s and a setpoint of 3nN. Each area of the sample was measured at 
least 10 times to give an average of each sample point and allowed the removal of 
unsuitable curves while maintaining multiple useable curves for each sample point. 
For each experiment at least 15 cells were measured for each sample.  
 
2.3.8 Nucleus Data Acquisition 
 
As described in section 2.4.7 except only functionalised MLCT-O10 cantilevers were 
used with an extend speed of 3µm/s and a setpoint of 1nN. For each experiment at 
least 10 nuclei were measured for each sample.  
 
2.3.9 Data Analysis 
 
Data analysis was carried out using the JPK SPM data processing software. The curves 
for each sample point are processed as a batch where the baseline is subtracted to 
return everything to zero, the offset point is adjusted to determine the point of 
contact, the correct hight for cantilever bending is determined by subtracting the 
sensitivity measurement and converts the force-distance curve into a force-
indentation curve. Any unsuitable curves are identified manually and are discarded 
during this process and are not included in the later analysis. Following this the 
elasticity for each curve is determined from the indentation using the Hertz/Sneddon 
model. The average Young’s modulus for each sample point is then determined using 







2.4.1 Immunofluorescence Microscopy 
 
Cells were seeded at required density in a 6 well or 12 well plate containing 13mm 
coverslips. 24-hours post-seeding the media was aspirated and cells were washed 
twice with 1x ice-cold PBS. 2ml of 3.7% (v/v) paraformaldehyde (PFA; Sigma-Aldrich) 
was added to each well and incubated at room temperature for 10 minutes to fix the 
cells. The PFA was then removed, and cells were washed twice with 1x ice-cold PBS. 
Cells were then permeabilised using 2ml of 0.2% Triton X-100 (Sigma-Aldrich) in PBS 
and incubated at room temperature for 3 minutes. The Triton X-100 solution was 
then removed and cells washed twice with 1x ice-cold PBS and kept at 4°C until 
staining. Coverslips were blocked using blocking buffer (3% BSA (w/v), 5% FBS (w/v) 
in PBS) for 1 hour in a humidified environment, following this 10µl of primary 
antibody (Table 2.2) diluted in blocking buffer was added to each coverslip and 
incubated for at least 2 hours in a humidified environment at 4°C. Coverslips were 
then washed three times in 1x PBS and 10µl of fluorescent conjugated secondary 
antibody (Table 2.3) diluted in blocking buffer was added to each coverslip and 
incubated at room temperature in a humidified environment for 1 hour. The 
coverslips were then washed twice in 1x PBS and once in dH2O and allowed to dry. 
Following drying they were mounted onto 4µl hydromount (National Diagnostics) 
containing 2.5% 1,4-Diazabicyclo[2.2.2] octane (DABCO; Sigma-Aldrich) as an 
antifade preservative and the nuclear counterstain DAPI (Sigma-Aldrich) at 10ng/ml 
on glass slides (Fisher, 0.8-1.0mm). Coverslips were secured using nail varnish and 
stored in the dark at 4°C until imaging.  
 
Table 2.2 List of primary antibodies used for immunofluorescence detection. 
Antibody Target Species Company Concentration 




Rabbit  1:20 
JAF1 (b-DG) Rabbit  1:500 
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LG5 (b-DG) Rabbit  1:500 
C-20 (b-DG) Goat Santa Cruz 1:250 
Lamin A/C Mouse Cell Signalling 
Technology (4C11) 
  
Lamin B1 Rabbit ProteinTech 1:500 




Emerin Rabbit Santa-Cruz (FL-
254) 
1:250 
gH2AX Mouse EMD Millipore 1:250 
H3K9me3 Rabbit BioVision 1:200 
GFP Mouse Roche 1:250 
HA-tag Rat Roche 1:250 
 
 
Table 2.3 List of secondary antibodies used for immunofluorescence detection. 
Antibody Target Species Company Concentration 
Anti-Mouse 
AlexoFlore 594 
Goat Life Technologies  1:500 
Anti-Rabbit 
AlexoFlore 594 
Goat Life Technologies 1:500 
Anti-Rabbit 
Alexoflore 488 
Donkey Life Technologies 1:500 
Anti-Goat Alexoflore 
488 
Donkey Life Technologies 1:500 
Anti-Rat Alexoflore 
488 
Rabbit Life Technologies 1:500 
 
 
2.4.2 Leica Fluorescence Microscope  
 
Fluorescent images were acquired using a Leica DMIRE2 inverted fluorescent 
microscope which was controlled by a Leica CTRMIC controller. Leica filters A4 (DAPI; 
excitation at 360nm and emission at 400nm), N2.1 (TexasRed, AlexaFluor 594; 
excitation515-560nm and emission at 580nm) and L5 (GFP, FITC, AlexaFluor 488; 
excitation at 480nm and emission at 505nm) were used. A Leica DC350F CCD camera 
was used and the images were acquired using Lieca Q-Fluoro software. 
 
2.4.3 Nikon A1 Confocal  
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Confocal images were acquired using the inverted Nikon A1 Confocal system for both 
slides and glass bottom dishes. The CFI Plan Apochromat VC 60x oil (NA 1.4) objective 
was used. The excitation sources were 405nm, 457-514nm argon laser, 561nm 
sapphire laser, 642nm diode laser. Image acquisition used Nikon Elements Software. 
 
Images were acquired with a pinhole of 1.0 Airy Units (A.U), a pixel size of 1024 x 
1024, a pixel dwell of 1.1 and a Z-step of 0.4µm for intensity measurement 
experiments and 0.125µm for nuclear volume analysis. For all immunofluorescent 
experiments the laser power was set to 5.0 and the gain was set to 0. The exposure 
time was varied depending on sample and intensity to ensure a dynamic range for 
intensity quantification. Images were then processed and analysed in Fiji (is just 
ImageJ) software.  
 
2.4.4 Live Cell Imaging for Cell Migration 
 
Live cell images were acquired using the inverted Ti eclipse Nikon Widefield system 
for glass bottom dishes and cell migration chambers. The Plan Apo 20x (NA 0.75) 
objective was used. The excitation source was SpectraX LED excitation (395nm, 
440nm, 470nm, 508nm, 561nm, 640nm) using the Quad filter for DAPI/GFP/RFP/Cy5 
with matching emission filter wheel. The detection source used was Andor Zyla 
sCMOS (2560 x 2160; 6.5μm pixels). The environmental conditions of 37°C with 5% 
CO2 were maintained using the Oko-lab environmental control chamber. Image 
acquisition used NIS Elements Software.  
 
Control and KO cells were stained with CellTracker™ Red CMTPX (Invitrogen) and 
CellTracker™ Green CMFDA (Invitrogen) respectively. Control and KO cells were then 
co-cultured in a glass bottom petri dish (Ibidi). The environmental control chamber 
was equilibrated at 37°C with 5% CO2 and the petri dish added. Each experiment was 
imaged over 15 hours with each XY position imaged every 10 minutes. For each time 
point a brightfield image was taken in addition to images in the red and green 
channels in order to identify the two cell types.  
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2.4.5 Propidium Iodide Staining for FACS 
 
Cells were washed twice with 1x PBS and treated with 25%(v/v) trypsin-EDTA and 
incubated at 37°C for 5 minutes. Cells were then collected in 7ml of 1x PBS and 
centrifuged at 700x g for 5 minutes to pellet the cells – the supernatant was 
discarded. Cells were resuspended in 0.5ml ice-cold PBS with 2mM EDTA. The cell 
suspension was then added drop-by-drop into ice-cold 70% (v/v) ethanol and 
incubated at 4°C for at least 24 hours and stored at 4°C until staining. Fixed cells were 
pelleted by centrifugation at 800x g for 10 minutes. Cells were washed twice with 1x 
PBS and collected by centrifugation. The cell pellet was resuspended in 1x PBS 
containing 200µg/ml ribonuclease A (Sigma-Aldrich) to prevent RNA staining, this 
was incubated on ice for 5 minutes. The propidium iodide (Sigma-Aldrich) was added 
to a final concentration of 50µg/ml and incubated for at least 3 hours at 4°C in the 
dark until it was imaged.  
 
2.4.6 Fluorescence-Activated Cell Sorting (FACS) 
 
All FACS experiments and data processing was carried out by the flow cytometry core 
facility in the medical school. 
 
2.4.7 Scanning Electron Microscopy 
 
All electron microscopy was carried out by Chris Hill in the electron microscopy 
facility. AFM cantilevers were mounted onto an aluminium SEM examination stub 
with Liet-C carbon sticky tab and Leit-C carbon moulding putty. The cantilever was 
gold coated using an Edwards 150b Gold Coater. The cantilevers were then examined 




2.5 Image Analysis 
 
2.5.1 Nuclear Morphology 
 
In order to quantify the 2D nuclear morphology (area and shape) a specific macro 
was written for FIJI. Briefly, the macro split the green, blue and red channels and if 
applicable the Z-stack for each channel was converted into a maximum projection in 
order to retain all the signal from all the slices. Then the script was instructed to wait 
for user so the intensity could be thresholded to ensure the full nuclear area was 
selected. The analyse particles (set to size >100µm, circularity >0.3 and exclude on 
edges was selected) command was used on the thresholded image. The 
measurements collected were area and shape descriptors (circularity, aspect ratio, 
roundness and solidity). The data was copied from Fiji into Excel and GraphPad Prism 
for statistical analysis.  
 
2.5.2 Nuclear/Cell Area Ratio 
 
In order to determine the ratio between nuclear/cell area the area of the nucleus 
was determined as outlined in section 2.5.1 but without using the measurement 
shape descriptors. The area of the whole cell was determined using phalloidin 
staining where the cell was manually traced. This produced the area of nuclei and the 
area of the whole cell which was then copied into Excel. The nuclear area was divided 
by the cell area to give a ratio per cell and this was then exported to GraphPad Prism 
for statistical analysis.  
 
2.5.3 Nuclear Fluorescence Intensity Quantification 
 
In order to determine nuclear intensity a script for Fiji was written. This script, as with 
those discussed previously, split the channels and where necessary produced a 
maximum projection image. The DAPI channel was then used to determine nuclear 
area and the mask for each nucleus was added to the ROI manager. The mean grey 
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value within that mask on the channel of interest was then measured. These data 
were then exported to Excel for further analysis. The mean grey value was then 
normalised to the largest value across that repeat. The normalised data was then 
exported to GraphPad Prism for statistical analysis.  
 
2.5.4 Cell Migration 
 
Generated time laps images were processed using FIJI using the Manual Tracking 
plugin and the Chemotaxis and Migration Tool 2.0 (ibidi) plugin. Each XY position was 
separated into an individual time laps image sequence and then the three channels 
were split. Cells were manually tracked and this data was then entered into the 
Chemotaxis and Migration Tool which then calculated migration velocity and total 
migration distance. This data was then exported to Excel to collate and organise and 





2.6.1 Whole Cell Lysate Sample Preparation 
 
Cells were grown to required density and then washed twice with 1 x ice cold PBS 
and then lysed with radio immunoprecipitation assay buffer (RIPA; 150mM NaCl, 1% 
NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 25mM Tris pH 7.4) supplemented with 
appropriate protease and phosphatase inhibitors on ice for 15 minutes. Lysed cells 
were then harvested using a cell scraper. The lysed samples were then sonicated 
(Sanyo Soniprep 150) three times for 10 seconds with 10 seconds rest on ice between 
each. Samples were then centrifuged (Sigma 1-15K) for 15 minutes at 18,000x g at 
4°C. The supernatant was retained and either used immediately or stored at -20°C 
until use.  
 
2.6.2 Nuclear Fractionation Sample Preparation 
 
See section 2.3.5. 
 
2.6.3 Determining Protein Concentration 
 
The protein concentration of samples was determined using the MicroBCA™ protein 
assay kit (Thermo Scientific) as per the manufacturer’s instructions.  
 
2.6.4 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 
SDS-PAGE mini-gels were cast using the Bio-Rad casting system, each gel was cast 
individually and consisted of 12% resolving gel (2ml H2O, 4.15ml 40% Bis-Acrylamide, 
5µl TEMED, 100µl 10% ammonium persulphate and 3.75ml gel stock pH 8.8 which 
consists of 1.5M tris and 0.4% SDS) and a 5% stacking gel (3.525ml H2O, 800µl 40% 
Bis-Acrylamide, 15µl TEMED, 50µl 10% ammonium persulphate and 625µl gel stock 
pH 6.8 which consists of 1M tris and 0.75% SDS). Samples were boiled in Laemelli 
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sample buffer and loaded onto the cast mini-gels along with a molecular weight 
protein ladder. The mini-gels were run in Bio-Rad tanks that contained 1 x SDS 
running buffer (28.8g glycine, 6g Tris, 2g SDS, made up to 2L ddH2O), the samples run 




Proteins that were separated via SDS-PAGE were electroblotted from the mini-gels 
to Polyvinylidene fluoride (PVDF; Immobilon-P, Merck) membranes using a mini 
Trans-Blot electrophoretic transfer cell (Bio-rad). The SDS-PAGE gel was then added 
to 1 x Towbin (2.5mM Tris, 19.2mM glycine, 20%(v/v) methanol, 0.025% SDS) 
transfer buffer in addition to methanol activated PVDF, filter paper and fibre pads. 
The components were then assembled into the transblot caseate, an ice pack was 
added to prevent excessive warming and Towbin transfer buffer was added as 
described by the manufacturer’s instructions. The membranes were blotted at 100V 
for 75 minutes and then removed from the transfer apparatus. 
 
2.6.6 Western Blotting 
 
The electroblotted membranes were blocked using 5% (w/v) skimmed milk powder 
in tris-buffered saline with Tween 20 (TBST; 5mM Tris-Cl, 15mM NaCl, pH 7.6) for 1 
hour at room temperature with slight rocking. Then primary antibody (3-10ml), 
diluted in blocking buffer to the required concentration (Table 2.4), was added to the 
membrane and incubated at 4°C overnight with slight rocking. The membrane was 
then washed once with TBST for 10 minutes and then twice for 5 minutes. Following 
washing, secondary antibody conjugated to HRP (5-10ml) was diluted in blocking 
buffer to the required concentration (Table 2.5) and added to the membrane where 
it was gently rocked at room temperature for 1 hour. The membrane was then 
washed once with TBST for 10 minutes and twice for 5 minutes. A chemiluminescent 
signal was produced using ECL western blot detection kit (GE Life Sciences) with equal 
volumes of ECL I and ECL II being added to the membrane. This was incubated at 
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room temperature for 5 minutes and then imaged using the Bio-Rad ChemiDoc XRS+ 
system. The chemiluminescence signal was recorded over a time course of between 
5 seconds and 30 minutes. 
 
Table 2.4 List of primary antibodies used for western blotting. 
Antibody Target Species Company Concentration 




Rabbit  1:20 
JAF1 (b-DG) Rabbit  1:500 
LG5 (b-DG) Rabbit  1:500 
Lamin A/C Mouse Cell Signalling 
Technology (4C11) 
1:500 
Lamin B1 Rabbit ProteinTech 1:500 
Emerin Rabbit Santa-Cruz (FL-
254) 
1:1000 
Calnexin   Santa-Cruz (C-20)   
GAPDH Mouse Santa-Cruz (0411) 1:1000 
 
 
Table 2.5 List of secondary antibodies used for western blotting. 
Antibody Target Company Concentration 
Anti-Mouse HRP Sigma-Aldrich 1:10,000 
Anti-Rabbit HRP Sigma-Aldrich 1:10,000 
GAPDAH HRP Sigma-Aldrich 1:10,000 
 
 
2.6.7 Membrane Stripping 
 
Where the membrane was re-probed for a second protein then the antibodies were 
removed using mild stripping buffer (15g Glycine, 1g SDS, 10ml Tween 20 in 1L and 
pH adjusted with HCl to pH 2.2). The membrane was incubated twice with mild 
stripping buffer for 15 minutes at room temperature with gentle rocking. This was 
then followed by two 10 minute PBS washes and two 5 minute TBST washes. The 
membrane was then blocked and probed as described above.  
 
2.6.8 Quantification of Western Blots 
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Intensity analysis of western blot bands was carried out using the Bio-Rad Image Lab 
Software. The band was manually outlined using the outline tool, 3 background areas 
were also selected, the background setting was set to global to automatically 
subtract the background. The adjusted intensity along with other data was exported 
to Excel where the intensity was normalised to the adjusted intensity of the loading 




2.7 Cellular Stress Assays 
 
2.7.1 Oxidative Stress 
 
Cells were seeded at 80% confluency as described in section 2.2.3 and allowed to 
settle and adhere to the coverslip for 24 hours. H2O2 (Sigma) was then diluted in 
media and added to cells at the described concentrations and incubated at 37°C, 5% 
CO2 for the described time period. Following incubation, the cells on the coverslips 
were fixed and stained for immunofluorescence analysis. Nuclear shape and size 
were measured in addition to gH2AX intensity as outlined in sections 2.4.1 and 2.6. 
 
2.7.2 Osmotic Stress 
 
Hypertonic cell stress was induced using NaCl (Sigma) and Polyethylene Glycol 4000 
(PEG4000; Sigma). Cells were seeded at 80% confluency as described in section 2.2.3 
and allowed to settle and adhere to the coverslip for 24 hours. NaCl or PEG4000 was 
added at the described concentrations and incubated at 37°C, 5% CO2 for the 1 hour 
or 30 minutes respectively. Following incubation, the cells on the coverslips were 
fixed and stained for immunofluorescence analysis. Nuclear shape and size were 
measured in addition to gH2AX intensity as outlined in section 2.4.1 and 2.6. 
 
2.7.3 Mechanical Stress 
 
2.7.3.1 Transwell Migration Assay 
 
For these experiments 24-well Transwell migration inserts (Thermo Fisher) were 
used with either 8µm or 3µm pores. 1ml of media was added to the Transwell insert 
and incubated for 30 minutes prior to cell seeded. 2 x 106 cells/ml were seeded 
directly into the pre-warmed media and on top of the insert membrane, 1ml of media 
was also added to the bottom of the insert. Cells were then incubated at 37°C, 5% 
CO2 for 48 hours to allow sufficient cell migration. Following migration, cells were 
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fixed and permeabilised as described in 2.4.1. The side of the membrane not being 
imaged was scrapped with a cotton bud to remove the cells that were not being 
imaged. Each individual membrane was then cut from the insert in order to stain cells 
using immunofluorescence. Once the inserts were removed, they were stained and 
mounted as described in section 2.4.1. Membranes were then imaged and nuclear 
shape and gH2AX intensity were measured as outlined in sections 2.4.1 and 2.6. 
 
2.7.3.2 Passive Cell Compression 
 
Cells were grown in glass bottom petri dishes (ibidi) and allowed to settle and attach 
for 24 hours. 1% agarose solution was made using 1g agarose in 100ml of cell culture 
media and this was poured into a 10cm petri dish and allowed to set. Once set it was 
incubated at 37°C, 5% CO2 for 24 hours. After 24 hours cells were washed twice with 
PBS and fresh media containing Hoechst 33342 (Thermo Fisher) was added to the 
cells. 1.5cm discs of 1% agarose were cut out and placed over the top of the cells 
followed by a weighted insert (kindly provided by Ben Phillips, King lab). Cells were 
then incubated for 1 hour before imaging. Nuclear shape was then measured and 
analysed as described in section 2.6.  
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3 Investigating the effect of disrupting DG on nuclear 




3.1.1 Nuclear Shape 
 
Nuclear shape is determined by the underlying structural components of the nucleus 
such as the nuclear lamina and the NE proteins (Chen et al., 2018; Lammerding et al., 
2006). Additionally, nuclear shape is organised and maintained by interactions with 
the cytoskeleton through the linker of nucleoskeleton and cytoskeleton (LINC) 
complex (Lüke et al., 2008). The maintenance of overall nuclear shape is determined 
by the balance between the nucleoskeleton and the cytoskeleton with the LINC 
complex bridging the two.  
 
Experimentally, analysis of nuclear shape is generally reported in terms of nuclear 
circularity, nuclear sphericity or a nuclear contour ratio. The maintenance of nuclear 
shape is coordinated by the key structural components of the cells. Cytoskeletal 
actin, microtubules and intermediate filaments are required for maintaining nuclear 
shape as disruption of these structures results in abnormal shaped nuclei (Jacob et 
al., 2020; Patteson et al., 2019a; Sankaran et al., 2020). Additionally, the LINC 
complex which connects the cytoskeleton with the nucleoskeleton plays an essential 
role in maintaining nuclear shape as a reduction in levels of Klarsicht, ANC-1, Syne 
homology (KASH) domain protein nesprin 2G resulted in an increase in proportion of 
abnormally shaped nuclei (Lüke et al., 2008).  
 
In addition to the role of the cytoskeleton in nuclear shape maintenance, the 
nucleoskeleton also plays an essential role. Multiple studies have investigated the 
effect of disrupting lamins or emerin on nuclear morphology. When emerin is 
perturbed there is a clear nuclear shape phenotype, in KD cardiomyocytes there was 
a decrease in nuclear invaginations (Shimojima et al., 2017) while in emerin null 
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mouse embryonic fibroblasts (MEFs) there was a greater proportion of irregularly 
shaped nuclei compared with controls and a lower nuclear contour ratio which is a 
similar measurement to circularity (Lammerding et al., 2005). 
 
Lamin B1 is different, when lamin B1 is perturbed there is no increase in the number 
of abnormally shaped nuclei or contour ratio but there is a decrease in nuclear 
circularity. This was confirmed in two separate studies both using lmnb1-/- MEFs 
(Chen et al., 2018; Lammerding et al., 2006). The decrease in nuclear circularity was 
because lmnb1-/- MEFs had an increase in nuclear blebs (Chen et al., 2018). 
Additionally, it has been noted that overexpression of lamin B1 also results in a 
decrease in nuclear circularity but it is unclear if this is due to abnormal shape or 
nuclear blebs (Barascu et al., 2012). 
 
The contribution of lamin A/C on the nuclear shape has been well studied in lmna-/- 
MEFs which result in no expression of lamin A or lamin C. Similarly to emerin null 
MEFs, lmna-/- MEFs have more irregularly shaped nuclei and a lower contour ratio 
compared with lmna+/+ cells (Kim et al., 2017; Lammerding et al., 2005, 2006). 
Interestingly, when separating the functions of lamin A and lamin C it was found that 
cells lacking only lamin A had irregularly shaped nuclei and lower contour ratio while 
cells lacking only lamin C did not (Lammerding et al., 2006). Taken together this data 
suggests that lamin A and emerin are primarily responsible for the abnormal nuclear 
shape and not lamin C or B1. 
 
3.1.2 Nuclear Membrane Integrity 
 
Nuclear membrane integrity, or more specifically a loss of integrity, is often 
characterised by the presence of chromatin protrusions which are termed nuclear 
blebs, nuclear rupture events or membrane enclosed extranuclear DNA which are 
generally termed micronuclei. The presence of nuclear blebs, nuclear rupture events 




Nuclear blebs are weak points in the nuclear membrane which can go on to become 
sites of nuclear rupture (Chen et al., 2018). A cell population that had a higher 
proportion of nuclei with nuclear blebs would therefore be expected to have a higher 
proportion of nuclear rupture. This is confirmed in lmnb1-/- and lmna-/- cells, where 
lmnb1-/- cells have a greater number of nuclear rupture events compared with 
controls and lmna-/- cells. Additionally, a triple lamin KO – lamin A/C, B1 and B2 – 
resulted in increased nuclear ruptures. Interestingly, the treatment of triple KO cells 
with the actin perturbing agent Cytochalasin D rescues the nuclear rupture 
phenotype suggesting that the actin cytoskeleton plays a role in maintaining nuclear 
membrane integrity (Chen et al., 2018). Further evidence indicating the role of the 
cytoskeleton in membrane integrity is observed in vimentin null cells which also have 
greater numbers of nuclear rupture events (Patteson et al., 2019a).  
 
As mentioned above lamin B1 appears to play a key role in preventing nuclear blebs. 
In lmnb1-/- MEFs there is a larger proportion of nuclei with blebs compared with 
controls and lmna-/- MEFs. When comparing lmna-/- with controls there is an increase 
but not as significant as lmnb1-/-. This indicates lamin B1 plays more of a role in 
regulating nuclear membrane integrity than lamin A/C (Chen et al., 2018; 
Lammerding et al., 2006). When lamin localisation within the nuclear blebs was 
investigated it was found that lamin A/C staining within the bleb was continuous as 
observed throughout the nucleus whereas lamin B1 is not present in the bleb at all 
(Nmezi et al., 2019).  
 
The presence of chromatin outside the nuclear membrane is generally due to severe 
DNA damage resulting in the release of fragmented DNA or due to an error in 
chromosome segregation (Fenech et al., 2011; Soto et al., 2018). There is almost no 
evidence to indicate that micronuclei occur following genetic perturbation of lamins 
or emerin, but these proteins are often present in the micronuclei (Maass et al., 
2018). However, when the lamin B1 receptor was knocked down there was a greater 
number of cells with micronuclei compared with control cells (En et al., 2020). Lamin 
B1 receptor is a transmembrane protein that plays a role in binding and anchoring 
lamin B1 and tethering chromatin to the NE. It was also found that DIAPH3 KD cells 
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also had a greater proportion of cells with micronuclei and that these KD cells also 
had decreased levels of emerin and lamin A/C (Reis-Sobreiro et al., 2018). 
 
3.1.3 Nuclear Size 
 
Nuclear size is thought to scale with cell size (Edens et al., 2013). Nuclear size is an 
interesting parameter as many publications refer to it, particularly when 
investigating nuclear morphology. An increase or decrease in nuclear size is often 
used to imply a nuclear abnormality, however, the regulatory mechanisms that 
control nuclear size are not well characterised.  
 
The perturbation of cytoskeletal and nuclear proteins often results in changes in 
nuclear size. Reducing the levels of mDia2 resulted in an increase in nuclear height 
(Sankaran et al., 2020) while vim-/- MEFs have larger nuclear area and volume 
compared with controls (Patteson et al., 2019a). Additionally, the depletion of 
nesprin-2G results in larger nuclei as does a nesprin-2G mutant lacking the actin 
binding domain (Lüke et al., 2008). Taken together these data suggest that the 
cytoskeleton plays a role in regulating nuclear size.  
 
NE and nucleoskeleton proteins have also been implicated in the regulation of 
nuclear size, with increased nuclear area and volume being observed in emerin KD 
experiments and emd-/- MEFs (Lammerding et al., 2005; Shimojima et al., 2017). KO 
of another Lap2-Emerin-Man1 (LEM) domain protein, ANKLE2 which lacks a TM 
domain, also results in larger nuclear area compared with controls (Snyers et al., 
2017). Lamin A/C null MEFs display increased nuclear area and volumes compared 
with controls (Kim et al., 2017; Lammerding et al., 2005) and KD or overexpression of 
lamin B1 also results in a significant change in nuclear size compared with controls 
(Barascu et al., 2012; Jevtić et al., 2015). 
 
Understanding how nuclear size is regulated is an area that remains poorly 
understood, however, there have been recent studies using fission yeast in an 
attempt to understand the genetics and mechanics of nuclear size regulation. Fission 
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yeast make use of a homeostatic process to maintain their nuclear/cytoplasmic (N/C) 
ratio. Following size perturbation using a Pom1 (a kinase involved in regulating cell 
division) deletion to induce asymmetric division the N/C ratio is rapidly restored 
(Cantwell and Nurse, 2019a). In a genetic screen looking for mutant yeast with higher 
or lower N/C ratios than WT yeast, 25 genes were identified (Cantwell and Nurse, 
2019b). Among the identified genes were many involved in RNA and mRNA 
processing and gene expression. LINC complex proteins were also identified but 
resulted in opposing phenotypes – kms1 which is the fission yeast KASH protein 
results in a higher N/C ratio while sad1 the Sad and UNC-84 (SUN) domain protein 
results in a lower N/C ratio suggesting the link between the cytoskeleton and 
nucleoskeleton plays an important role in regulating nuclear size (Cantwell and 
Nurse, 2019b). The protein lem2 which is a NE protein containing a LEM domain has 
also been implicated in maintain the N/C ratio in fission yeast. It is suggested to do 
this by regulating the flow of membrane between ER and the NE (Kume et al., 2019). 
 
Two recent studies by Jevtić and colleagues have looked at nuclear size regulation in 
mammalian cell lines and have suggested lamins and nuclear import/export play 
important roles in size regulation. The first of these studies originally identified the 
effect of lamins on nuclear size in Xenopus egg nuclei and found that nuclear size 
varied depending on lamin concentrations. Low concentrations of lamin A, B1 or B2 
resulted in increased nuclear size while higher concentrations resulted in a decrease 
in nuclear size. This was also investigated in HeLa and MRC-5 cells where 
overexpression of lamin A/C, B1 or B2 resulted in increased nuclear size while KD of 
lamin A/C, B1 or B2 resulted in decreased nuclear size (Jevtić et al., 2015). The second 
study involved using an siRNA screen to identify proteins that resulted in a decreased 
nuclear area. They identified multiple proteins including SUN3 but focused on ELYS 
which is a nucleoporin that plays an important role in NPC formation. KD of ELYS 
resulted in smaller nuclei but also resulted in decreased levels of lamin B2 and 
mislocalisation of lamin B1. Conversely, overexpression (OE) of ELYS resulted in an 
increase in nuclear area. They also identified nuclear import and export as important 
mechanisms for maintaining nuclear size as when nuclear import was blocked 
nuclear size decreased and blocking nuclear export resulted in increased nuclear size 
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(Jevtić et al., 2019). Taken together these two studies imply a mechanistic role for 
nuclear lamins and nuclear import/export in the maintenance of nuclear size.   
 
It is important to note that a larger nuclear size is likely to be correlated with a larger 
cell size (Edens et al., 2013). Some of the studies above have focused on abnormal 
nuclear size compared with cell size as reported by the N/C ratio, however, many 
have not discussed the possibility that increased or decreased cell size may be the 
reason for the observed nuclear phenotype. This is important as cell size and 
correspondingly nuclear size increase when cells become senescent (Sadaie et al., 
2015). Lamin B1 is strongly implicated in the cell senescence phenotype with both 
increases and decreases in lamin B1 levels being associated with senescence 
phenotypes (Barascu et al., 2012; Dreesen et al., 2013; Freund et al., 2012).  
 
3.1.4 Hypothesis and Aims 
 
It has been suggested by the Cisneros lab that KD of b-DG or KO of the DAG1 gene 
results in multiple nuclear phenotypes including a larger proportion of abnormally 
shaped nuclei, lower nuclear circularity, reduced nuclear integrity, increased nuclear 
and cell size, reduced levels of lamin A/C, lamin B1 and emerin and aberrant 
localisation of lamin B1 and emerin. They have also identified a number of nucleolar 
morphological defects in cells with reduced levels of DG. All of these nuclear and 
nucleolar phenotypes have been observed in C2C12 mouse myoblast cell lines 
(Azuara-Medina et al., 2019; Gómez-Monsiváis et al., 2020; Martínez-Vieyra et al., 
2013; Vélez-Aguilera et al., 2018). 
 
The aim of the experiments presented in this chapter is to validate these results in a 
human myoblast cell line that has a disrupted DAG1 gene and therefore has no 
expression of b-DG. The original experiments in the C2C12 cell lines lack any rescue 
experiments, therefore the secondary aim here is to rescue any observed nuclear 
phenotypes to conclusively demonstrate the contribution of b-DG in maintaining and 





3.2.1 b-DG localises to the nucleus in KM155 human myoblast cell lines 
 
It has been frequently reported that b-DG is localised both within the nucleus and at 
the NE in multiple cell lines (Fuentes-Mera et al., 2006; Gonzalez-Ramirez et al., 2008; 
Martínez-Vieyra et al., 2013; Villarreal-Silva et al., 2010). The nuclear localisation of 
b-DG in the KM155 human myoblast cell line was examined using both 
immunofluorescence imaging (Figure 3.1) and cell fractionation followed by western 
blotting analysis (Figure 3.2). To demonstrate the localisation visually, five different 
antibodies against b-DG were used, all of which detect the C-terminal cytoplasmic 
region of b-DG. Four of these antibodies; MANDAG2, JAF1, LG5 and C-20 are specific 
for b-DG irrespective of the phosphorylation state. 1709 on the other hand is specific 
for the phosphorylated version of b-DG at the Y892 residue. Despite all of these 
antibodies binding to very similar regions of b-DG there are some noticeable 
differences in the staining patterns. The clearest NE staining can be observed using 
MANDAG2 and 1709 which both display a clear nuclear ring (Figure 3.1). Cells stained 
with LG5 or JAF1 have a more prominent perinuclear staining with the nucleus clearly 
outlined. However, there is still clear nuclear staining, but the NE ring staining is more 
difficult to observe using these antibodies. The commercially purchased C-20 
antibody gives slightly different staining than the other antibodies, with very striking 
nucleoli staining and an almost complete absence of NE staining. All these antibodies 
clearly bind to b-DG as determined by peptide SPOT arrays (Jacobs, 2017), however, 
they have high levels of background signal when used for immunofluorescence 
assays. Despite this it can be concluded that b-DG appears to be localised to the 
nucleus as cells stained with all of the b-DG antibodies have nuclear staining with 




Figure 3.1 Immunofluorescence staining with the b-DG antibodies MANDAG2, LG5, JAF1, C20 and 1709 
demonstrate nuclear localisation. Representative immunofluorescence images where b-DG staining is visible at 
the NE as indicated by black arrows. It is also present to some extent at the nucleoli as indicated by white arrows. 
MANDAG2 and 1709 have clear NE ring staining, JAF1 and LG5 have perinuclear staining and C-20 has nucleoli 
staining. All antibodies indicate nucleoplasmic staining. Scale bar = 20µm. 
 
The localisation of b-DG to the nucleus of KM155 human myoblast cells was also 
confirmed using a fractionation experiment (Figure 3.2). Here, cells are separated 
into cytoplasmic and nuclear fractions using a combination of detergent and 
centrifugation. The non-fractionated sample (or whole cell lysate; WCL) was used as 









by probing for the exclusively cytoplasmic protein GAPDH, the exclusively nuclear 
protein lamin A/C and the ER marker calnexin. The cytoplasmic marker was detected 
in both WCL sample and the cytoplasmic sample while the nuclear marker was 
detected in the WCL sample and the nuclear sample confirming the success of 
fractionation. Additionally, the ER marker calnexin was used as a finer quality control. 
As the ER is closely associated with the NE it is important to ensure that the nuclear 
proteins do not include ER proteins. The presence of calnexin in the WCL sample and 
the cytoplasmic sample but not the nuclear sample suggests that the nuclear sample 
is not contaminated by ER proteins. Based on these controls these data suggest that 
the strong b-DG band in the nuclear sample is due to the presence of b-DG in the 
nucleus and not due to contaminants from the cytoplasm or ER. Interestingly, only 
one b-DG band was identified in the WCL, nuclear and cytoplasmic fractions. This 
band was between the 36kDa and 55kDa marker suggesting it is the full-length 43kDa 
protein being detected. This suggests that b-DG is present in the nucleus of KM155 
human myoblast cells as full-length protein rather than the smaller fragments. 
Alternatively, the smaller fragments may have been present at a much lower 


















Figure 3.2 Cell fractionation demonstrates the nuclear localisation of b-DG. Whole cell lysate (WCL), 
cytoplasmic (Cyto) and nuclear (Nuc) samples were probed for the cytoplasmic marker GAPDH, the nuclear 
marker lamin A/C and the ER marker calnexin to demonstrate purity of fractions. The b-DG antibody MANDAG2 
produced a band at 43kDa in all three samples indicating nuclear localisation in KM155 human myoblast cells.     
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Taken together the immunofluorescence and fractionation evidence suggests the 
localisation of full-length b-DG to the nucleus of KM155 human myoblasts. However, 
we cannot rule out the possibility that shorter fragments of b-DG are also present at 
much lower concentrations.  
 
3.2.2 DAG1 disruption results in loss of b-DG protein 
 
The DAG1 gene of KM155 human myoblasts was disrupted using CRISPR/Cas9 as 
described in Matthew Cook’s thesis (Cook, 2021). The disrupted gene results in a loss 
of b-DG, therefore cells with disrupted DAG1 will be termed DAG1 KO for 
convenience. In addition to multiple DAG1 KO cell lines termed KO A, B, C, D, E and 
F, a gRNA control cell line referred to henceforth as control (or simply C) was also 
generated. The resultant levels of b-DG were determined in all of these cell lines 
using immunofluorescence staining (Figure 3.3) and western blot analysis (Figure 3.4) 
to determine their suitability for further experiments and also verify the specificity 
of each of the b-DG antibodies.   
 
For the immunofluorescence assay, control and KO cells were stained with each of 
the five antibodies specific for b-DG; MANDAG2, JAF1, LG5, C-20 and 1709. Each of 
these antibodies resulted in different levels of staining in the KO cells. MANDAG2 
staining of control cells resulted in signal detected throughout the cell, in both the 
cytoplasm and nucleus in addition to PM, NE and ER staining. Conversely, when the 
KO cells were stained with MANDAG2 there was a slight decrease in intensity 
throughout the cell. Interestingly, the NE ring staining present in the control cells is 
not present in the KO cells, neither is the strong PM staining (Figure 3.3).  These 
observations suggest that MANDAG2, as expected, is specific for b-DG. Staining with 
LG5 indicates more non-specific binding compared with MANDAG2, in the control 
sample the staining is throughout the cell but is most intense at the perinuclear 
region where the nucleus is clearly identifiable, there is also intense staining at the 
PM. In the KO cells the perinuclear staining is lost and the nuclei are no longer 
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discernible from the background staining, the PM staining is also reduced. There is 
reduced overall staining in all KO samples except KO B which appears to have a similar 
intensity to the control sample which again suggests issues with specificity. When 
control and KO cells were stained using JAF1 there is a very clear difference in staining 
intensity, the control cells had intense perinuclear and PM staining similar to LG5 
with the nuclei clearly identifiable. In the KO cells stained with JAF1 there is a stark 
reduction in all cellular staining where the PM and nucleus are no longer visible from 
the background. In the case of C-20 staining in the controls there is general staining 
throughout the cell with the most intense signal at the nucleoli. In the KO cells 
stained with C-20 there is very little difference compared with the controls – there is 
a slight reduction in overall intensity but there is still prominent nucleoli staining 
suggesting the nucleoli signal is an artifact and not due to binding with b-DG. When 
control and DG KO cells were stained with 1709, which is specific for the 
phosphorylated version of b-DG, there is an overall reduction in signal intensity in 
the KO cells compared with the control. In the control cells there is intense staining 
throughout the cells with increased intensity at the PM and NE, this is not present in 
the KO cells (Figure 3.3). All these data together indicate that the CRISPR/Cas9 
disruption of the DAG1 gene results in reduced levels of b-DG, but it is not possible 
to conclude that there is a complete loss of protein due to the poor signal to noise 
ratios inherent in the use of these particular antibodies. Additionally, it gives some 
information on which antibodies are best for investigating b-DG via 
immunofluorescence. The data would suggest that MANDAG2, JAF1 and 1709 are 
the best antibodies, with the lowest background noise levels for 
immunofluorescence assays. 
 
In addition to immunofluorescence analysis the control and KO cells were 
characterised using western blotting analysis (Figure 3.4). Here, whole cell lysate of 
control and KO samples were prepared and tested for levels of b-DG using the 
antibodies MANDAG2 and LG5 with GAPDH as a loading control. For the two b-DG 
antibodies there was a band present at 42kDa, with no other bands detected at any 
other molecular weight, in the control sample while there was no detectable band in 
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the KO sample (Figure 3.4). Based on this evidence it is clear that b-DG is perturbed, 
and the levels are reduced to the extent that it is not detectable in this assay. This 
does not confirm that there is no expression of DG it simply confirms that the levels 









KO A KO B KO C KO D
Figure 3.3 Disruption of the DAG1 gene in human myoblasts results in a reduction in b-DG 
immunofluorescence staining. Representative immunofluorescence images of control and DAG1 KO clones A-E 
stained with b-DG antibodies MANDAG2, LG5, JAF1, C-20 and 1709. Cells were grown for 24 hours prior to 
fixation and staining with DAPI and b-DG. Representative image of each cell line stained with each antibody. 3 
independent repeats were carried out with at least 3 images per sample. Scale bar = 20µm. 
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3.2.3 The effect of DAG1 disruption on nuclear shape in KM155 cells 
 
There are multiple parameters that can be used to indicate the shape of the nucleus 
in 2D, these are primarily nuclear circularity, nuclear aspect ratio and nuclear 
roundness. During analysis of nuclear shape all of these parameters are measured, 
however, for simplicity and consistency circularity will be discussed henceforth. The 
reason for this is that circularity generates a greater deviation from 1 for nuclei with 
protrusions and abnormal shapes compared with simply elongated nuclei. 
 
Nuclear circularity was measured in a number of ways to ensure accurate results. The 
majority of the data was generated using DAPI staining and imaged using a Leica 
fluorescent microscope (Figure 3.5). The nuclear circularity of control and five DAG1 
KO clones (A-E) were measured (Figure 3.6). The average circularity of all DAG1 KO 
clones was lower than that of the control but for clones A-C this difference was not 
significant. However, for clones D and E the difference was significant with a P value 
of 0.0012 and 0.0007 respectively. The difference between the control and KO clones 
D and E is unlikely to be due to a lack of DG and more likely to be a side effect of the 


























































Figure 3.4 Disruption of the DAG1 gene in human myoblasts results in a loss of b-DG in a western blot 
analysis. Whole cell lysate of control and DAG1 KO clones A-E probed for b-DG using MANDAG2 or LG5. GAPDH 
was used as a loading control. The two separate blots are used to demonstrate the variation in quality of 
MANDAG2 between batches. MANDAG2 and LG5 only detected a band in the control samples and not in any of 
the DAG1 KO clones.    
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Control DAG1 KO A DAG1 KO B
DAG1 KO C
DAG1 KO D DAG1 KO E
Figure 3.5 Representative nuclei from control and DAG1 KO clones. Cells were grown for 24 hours before fixing 
and staining with DAPI to identify nuclear region. Cells were imaged using the Leica fluorescence microscope. 
Scale bar = 20µm. 
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This lack of difference between control and DAG1 KO clones A-C was further 
confirmed with the use of confocal microscopy to confirm the type of microscopy did 
not affect the result. Additionally, nuclei stained with the nuclear marker lamin B1 















































Nuclear Circularity of Control and 
multiple DAG1 KO clones





Control 0.8325 0.0243 N/A N/A
DAG1 KO A 0.8260 0.0182 0.7884 ns
DAG1 KO B 0.8157 0.0207 0.4467 ns
DAG1 KO C 0.8113 0.0340 0.3201 ns
DAG1 KO D 0.7588 0.0613 0.0012 **
DAG1 KO E 0.7550 0.0600 0.0007 ***
Figure 3.6 Average nuclear circularity of control and DAG1 KO clones A-E using DAPI to identify the nuclear 
region. Cells were grown for 24 hours before fixing and staining with DAPI to identify nuclear region. Cells were 
imaged using the Leica fluorescence microscope and the nuclear shape determined for analysis. Small black 
points indicate values from individual cells while larger coloured points indicate the average for each 
independent experiment. 7 independent experiments were carried out with at least 25 individual nuclei 
measured per experiment. Graph shows mean and standard deviation. A significant difference was determined 
between the control and DAG1 KO D-E as determined by one-way ANOVA test p = 0.0014. p values for multiple 
comparisons using Dunnett’s multiple comparisons test are in the table. Control n = 789, KO A n = 781, KO B n = 
772, KO C n = 784, KO D n = 738, KO E n = 752. 
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validate the methodology. When control and DAG1 KO clone A cells were stained 
with DAPI and imaged on the confocal microscope there was again no difference 
between the two samples (Figure 3.7a). In agreement with this when control and 
DAG1 KO clone A and B cells were stained for lamin B1 and imaged using either the 
Leica fluorescent microscope (Figure 3.7b) or the confocal microscope (Figure 3.7c) 
the nuclear circularity result was the same – there is no difference between the 
circularity of the DAG1 KO clones and the circularity of control cells.  
 
 
Figure 3.7 Average nuclear circularity of control and DAG1 KO clones A and B using DAPI or lamin B1 to identify 
the nuclear region and imaged using two different microscopes. (a) Cells were grown for 24 hours before fixing 
and staining with DAPI to identify nuclear region. Cells were imaged using the Nikon A1 confocal and the nuclear 
shape determined for analysis. Coloured points indicate the average value for each independent experiment. 7 
independent experiments were carried out with 183 control and 177 KO A nuclei measured. Graph shows mean 















Nuclear Circularity of Control and DAG1 KO 






























Nuclear Circularity of Control and DAG1 KO
 clone A & B using Leica Microscope 





























Nuclear Circularity of Control and DAG1 KO
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and standard deviation. A significant difference was not determined between the control and DAG1 KO A as 
determined by t test p = 0.9429. (b) Cells were grown for 24 hours before fixing and staining with lamin B1 and 
DAPI to identify nuclear region. Cells were imaged using the Leica fluorescence microscope and the nuclear shape 
determined for analysis. Small black points indicate values from individual cells while larger coloured points 
indicate the average value for each independent experiment. 3 independent experiments were carried out with 
83 control, 76 KO A and 96 KO B nuclei measured per experiment. Graph shows mean and standard deviation. A 
significant difference was not determined between the control and DAG1 KO A or B as determined by one-way 
ANOVA test p = 0.1476. p values for multiple comparisons using Dunnett’s multiple comparisons test are in the 
table. (c) As above, except Nikon A1 confocal was used. A significant difference was not determined between the 
control and DAG1 KO A or B as determined by one-way ANOVA test p = 0.9688. p values for multiple comparisons 
using Dunnett’s multiple comparisons test are on the graph. Control n = 102, KO A n = 100 and KO B n = 114. 
 
Circularity gives an indication of how close the nuclei are to a perfect circle in 2D but 
it does not provide any 3D information. The 3D equivalent of circularity is sphericity 
which indicates how close the nuclei are to a perfect sphere. Using multiple Z-stacks 
from a confocal image the nuclei can be reconstructed and a value for sphericity can 
be determined. As this is a more time intensive experiment only control and DAG1 
KO B cells were compared (Figure 3.8). As with nuclear circularity there is no 
difference in sphericity values between the control or DAG1 KO sample which 
confirms that the results observed in 2D also hold true in 3D. 
 
 
In addition to measuring the circularity and sphericity of control and DAG1 KO nuclei 
the proportion of cells with micronuclei was also assessed. Inspecting >800 cells per 















Nuclear Sphericity of Control and
 DAG1 KO clone B
0.9066
Figure 3.8 Average nuclear sphericity of control and DAG1 KO clone B using DAPI to identify the nuclear 
region. Cells were grown for 24 hours before fixing and staining with DAPI to identify nuclear region. Cells were 
imaged using the Nikon A1 confocal and the 3D nuclear shape determined for analysis. Small black points 
indicate values from individual cells while larger coloured points indicate the average value for each 
independent experiment. 3 independent experiments were carried out with 45 control and 49 KO B nuclei 
measured. Graph shows mean and standard deviation. A significant difference was not determined between 
the control and DAG1 KO B as determined by t test p = 0.9066. 
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cell line the results are similar to those observed for nuclear circularity. There is no 
difference between the percentage of control cells and the percentage of DAG1 KO 
clone A-C cells with micronuclei. 0.61% of control cells had micronuclei while DAG1 
KO A, B and C cells had 0.94%, 1.12% and 1.39% respectively. In the case of DAG1 KO 
D and E the percentage of micronuclei was larger with KO D having 4.27% and KO E 
having 7.66% (Figure 3.9). 
 
 
Taken together this data suggests that the majority of DAG1 KO cell lines have a 
normal nuclear shape as compared with control cells. However, two of the five DAG1 
KO cell lines have abnormal nuclear shape, and this will be discussed in further detail 
below. 
 
3.2.4 Comparing the nuclear and cell size of control and DAG1 KO cells 
 
When discussing nuclear size, nuclear area is the main parameter. As with nuclear 
circularity the nuclear area of control and DAG1 KO cells has been determined in 
multiple ways to confirm accuracy of the methodology. Determination of nuclear 
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Figure 3.9 Percentage of control or DAG1 KO clone A-E cells that had micronuclei. Images were manually 
inspected and the number of cells containing micronuclei and the total number of cells was determined. 
Control n = 789, KO A n = 781, KO B n = 772, KO C n = 784, KO D n = 738, KO E n = 752, a very low percentage 
having micronuclei. (Inset) Zoomed in view of 0-10%. 
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fluorescence microscope. When nuclear area was measured for control and all DAG1 
KO clones (A-E) there was a clear difference in nuclear area (Figure 3.10). The average 
nuclear area of control cells was 149±7µm while the average nuclear area for DAG1 
KO clones A-E were 163±6µm, 177±7µm, 173±19µm, 221±34µm and 220±32µm 
respectively. The difference between the average control area and each of the KO 
averages was statistically significant for all cell lines except clone A where the average 
nuclear size was consistently larger than the control, but the difference was not 
statistically significant. 
 
Nuclear area was also measured using DAPI stained nuclei imaged on the confocal 
microscope (Figure 3.11a) and lamin B1 stained nuclei on both the Leica fluorescence 
microscope (Figure 3.11b) and the confocal microscope (Figure 3.11c). Each of these 
results gives different absolute values for nuclear area but they all show the same 
overall result – there is no difference between control and DAG1 KO clone A but a 
significant difference between control and DAG1 KO clone B. 
 
After confirming the DAG1 KO cell lines had a larger nuclear area than the controls 
the nuclear volume was then investigated. This is important to understand if the KO 
nuclei were simply flatter and wider, giving them a larger cross-sectional area, or if 
they have an increased volume. Control and DAG1 KO B cells were imaged following 
DAPI staining to define the nucleus. The resultant Z-stacks were then processed to 
generate a 3D reconstruction of each nuclei (Figure 3.12a). The volume of each 
reconstructed nucleus was then measured for the two samples (Figure 3.12b). The 
control nuclei had an average nuclear volume of 583±62µm3 while the DAG1 KO B 
nuclei had an average nuclear volume of 741±27µm3. The difference between these 
two values is statistically significant as determined by a Student’s t test with a p value 
of 0.0152. Based on this data it can be concluded that the nuclei of the KO cells have 




Figure 3.10 Average nuclear area of control and DAG1 KO clones A-E using DAPI to identify the nuclear region. 
Cells were grown for 24 hours before fixing and staining with DAPI to identify the nuclear region. Cells were 
imaged using the Leica fluorescence microscope and the nuclear area determined for analysis. Small black points 
indicate values from individual cells while larger coloured points indicate the average for each independent 
experiment. 7 independent experiments were carried out with control n = 789, KO A n = 781, KO B n = 772, KO C 
n = 784, KO D n = 738, KO E n = 752. Graph shows mean and standard deviation. A significant difference was 
determined between the control and DAG1 KO B-E as determined by one-way ANOVA test, p = <0.0001. p values 
for multiple comparisons using uncorrected Fisher’s least significant difference test are in the table. 
 
 





Control 148.8 6.6 N/A N/A
KO A 163.2 5.6 0.2569 ns
KO B 176.7 6.9 0.0185 *
KO C 173.4 18.6 0.0310 *
KO D 220.6 33.8 <0.0001 ****
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Figure 3.11 Average nuclear area of control and DAG1 KO clones A and B using DAPI or lamin B1 to identify the 
nuclear region and imaged using two different microscopes. (a) Cells were grown for 24 hours before fixing and 
staining with DAPI to identify nuclear region. Cells were imaged using the Nikon A1 confocal and the nuclear area 
determined for analysis. Coloured points indicate the average value for each independent experiment. 3 
independent experiments were carried out with control n = 77 and KO B n = 77. Graph shows mean and standard 
deviation. A significant difference was determined between the control and DAG1 KO B as determined by t test, 
p = 0.0032. (b) Cells were grown for 24 hours before fixing and staining with lamin B1 and DAPI to identify nuclear 
regions. Cells were imaged using the Leica fluorescence microscope and the nuclear area determined for analysis. 
Small black points indicate values from individual cells while larger coloured points indicate the average value for 
each independent experiment. 3 independent experiments were carried out with 83 control, 76 KO A and 96 KO 
B nuclei measured. Graph shows mean and standard deviation. A significant difference was determined between 
the control and DAG1 KO A or B as determined by one-way ANOVA test, p = 0.0082. p values for multiple 
comparisons using Dunnett’s multiple comparisons test are on the graph (c) As above, except Nikon A1 confocal 
was used. A significant difference was determined between the control and DAG1 KO A or B as determined by 
one-way ANOVA test, p = 0.0222. p values for multiple comparisons using Dunnett’s multiple comparisons test 
are on the graph. Control n = 102, KO A n = 100 and KO B n = 114. 
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As the nuclei of DAG1 KO cells are larger in both area and volume, the next important 
question is whether it is just the nuclei that are larger or is it in fact the cells are 
larger, and the nuclei are simply scaling with the cells. This question was addressed 
by staining cells with phalloidin to identify the whole cell. Control cells were 
compared with both DAG1 KO clones A and B with similar results to those observed 
for nuclear area (Figure 3.13a). The two KO clones had larger cell areas than the 
control cells. Control cells had an average area of 1494±341µm2 while DAG1 KO 
clones A and B had an average cell area of 2077±239µm2 and 2199±453µm2 
respectively. As with nuclear area, both clones have a larger average cell area 
compared with the control but only for clone B is this difference statistically 
significant. Additionally, when the nuclear/cell area ratio is calculated for all cell lines 
there is no difference in the ratio for either KO clone compared with the control 
(Figure 3.13b). This indicates that the increased nuclear size is also accompanied by 
an increase in cell size – thus the nucleus size scales with the cell size in all cell lines. 
 
 
Figure 3.12 Average nuclear volume of control and DAG1 KO clone B using DAPI to identify the nuclear region. 
Cells were grown for 24 hours before fixing and staining with DAPI to identify nuclear region. Cells were imaged 
















Nuclear Volume of Control and








using the Nikon A1 confocal and the 3D nuclear volume determined for analysis. (a) Representative 
reconstructions using Imaris software. (b) Graph showing nuclear volume of control and DAG1 KO clone B. Small 
black points indicate values from individual cells while larger coloured points indicate the average value for each 
independent experiment. 3 independent experiments were carried out with 45 control and 49 KO B nuclei 
measured. Graph shows mean and standard deviation. A significant difference was determined between the 




Figure 3.13 DAG1 KO cells are larger than control cells and cell size scales with nuclear size. Cells were grown 
for 24 hours before fixing and staining with DAPI and phalloidin to identify nuclear and cytoplasmic regions. Cells 
were imaged using the Leica fluorescence microscope and the nuclear and cellular area determined for analysis. 
(a) Whole cell area of control and DAG1 KO clones A-B. Small black points indicate values from individual cells 
while larger coloured points indicate the average for each independent experiment. 4 independent experiments 
were carried out with 66 control, 60 KO A and 72 KO B cells measured. Graph shows mean and standard deviation. 
A significant difference was determined by one-way ANOVA test, p = 0.0493. p values for multiple comparisons 
using Dunnett’s multiple comparisons test are on the graph (b) Nuclear area/cell area ratio for control and DAG1 
KO clones A-B. Small black points indicate values from individual cells while larger coloured points indicate the 
average for each independent experiment. 4 independent experiments were carried out with 66 control, 60 KO 
A and 72 KO B cells measured. Graph shows mean and standard deviation. A significant difference was not 
determined between the control and DAG1 KO clones A-B as determined by one-way ANOVA test, p = 0.1008. p 
values for multiple comparisons using Dunnett’s multiple comparisons test are on the graph. 
 
In order to determine whether the DAG1 KO nuclei are larger because of a lack of DG 
or simply because of off-target effects from generating the knockouts, full-length DG 
with a HA and a Myc tag (Cook, 2021) were transiently transfected into DAG1 KO B 
and C cells as they both display the larger nuclear phenotype. Control cells were 
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transiently transfected with a GFP construct while DAG1 KO cells were transfected 
with either GFP or DG constructs (Figure 3.14). Following transfection of GFP into 
control and DAG1 KO cell lines the nuclear area was measured and as with previous 
results of untransfected cells, the KO cell nuclei had a significantly greater area 
compared with the control (Figure 3.15a). This confirms that the transfection process 
does not affect the relative difference between nuclear area in control and DAG1 KO 
cell lines. Following this, control cells were transfected with GFP while both DAG1 KO 
clones were transfected with the HA/Myc tagged DG construct (Figure 3.15b). 
Addition of the DG construct to the DAG1 KO cells resulted in a reduction in nuclear 
area that did not differ significantly from that of the control cells. Additionally, there 
was a lower nuclear area for KO cell lines transfected with DG compared with when 
they were transfected with GFP (Figure 3.15c). The difference is statistically 
significant for DAG1 KO clone C and it is approaching significance for clone B with a 
p value of 0.0940. Taken together this data suggests that the addition of full-length 
DG rescues the large cell / large nuclei phenotype observed in untransfected and GFP 




Figure 3.14 Representative images of control and DAG1 KO clones B-C transiently transfected with GFP or HA 
and Myc tagged DG. (a) Representative images of control, DAG1 KO A and B transiently transfected with GFP as 
determined by anti-GFP antibody, co-stained with DAPI and lamin B1 to identify the nuclear region. One 
representative image from each sample, at least 10 images were taken per sample per experiment with 4 
independent experiments. (b) Representative images of DAG1 KO A and B transiently transfected with HA & Myc 
tagged DG as determined by anti-HA antibody, co-stained with DAPI and lamin A/C to identify the nuclear region. 
One representative image from each sample, at least 20 images were taken per sample per experiment with 4 
independent experiments. Scale bar = 20µm. 
Control
DAPI Lamin B1 GFP Merge
DAG1 KO B
DAG1 KO C







Figure 3.15 Average nuclear area of control and DAG1 KO clones B-C following transient transfection of GFP or 
HA & Myc tagged DG. Cells were grown for 24 hours before transfection and allowed to express proteins for at 
least 24 hours. Cells were then fixed and stained with DAPI, lamin A/C or B1 to identify the nuclear region and 
GFP or HA to identify transfected cells. Cells were imaged using the Leica fluorescence microscope and the nuclear 
area determined for analysis. (a) Nuclear area of control and DAG1 KO clones B-C following GFP transfection. The 
graph shows the mean with standard deviation, 4 independent experiments with 202 control, 200 KO A and 217 
KO B cells measured. Graph shows mean and standard deviation. The difference between the samples was 
significant as determined by one-way ANOVA, p = 0.0172. p values for multiple comparisons using Dunnett’s 
multiple comparisons test are on the graph (b) Nuclear area of control and DAG1 KO clones B-C following GFP 
transfection for control and DG transfection for DAG1 KO clones. The graph shows the mean with standard 
deviation, 4 independent experiments with 136 control, 147 KO A and 122 KO B cells measured . Graph shows 
mean and standard deviation. The difference between the samples was not significant as determined by one-way 
ANOVA, p = 0.8921. p values for multiple comparisons using Dunnett’s multiple comparisons test are on the graph 
(c) Nuclear area of control and DAG1 KO clones B-C following GFP or DG transfection. The graph shows the mean 
with standard deviation, 4 independent experiments with 136 control, 147 KO A and 122 KO B cells measured. 
The differences between the samples was approaching significance as determined by one-way ANOVA, p = 
0.0669. The difference between DAG1 KO clone C GFP and DG transfected was significantly different, p = 0.0345 
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3.2.5 Is increased nuclear size and cell size in DAG1 KO cell lines due to an increase 
in cellular senescence? 
 
One indicator of cellular senescence is impaired proliferation as the cells do not 
progress through the cell cycle and divide. Therefore, the proliferative ability of 
control and DAG1 KO cells was established. When the proliferation of the cells was 
assessed, it was clear that there is no reduction in the proliferation rate of the 
majority of DAG1 KO cell lines compared with the control (Figure 3.16). For DAG1 KO 
cell lines A and B there was no difference between the proliferation rates compared 
with the control at either day 4, 6 or 8. In the case of DAG1 KO clone C the signal 
intensity was significantly lower than the control at day 4 but by days 6 and 8 there 
was no difference. For DAG1 KO clones D and E there is a lower proliferation rate 
with a lower signal intensity for days 4, 6 and 8 when compared with the control. This 
data, taken together indicates that the majority of DAG1 KO cell lines do not have 
impaired proliferation when compared with the control cells. 
 
In addition to proliferation, an increase in the levels of euchromatin can be used as 
an indicator of cellular senescence. A change in the amount of decondensed 
chromatin can be detected by staining for the histone modification H3K9me3. An 
increase in intensity of H3K9me3 is indicative of increased heterochromatin while a 
decrease in intensity is indicative of an increase in euchromatin. The levels of 
H3K9me3 were assessed for DAG1 KO cell lines and normalised to the control cells 
for each experiment. There was a large amount of variation in the levels with some 
experiments indicating an increased level while others indicated a decreased level. 
Overall, the average normalised intensity for all DAG1 KO cell lines (A-E) was ~1 
(Figure 3.17) indicating no significant difference between the control and any of the 
KO cell lines. This data suggests that the levels of heterochromatin and euchromatin 




Increased levels of DNA damage can be a further indicator of cellular senescence. 
Staining for the histone modification gH2AX is a common method of identifying DNA 
damage within cells. When the levels of gH2AX were compared between control cells 
and DAG1 KO cell lines (A-E) there was no difference between control and KO cells 
A-C, whilst there was a significant increase in levels of gH2AX in DAG1 KO clones D 
and E (Figure 3.18). These data suggests that the majority of DAG1 KO clones have 
levels of DNA damage similar to that of control cells when detected using gH2AX. 
 
Taken together, these three pieces of evidence would suggest that the increased 
nuclear and cell size observed in DAG1 KO cell lines A-C is not due to an increase in 
Figure 3.16 Proliferation of control and DAG1 KO clones A-E over 8 days. Cells were seeded and allowed to 
grow for 2, 4, 6 or 8 days where they were fixed. Cells were then stained with DRAQ5 to stain cell nuclei and the 
signal intensity of DRAQ5 was used as a measure of proliferation. 3 independent experiments were carried out. 
Points shows mean and standard deviation. Only DAG1 KO clones D-E grew significantly slower than the control 
cells while there was no statistically significant difference between control and DAG1 KO clones A-C. Statistical 
analysis used two-way ANOVA with Dunnett’s multiple comparisons test, p values in the table. 
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Day 2 0.6574 0.7249 0.9858 0.1090 0.9169
Day 4 0.1091 0.1034 0.0315 0.0256 0.0379
Day 6 0.722 0.1311 0.1366 0.0158 0.0170
Day 8 0.6955 0.7061 0.9977 0.9999 0.3537
P values of KO compared with control
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cellular senescence. This is evidenced by similar proliferation rates to the control, no 
difference in heterochromatin levels and no difference in levels of DNA damage 
when compared with the control. On the other hand, DAG1 KO clones D and E show 
strong signs of cellular senescence as evidenced by the greatly decreased 
proliferation rates and the increased levels of DNA damage compared with control 




Figure 3.17 Relative H3K9me3 intensity for control and DAG1 KO clones A-E. Cells were grown for 24 hours 
before fixing and staining with DAPI and H3K9me3 to identify the levels of heterochromatin. Cells were imaged 
using the Leica fluorescence microscope and the nuclear H3K9me3 signal intensity was determined for analysis. 
Each coloured point indicates the average for each independent experiment which was normalised to the control 
value. 5 independent experiments were carried out with 173 control, 182 KO A, 169 KO B, 177 KO C, 156 KO D 
and 155 KO E nuclei measured. Graph shows mean and standard deviation. A significant difference was not 
determined by one-way ANOVA test, p = <0.9628. p values for multiple comparisons using Dunnett’s multiple 
comparisons test are in the table. Scale bar = 20µm. 





Control 1.000 N/A N/A N/A
DAG1 KO A 1.114 0.3367 0.4777 ns
DAG1 KO B 1.118 0.2639 0.4626 ns
DAG1 KO C 1.038 0.1169 0.8120 ns
DAG1 KO D 1.042 0.2699 0.7927 ns
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Figure 3.18 Relative gH2AX intensity for control and DAG1 KO clones A-E. Cells were grown for 24 hours before 
fixing and staining with DAPI and an antibody against gH2AX to identify the levels of DNA damage. Cells were 
imaged using the Leica fluorescence microscope and the nuclear gH2AX signal intensity was determined for 
analysis. Each coloured point indicates the average for each independent experiment which was normalised to 
the control value. 5 independent experiments were carried out with 179 control, 179 KO A, 183 KO B, 188 KO C, 
162 KO D and 150 KO E nuclei measured. Graph shows mean and standard deviation. A significant difference was 
determined between the samples as determined by one-way ANOVA test, p = <0.0179. p values for multiple 
comparisons using Dunnett’s multiple comparisons test are in the table. Scale bar = 20µm. 





Control 1.000 N/A N/A N/A
DAG1 KO A 0.9280 0.0497 0.3248 ns
DAG1 KO B 0.9871 0.1052 0.8455 ns
DAG1 KO C 1.054 0.1215 0.3019 ns
DAG1 KO D 1.166 0.2039 0.0276 *

























































yH2AX Intensity of Control and







3.2.6 Is increased nuclear and cell size in DAG1 KO cell lines due to changes in 
nuclear proteins lamin A/C, lamin B1 or emerin? 
 
Levels of lamin proteins have been implicated in the regulation of nuclear and cell 
size and it has also been shown previously that knockout or knockdown of DG can 
result in mislocalisation and a reduction in levels of lamin B1 and emerin in mouse 
C2C12 myoblasts (Jimenez-Gutierrez et al., 2020; Martínez-Vieyra et al., 2013). In 
order to investigate the total levels of these proteins in control and DAG1 KO cells, 
western blotting and immunofluorescence microscopy was used. Additionally, 
immunofluorescence microscopy was used to assess the protein localisation.  
 
3.2.6.1 Levels of lamin A/C in control and DAG1 KO human myoblasts 
 
Localisation of lamin A/C was investigated and was very clearly localised to the 
nuclear periphery in both control and DAG1 KO clones A and B (Figure 3.19a). Manual 
inspection of all images from control and KO samples did not identify any occurrences 
of lamin A/C localised anywhere other than the nuclear periphery or nucleoplasm. 
Therefore, quantification of this parameter was not carried out. Following the initial 
manual inspection for localisation the images were analysed to determine the 
relative intensity of lamin A/C in DAG1 KO nuclei compared with controls (Figure 
3.19b). The average relative intensity of lamin A/C for both DAG1 KO clones A and B 
was 0.75 and 0.78 respectively compared with a relative value of 0.96 for the control. 
Despite the average relative value being lower for the KO clones these differences 
were not statistically significant with p values of ~0.5.  
 
There was no clear difference in levels of lamin A/C in control and DAG1 KO cells 
when cells were grown at low cell density and therefore had minimal cell-cell 
contacts. It has been suggested that levels of lamins are regulated by cell density and 
cell-cell contacts. Therefore, levels of lamin A/C were also investigated in control and 
DAG1 KO cells grown at high cell density. Cells were grown to between 90% and 100% 
confluency and then stained for lamin A/C (Figure 3.20a). As with the cells at low cell 
confluency, manual inspection did not indicate any mislocalisation. Relative intensity 
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of lamin A/C at high cell confluency gave similar results to the low cell confluency 
experiments with the average intensity being slightly lower for the DAG1 KO clones 
but not significantly so (Figure 3.20b). Control nuclei had a relative lamin A/C 
intensity of 0.94 while DAG1 KO clones A and B had relative lamin A/C intensities of 
0.84 and 0.59 respectively however, neither of these differences were significant.  
 
 
Figure 3.19 Relative Lamin A/C intensity for control and DAG1 KO clones A-B at a low cell density determined 
by immunofluorescence. Cells were grown for 24 hours before fixing and staining with DAPI and lamin A/C to 
identify the levels of nuclear lamin A/C. Cells were imaged using the Nikon A1 confocal and the nuclear lamin A/C 
signal intensity was determined for analysis. Scale bar = 15µm. (a) Representative maximum projection images 
of lamin A/C stained control and DAG1 KO clone A and B cells grown at a low cell density. (b) Normalised lamin 
A/C intensity in control and DAG1 KO clones A-B. The different coloured points indicate the 4 independent 
experiments. Control n = 145, KO A n = 139 and KO B n = 162. Graph shows mean and standard deviation. There 
is no significant difference between the samples as determined by one-way ANOVA, p = 0.4988. p values for 
multiple comparisons using Dunnett’s multiple comparisons test are on the graph. 
 
In addition to there being no clear difference in levels of lamin A/C as determined by 
immunofluorescence staining, the total cellular levels of lamin A/C were further 
determined by western blot analysis. Whole cell lysate for each sample at high cell 
density was probed with lamin A/C antibody and GAPDH was used as a loading 
control (Figure 3.21). There was great variation between each biological repeat as 
observed with the immunofluorescence staining but overall, there was no 
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statistically significant difference between the control levels of lamin A/C and the 
DAG1 KO levels. DAG1 KO clone A had a slightly increased normalised level while 
clone B had a slightly decreased normalised level, however, neither of these 
differences are statistically significant. Taken together this data demonstrates that 
there is no difference in the levels of lamin A/C between control and DAG1 KO human 
myoblasts, indicating b-DG does not influence levels or localisation of lamin A/C in 




Figure 3.20 Relative Lamin A/C intensity for control and DAG1 KO clones A-B at a high cell density determined 
by immunofluorescence. Cells were grown for 24 hours before fixing and staining with DAPI and an antibody 
against lamin A/C to identify the levels of nuclear lamin A/C. Cells were imaged using the Nikon A1 confocal and 
the nuclear lamin A/C signal intensity was determined for analysis. Scale bar = 15µm. (a) Representative 
maximum projection images of lamin A/C stained control and DAG1 KO clone A and B cells grown at a high cell 
density. (b) Normalised lamin A/C intensity in control and DAG1 KO clones A-B. The different coloured points 
indicate the 4 independent experiments. Control n = 132, KO A n = 137 and KO B n = 129. Graph shows mean and 
standard deviation. There is no significant difference between the samples as determined by one-way ANOVA, p 
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Figure 3.21 Relative Lamin A/C levels of control and DAG1 KO clones A-B at a high cell density determined by 
western blot. Western blot analysis of lamin A/C levels using densitometry analysis from BioRad ImageLab 
software and normalised to GAPDH. Representative blot from 6 independent experiments. Graph shows mean 
and standard deviation. There is no significant difference between the samples as determined by one-way 
ANOVA, p = 0.1572. p values for multiple comparisons using Dunnett’s multiple comparisons test are on the 
graph. 
 
3.2.6.2 Levels of lamin B1 in control and DAG1 KO human myoblasts 
 
As with lamin A/C levels, the levels of lamin B1 were assessed using 
immunofluorescence microscopy and western blotting. Lamin B1 stained cells were 
imaged and assessed manually for localisation outside of the nucleus but this was 
not observed in control or DAG1 KO images (Figure 3.22a). These images were then 
run through a FIJI script to measure the intensity of lamin B1 within the nucleus. Each 
mean grey value for each independent experiment was normalised to the largest 
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0.89 and 0.99 for DAG1 KO clone A and B respectively (Figure 3.22b). The difference 
between the control value and the two KO values does not differ significantly 
suggesting the levels of lamin B1 are not affected by an absence of DG.  
 
 
Figure 3.22 Relative Lamin B1 intensity for control and DAG1 KO clones A-B at a low cell density determined by 
immunofluorescence. Cells were grown for 24 hours before fixing and staining with DAPI and lamin B1 to identify 
the levels of nuclear lamin B1. Cells were imaged using the Nikon A1 confocal and the nuclear lamin B1 signal 
intensity was determined for analysis. Scale bar = 15µm. (a) Representative maximum projection images of lamin 
B1 stained control and DAG1 KO clone A and B cells grown at a low cell density. (b) Normalised lamin B1 intensity 
in control and DAG1 KO clones A-B. The different coloured points indicate the 3 independent experiments. 
Control n = 102, KO A n = 97 and KO B n = 110. Graph shows mean and standard deviation. There is no significant 
difference between the samples as determined by one-way ANOVA, p = 0.2910. p values for multiple comparisons 
using Dunnett’s multiple comparisons test are on the graph. 
 
In addition to the levels of lamin B1 at a low cell density, the levels were also assessed 
at a high cell density to determine whether DG affects the levels of lamin B1 when 
cells are 90-100% confluent. Again, on manual inspection there was no evidence of 
any localisation to the cytoplasm in either control or DAG1 KO clones (Figure 3.23a). 
Following analysis of the relative intensity of lamin B1 in control and DAG1 KO cell 
lines there appears to be a significantly lower level of lamin B1 in DAG1 KO clone A 
compared with the control but no difference for clone B (Figure 3.23b). The average 
normalised value for control cells was 0.97 and 1.00 for DAG1 KO clone B, the value 
for DAG1 KO clone A was 0.72. The variation for these experiments was much lower 
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than observed for the low cell density experiment. This is a clear difference however, 
given the same trend is not observed in both KO clones this is unlikely to be due to 
the lack of DG and may be due to some other factor.  
 
In order to confirm or contradict the finding that levels of lamin B1 are significantly 
reduced in DAG1 KO clone A when cells are grown at a high cell confluency western 
blot analysis was used (Figure 3.24). The total levels of lamin B1 were assessed using 
a lamin B1 antibody and GAPDH as a loading control and total levels were normalised 
to GAPDH. Contradictory to the immunofluorescence data the western blot data 
suggests there is no difference in the total levels of lamin B1 in either DAG1 KO clone 
A or B when compared with the control. The average levels are slightly higher in KO 
samples but again there was large variation meaning these small differences were 
not statistically significant. Taken together this data would indicate that the levels of 





Figure 3.23 Relative Lamin B1 intensity for control and DAG1 KO clones A-B at a high cell density determined 
by immunofluorescence. Cells were grown for 24 hours before fixing and staining with DAPI and lamin B1 to 
identify the levels of nuclear lamin B1. Cells were imaged using the Nikon A1 confocal and the nuclear lamin B1 
signal intensity was determined for analysis. Scale bar = 15µm. (a) Representative maximum projection images 
of lamin B1 stained control and DAG1 KO clone A and B cells grown at a high cell density. (b) Normalised lamin 
B1 intensity in control and DAG1 KO clones A-B. The different coloured points indicate the 3 independent 
experiments. Control n = 93, KO A n = 100 and KO B n = 98. Graph shows mean and standard deviation. There is 
a significant difference between the samples as determined by one-way ANOVA, p = 0.0053. p values for multiple 
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Figure 3.24 Relative Lamin B1 levels of control and DAG1 KO clones A-B at a high cell density determined by 
western blot. Western blot analysis of lamin B1 levels using densitometry analysis from BioRad ImageLab 
software and normalised to GAPDH. Representative blot from 5 independent experiments. Graph shows mean 
and standard deviation. There is no significant difference between the samples as determined by one-way 
ANOVA, p = 0.7102. p values for multiple comparisons using Dunnett’s multiple comparisons test are on the 
graph. 
 
3.2.6.3 Levels of emerin in control and DAG1 KO human myoblasts 
 
Levels of emerin were assessed in the same manner as lamin A/C and B1. Relative 
emerin intensity was determined using immunofluorescence microscopy (Figure 
3.25a). As with both lamin A/C and B1 there is no difference in the relative levels of 
emerin in DAG1 KO clones A and B when compared with control cells (Figure 3.25b). 
Control nuclei had a relative intensity value of 0.82 while DAG1 KO clone A and B had 
relative intensity values of 0.94 and 0.85 respectively. These differences were not 
statistically significantly different with p values >0.7 as determined by a one-way 
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Figure 3.25 Relative nuclear Emerin intensity for control and DAG1 KO clones A-B at a low cell density 
determined by immunofluorescence. Cells were grown for 24 hours before fixing and staining with DAPI and 
emerin to identify the levels of nuclear emerin. Cells were imaged using the Nikon A1 confocal and the nuclear 
emerin signal intensity was determined for analysis. Scale bar = 15µm. (a) Representative maximum projection 
images of emerin stained control and DAG1 KO clone A and B cells grown at a low cell density. (b) Normalised 
emerin intensity in control and DAG1 KO clones A-B. The different coloured points indicate the 3 independent 
experiments. Control n = 92, KO A n = 104 and KO B n = 99. Graph shows mean and standard deviation. There is 
no significant difference between the samples as determined by one-way ANOVA, p = 0.7622. p values for 
multiple comparisons using Dunnett’s multiple comparisons test are on the graph. 
 
Unlike lamin A/C and B1 which localise almost exclusively to the nuclear periphery 
and nucleoplasm, emerin has some cytoplasmic localisation in addition to the nuclear 
localisation. From a manual assessment of all the images from control and DAG1 KO 
samples it appeared that there was no difference in the localisation of emerin 
between these samples, so it was not tested quantitatively. A previous study 
suggested that perturbation of DG resulted in emerin aggregates accumulating in the 
cytoplasm (Martínez-Vieyra et al., 2013; Vélez-Aguilera et al., 2018) which was not 
observed in any cells of any sample in these experiments. However, given not all the 
emerin present within the cells is localised to the nucleus a follow up experiment was 
carried out where the levels of emerin within the whole cell were determined rather 
than just the nucleus (Figure 3.26).  As with just nuclear emerin there was no 
difference in the total levels of emerin when comparing DAG1 KO clone A and B with 
controls. The control average relative value was 0.89 while DAG1 KO clone A and B 
were 0.83 and 0.87 respectively.  
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Figure 3.26 Relative whole cell Emerin intensity for control and DAG1 KO clones A-B at a low cell density 
determined by immunofluorescence. Normalised whole cell emerin intensity in control and DAG1 KO clones A-
B. The different coloured points indicate the 3 independent experiments. Control n = 92, KO A n = 104 and KO B 
n = 99. Graph shows mean and standard deviation. There is no significant difference between the samples as 
determined by one-way ANOVA, p = 0.9377. p values for multiple comparisons using Dunnett’s multiple 
comparisons test are on the graph. 
 
The relative intensity of emerin in cells seeded and grown to a high density was again 
similar to that observed for low cell density (Figure 3.27a). Each independent 
experiment had a large amount of variation with a different cell line having the 
largest value in each of the three independent experiments. This resulted in an 
average relative value of 0.60, 0.64 and 0.72 for control, DAG1 KO A and B 
respectively (Figure 3.27b). Based on this evidence there is no apparent difference in 
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Figure 3.27 Relative emerin intensity for control and DAG1 KO clones A-B at a high cell density determined by 
immunofluorescence. Cells were grown for 24 hours before fixing and staining with DAPI and emerin to identify 
the levels of nuclear emerin. Cells were imaged using the Nikon A1 confocal and the nuclear emerin signal 
intensity was determined for analysis. Scale bar = 15µm (a) Representative maximum projection images of emerin 
stained control and DAG1 KO clone A and B cells grown at a high cell density. (b) Normalised emerin intensity in 
control and DAG1 KO clones A-B. The different coloured points indicate the 3 independent experiments. Control 
n = 107, KO A n = 94 and KO B n = 97. Graph shows mean and standard deviation. There is no significant difference 
between the samples as determined by one-way ANOVA, p = 0.8934. p values for multiple comparisons using 
Dunnett’s multiple comparisons test are on the graph. 
 
The total levels of emerin at high cell density were also assessed using western blot 
analysis. Emerin was probed for using an emerin specific antibody and GAPDH was 
used as a loading control and the emerin intensity values were normalised to the 
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independent experiment resulted in a large amount of variation but gave the same 
result. There is no difference between the total levels of emerin when comparing 
DAG1 KO clones A and B with control cells. Taken together, these data indicated that 
the total levels of emerin are not affected by the presence or absence of DG in human 
myoblasts at either high or low cell density. It is also clear from the microscopy 
images that emerin is not mislocalised in DAG1 KO cell lines.  
 
 
Figure 3.28 Relative Emerin levels of control and DAG1 KO clones A-B at a high cell density determined by 
western blot. Western blot analysis of emerin levels using densitometry analysis from BioRad ImageLab software 
and normalised to GAPDH. Representative blot from 4 independent experiments. Graph shows mean and 
standard deviation. There is no significant difference between the samples as determined by one-way ANOVA, p 
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The results described in this chapter aimed to answer the question of whether 
perturbing DG in human myoblast cells resulted in abnormally shaped nuclei. An 
additional aim was to determine whether previously reported data, suggesting b-DG 
was required for correct localisation and regulation of lamin B1 and emerin in mouse 
C2C12 muscle cells (Martínez-Vieyra et al., 2013; Vélez-Aguilera et al., 2018), was 
also true in human myoblasts.   
 
3.3.1 Limitations of b-DG antibodies 
 
The primary antibodies against b-DG used in this study have long been used in the 
detection of b-DG for both western blot and immunofluorescence analysis. However, 
it has become apparent there are a number of limitations in their use. For all 
antibodies used here; MANDAG2, LG5, JAF1, C-20 and 1709 the binding site is located 
within the C-terminal region of the cytoplasmic region. This region has been 
identified as the binding site for the majority of the interacting partners that binds b-
DG (see section 1.1.3.3). This being the case, the antibody binding site is likely to be 
in competition for binding with many other proteins which may reduce the efficacy 
of the antibody. The other issue with all of these antibodies is they have a high degree 
of background signal as can be seen in Figure 3.3. This is because all these antibodies, 
except MANDAG2 are polyclonal which results in a large amount of background 
signal due to the presence of non-specific antibodies in the serum. The other issue 
with these antibodies is the lack of batch-to-batch consistency which can cause 
difficulties when trying to reproduce data, this can be seen in part in Figure 3.4. 
 
Despite these issues, MANDAG2, LG5, JAF1 and 1709 appear to have reduced signal 
in the DAG1 KO cell lines as expected. However, C-20 appears to have almost 
identical staining in control and DAG1 KO cells, additionally, there appears to be very 
prominent nucleoli staining in cells both containing and lacking DG. This is a concern 
as many of the reports in the literature relating to the role of b-DG in the nucleus use 
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this antibody. In early studies C-20 was used in immunofluorescence colocalisation 
studies to suggest co-localisation with nucleoli proteins Nopp140 and SC35. 
Additionally, it was used in co-immunoprecipitation assays to suggest a direct 
interaction between b-DG and Nopp140 (Martínez-Vieyra et al., 2013). C-20 has also 
been used more recently in a paper discussing the potential role of b-DG in the 
nucleoli (Azuara-Medina et al., 2019). In addition to the issue of C-20 binding non-
specifically to the nucleoli, there is also data suggesting that a large amount of cross-
reactivity occurs between C-20 and other primary antibodies – particularly those 
raised in mouse or rabbit (Figure 3.29) (Matt Cook, personal communication). The 
evidence of cross-reactivity makes this antibody particularly unreliable for 
colocalisation analysis as presented in the Martínez-Vieyra et al. (2013) study 
described above. 
 
The b-DG antibodies used in this chapter have some limitations as discussed, one of 
the main issues with this is obtaining an accurate understanding of specific 
localisation of b-DG because of the background noise. However, despite this issue it 
appears that b-DG staining is present within the nucleus in KM155 and CRISPR/Cas9 
control cells and this nuclear staining is generally lost in the KO cells lacking b-DG. It 
is important when using these antibodies to be aware of these limitations and take 




Figure 3.29 Cross-reactivity between b-DG antibody C-20 and emerin antibody in KM155 human myoblast cells. 
Representative images of KM155 myoblasts stained with either C-20 alone or stained with C-20 and emerin 
together. There is clear nuclear envelope stanning for C-20 in the C-20 + emerin sample which is not present 
when C-20 is used alone. Scale bar = 20µm.  
 
3.3.2 Differences in observed nuclear shape phenotype 
 
Changes in nuclear shape are often indicative of nuclear damage either mechanically 
or due to aberrant expression of nuclear lamina proteins including lamin A/C, B1 and 
emerin (Chen et al., 2018; Lammerding et al., 2006). Mutations in the DAG1 gene, 
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(Jacobs, 2017). In addition to this there have been multiple studies from the Cisneros 
lab group investigating the effects that perturbing b-DG has on the nucleus. In the 
original paper investigating this, they suggest that shRNA knockdown of b-DG 
resulted in an increase in abnormally shaped nuclei compared with the control 
(Martínez-Vieyra et al., 2013). However, the few images presented in this paper do 
not appear to be abnormally shaped. Additionally, nuclear abnormality has been 
assessed in an unblinded experiment which leaves it susceptible to bias. There is also 
no additional quantification such as nuclear circularity which would give a numerical 
value and allow a more confident conclusion to be drawn. In a follow up paper where 
the same group investigate the effects of knocking down a-dystrobrevin, another 
component of the DAPC, they conclude that the knock down results in more 
abnormally shaped nuclei (Aguilar et al., 2015) but this is assessed as above with no 
numerical values for shape.  
 
In the most recent publication from the Cisneros lab, where a possible senescence 
phenotype is investigated, CRISPR/Cas9 knockout C2C12 cells are generated, and 
nuclear shape is assessed. They find that the nuclear circularity index for two DAG1 
KO clones is lower than the WT (Jimenez-Gutierrez et al., 2020). One criticism of this 
experiment is they did not compare the circularity of the KO nuclei with a suitable 
CRISPR/Cas9 treated control. Therefore, it is not possible to be sure that the tiny 
reduction in circularity is not due to the CRISPR/Cas9 treatment rather than a lack of 
DG. This should also be further confirmed by a rescue experiment to confirm it is 
indeed DG responsible for the phenotype. The same study also looked for the 
presence of micronuclei in the WT and DAG1 KO cells and found that significantly 
more of the KO cells had micronuclei compared with the WT (Jimenez-Gutierrez et 
al., 2020). 
 
It is clear from these studies that despite the issues with the methodology, the 
general conclusion from the data presented is that knocking out/down DG results in 
a small change in nuclear shape in less than 50% of the cells. This data is in stark 
contrast to the data presented in this chapter and the data presented by other 
members of the Winder lab (Cook, 2021). The obvious difference between this study 
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and the previous ones is the cell type that is used. This study focuses on human 
myoblasts whereas the previous investigations by the Cisneros lab have focused on 
mouse C2C12 myoblasts. However, I believe the most likely explanation is that the 
C2C12 DAG1 KO cells used in the most recent study were senescent. In this chapter 
DAG1 KO cell lines D and E were the only cell lines to have a reduced circularity 
phenotype and these cells then went on to become senescent as will be discussed 
below. Given that three of the five DAG1 KO cell lines did not demonstrate this 
senescence phenotype it is more likely that this is a side effect of CRISPR/Cas9 or a 
result of clonal expansion. The fact only two KO cell lines were used means it is 
possible that their observed reduction in circularity is not a result of knocking out DG. 
A lack of a mock CRISPR/Cas9 control or a rescue experiment prevents any clear 
conclusions being made.        
 
3.3.3 Differences in observed nuclear size phenotype 
 
Unlike nuclear shape, the nuclear size of cells lacking DG has not been investigated 
until recently. The only report of nuclear size differences in cells with perturbed DG 
investigates the relationship between DG and cellular senescence as discussed in 
section 1.2.3.4 (Jimenez-Gutierrez et al., 2020). This study finds that the nuclei of 
C2C12 mouse myoblasts where DAG1 has been knocked out have a significantly 
greater area than WT nuclei. In addition, it is also found that the KO cells have a 
greater area when compared to WT (Jimenez-Gutierrez et al., 2020). This is in 
agreement with the data presented in this study where all DAG1 KO human 
myoblasts have larger nuclear and cellular areas compared with the control cells. 
Additionally, in this study we go on to show that the DAG1 KO nuclei are not just 
larger in 2-dimensions but indeed 3-dimensions as demonstrated by the greater 
nuclear volume in DAG1 KO clone B.  
 
The data presented by Jimenez-Gutierrez et al. (2020) would suggest that this 
increase in nuclear size is due to an increase in cellular senescence in the DAG1 KO 
cells. However, the data presented here do not fit with that general hypothesis. 
Either increased or decreased levels of lamin B1 are indicative of a senescent state 
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(Dreesen et al., 2013; Freund et al., 2012; Shah et al., 2013). A decrease in the levels 
of H3K9me3 which is indicative of reduced levels of heterochromatin is a common 
hallmark of cellular senescence (Deng et al., 2019; Sadaie et al., 2013), as is an 
increase in levels of DNA damage as indicated by gH2AX (Salunkhe et al., 2021; Zhang 
et al., 2016).  
 
Focusing on DAG1 KO clones A-C which exhibit a greater average nuclear and cellular 
size, however the experiments used to indicate senescence did not agree with the 
conclusion of a senescent phenotype. There is no reduction in the proliferation rate 
of KO cells compared with control, there is no difference in the relative levels of 
heterochromatin marker H3K9me3, the relative levels of gH2AX which is a marker of 
DNA damage or the relative levels of lamin B1. An additional argument against a 
senescent phenotype in DAG1 KO clones A-C is the evidence of a reversable 
phenotype. Rescue experiments of DAG1 KO clone B and C using tagged DG resulted 
in the rescue of the nuclear size phenotype. Given that cellular senescence is defined 
as irreversible cell-cycle arrest, if a lack of DG resulted in true cellular senescence this 
should not be rescued by the addition of exogenous DG.  
 
In the case of DAG1 KO clones D and E, they clearly have a significantly larger nuclear 
area than the control cells and are also the largest nuclei of all cell types measured 
with control nuclei being ~150µm2, DAG1 KO A-C ~170cm2 and DAG1 KO D-E 
~220cm2. In addition to this they had a significantly decreased proliferation rates 
compared with control cells – further they stopped growing altogether so they were 
unable to be used for the whole study. Additionally, clones D and E had increased 
levels of DNA damage as measured by levels of gH2AX. The only parameter these 
clones did not demonstrate an expected phenotype was levels of H3K9me3 where 
there was no difference in total levels between DAG1 KO clones D-E and the control. 
This is possibly due to antibody sensitivity as there was a large range of values across 
experiments for all cell lines used. Ideally, the DAG1 KO clones D-E would have been 
tested for cellular senescence using b-galactosidase senescence assay however, the 
cells stopped growing completely before this was carried out.  
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Based on the data presented here, there is very clear evidence that DAG1 KO clones 
D-E were senescent while clones A-C did not have the hallmarks of cellular 
senescence. This diversity of responses within a range of DAG1 KO cell lines calls into 
question the findings presented by Jimenez-Gutierrez et al. (2020). The data 
presented in that study is only based on two DAG1 KO clones, if by chance in this 
study only DAG1 clones D-E were used then we may have drawn the same 
conclusions. However, the lack of senescence phenotype observed in clones A-C 
suggests this is not the case. This calls into question the methodology of the Jimenez-
Gutierrez et al. (2020) study, the heterogenicity of clonal expansion is well 
established therefore it is prudent to use as many separate clones as possible before 
making any definitive conclusions. Additionally, rescue experiments should be 
attempted to further validate the role of DG and exclude the possibility of 
observations being due to clonal expansion. Finally, it is important to compare the 
DAG1 KO clones with passage matched clonally expanded controls in order to 
minimise differences, however, in the Jimenez-Gutierrez et al. (2020) study the DAG1 
KO clones were only compared with the WT C2C12 population.  
 
Ultimately, it is possible to conclude from these data presented here that 
perturbation of DG does lead to an average increase in nuclear and cellular size 
however, this increase is not due to cellular senescence. The exact reason for this 
increase in size is yet to be determined.   
 
3.3.4 Differences in observed nuclear envelope protein levels and localisation 
 
It has been suggested previously that nuclear b-DG is involved in interactions with 
lamin A/C, lamin B1 and emerin (Gómez-Monsiváis et al., 2020; Martínez-Vieyra et 
al., 2013). It has also been suggested that the perturbation of b-DG or the DAG1 gene 
results in reduced levels and mislocalisation of both lamin B1 and emerin but not 
lamin A/C. This then results in phenotypes associated with reduced levels of lamin 
B1 and emerin such as nuclear shape abnormalities and centrosome duplication 
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(Gómez-Monsiváis et al., 2020; Martínez-Vieyra et al., 2013; Vélez-Aguilera et al., 
2018).  
 
The results presented in these studies, conducted in the Cisneros lab, have shown 
consistently that in mouse C2C12 myoblasts either reduction or overexpression of b-
DG results in reduced levels of lamin B1 and emerin. However, this is in stark contrast 
to data presented in this study where there is no detectable difference in the levels 
of lamin A/C, lamin B1 or emerin in control and DAG1 KO cells. In addition to this 
there is no evidence to suggest any mislocalisation of lamin B1 and emerin in any cell 
lines investigated in this study. There are a few possibilities for the differences 
observed between the present study and previous studies. One possibility is the 
difference in cell lines used, in this study human myoblasts were used while previous 
studies have focused on mouse myoblasts. Despite mouse models being used 
extensively the disparity in results between this study and previous ones could be 
explained by this difference. However, when DG was knocked down in H2K mouse 
myoblasts, nuclear abnormalities were not reported suggesting there was no obvious 
nuclear morphology phenotype (Thompson et al., 2008). Alternatively, these 
differences could be a consequence of the different protocols used for the 
immortalisation of these cell lines.  
 
An alternative explanation of the difference could be due to methodological 
differences. In the mouse cell studies quantification of protein localisation involved 
unblinded manual determination of protein localisation which is susceptible to bias 
(Martínez-Vieyra et al., 2013; Vélez-Aguilera et al., 2018). This should have been 
quantified as a cytoplasmic intensity as this is simple to automate and reduces bias. 
However, in human myoblasts there was no evidence of protein mislocalisation in 
any of the cell lines tested so this automated analysis was not required. The total 
levels of lamin B1 and emerin were assessed using western blotting analysis in mouse 
myoblasts while in this study both immunofluorescence and western blotting 
analysis was used for human myoblasts. Finally, the type of control samples used 
were different when DAG1 was knocked out of mouse or human myoblasts. There 
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are the same issues relating to clonal expansion and a lack of any rescue experiments 
as discussed in section 3.3.3.  
 
The phenotypes that have been described in this study and those from previous 
studies differ and this is likely to be a combination of differences in cell types and 
differences in methodological approach. Ultimately, the results presented here are 
robust enough to confidently conclude that in human myoblasts the knockout of the 
DAG1 gene does not result in either mislocalisation or a reduction in levels of lamin 




4 Investigating the effect of perturbing DAG1 on the inherent 





4.1.1 Mechanical properties of cells and nuclei are determined by the cytoskeleton, 
nucleoskeleton and chromatin 
 
Measuring the mechanical properties of cells, particularly using atomic force 
microscopy, allows the determination of the stiffness of the different cellular 
compartments i.e. the cytoplasm and the nucleus. However, these two 
compartments are mechanically linked making it difficult to separate the specific 
contribution of each. It is well established that cells mechanically sense their 
environment and adjust the mechanical properties of the cells to match that of the 
underlying substrate, predominantly through the reorganisation of the actin 
cytoskeleton (Doss et al., 2020). In a recent study, multiple mammalian cell types 
were measured on PDMS substrates with varying stiffness from 0.5-3MPa and in all 
cell types the cell stiffness increased with increased substrate stiffness (Wala and 
Das, 2020). Similar results were observed when cells were grown on glass, 
polystyrene or poly-L-lysine coated glass. Polystyrene and Poly-L-lysine-coated glass 
have a lower Young’s modulus than glass and cells accordingly had reduced stiffness 
compared with those grown on uncoated glass (Caluori et al., 2018). However, it has 
been suggested that a decrease in cell stiffness at low substrate stiffness (<2kPa) is 
due to indenting the substrate as well as the sample but this can be accounted for 
depending on the model used to fit the data (Rheinlaender et al., 2020). 
 
Stiff cells grown on stiff substrates have increased levels of actin which is organised 
in more rigid actin cables (Doss et al., 2020; Wala and Das, 2020). Therefore, 
perturbation of the actin cytoskeleton results in a decrease in cellular stiffness. When 
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human bladder cancer cells T24 and RT4 (Wang et al., 2018) and mouse embryonic 
fibroblast NIH3T3 cells (Zhang et al., 2020) were treated with Cytochalasin D, 
treatment resulted in a significant decrease in cell stiffness compared with untreated 
controls. However, when cells in these studies were treated with nocodazole to 
perturb the microtubules there were differing effects. Wang et al. (2018) reported 
that nocodazole treatment resulted in a decrease in cellular stiffness but this 
decrease was not as severe as CytoD treatment (or a combination of CytoD and 
nocodazole). Conversely, Zhang et al. (2020) reported an increase in cellular stiffness 
following nocodazole treatment and they suggest this is because the depolymerised 
microtubules result in an increase in actin polymerisation ultimately resulting in 
stiffer cells. The discrepancy between these results is possibly due to difference in 
cell type or difference in measuring technique, Wang et al. (2018) used AFM while 
Zhang et al. (2020) used Brillouin microscopy. Despite the differences it is clear from 
these experiments that the microtubule network has a lower impact on the 
mechanical properties of cells compared with the actin cytoskeleton. Cytoplasmic 
intermediate filaments also make up part of the cytoskeleton and it has been found 
that vimentin, a type III intermediate filament, that forms a protective cage around 
the nucleus contributes to the cell stiffness (Patteson et al., 2019a). Measuring the 
stiffness of vim-/- mouse embryonic fibroblasts over the nucleus gave an average 
apparent Young’s modulus that was significantly lower than the vim+/+ control, 
suggesting intermediate filaments also contribute to the overall stiffness of a cell 
(Patteson et al., 2019b). 
 
Nuclear stiffness is determined by a combination of the nuclear lamina and 
chromatin (Hobson et al., 2020; Zhang et al., 2020). The contribution of lamin A to 
the mechanical properties of the nucleus was initially investigated in the nuclei of 
Xenopus oocytes due to their large nuclei (so reducing the impact of chromatin) and 
lack of endogenous lamins. Using this system it was found that the nuclear stiffness 
increased in a dose-dependent manner following lamin A expression (Schäpe et al., 
2009). Mutant lamins have also been investigated using this method, the mutation 
E145K found in Hutchinson-Gilford progeria syndrome resulted in increased nuclear 
stiffness compared with WT lamin (Kaufmann et al., 2011). This has also been 
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observed in human patient samples (Apte et al., 2017). The fact a single mutation in 
lamin A can result in a significant increase in nuclear stiffness emphasises the 
important role lamins play. Further evidence that lamins play an essential role in 
regulating nuclear stiffness is observed in autosomal dominant leukodystrophy 
patient samples. These samples have reduced levels of lamin B1 in addition to a 
decrease in nuclear stiffness. Further, depletion of lamin B1 in HEK293 and neuronal 
N2a cells resulted in a decrease in nuclear stiffness while overexpression of lamin B1 
resulted in an increase (Ferrera et al., 2014).  
 
In addition to lamins, chromatin significantly contributes to the stiffness of nuclei. 
The stiffness of the nucleus is regulated by the relative ratios of heterochromatin and 
euchromatin. The addition of trichostatin A, a small molecule inhibitor of histone 
deacetylase, results in an increase in the proportion of heterochromatin compared 
with euchromatin and a decondensing of the chromatin. Treatment of multiple cell 
lines with TSA prior to mechanical measurement results in a significant decrease in 
nuclear and cellular stiffness (Krause et al., 2013; Mazumder et al., 2008; Zhang et 
al., 2020). This decrease in stiffness occurred in a dose-dependent manner (Krause 
et al., 2013; Zhang et al., 2020). When cells were compressed with an extremely stiff 
AFM cantilever the nuclei were compressed to 20% of the original height while 
treatment with TSA resulted in an additional 5% decrease in height, suggesting the 
importance the chromatin plays in maintaining nuclear rigidity (Krause et al., 2013). 
 
Manipulating the levels of lamins and the state of chromatin influences the nuclear 
stiffness, however, these two components do not act independently of each other. 
When chromatin is no longer tethered to the INM by lamins and other INM proteins 
there is a reduction in nuclear stiffness (Schreiner et al., 2015). Additionally, 
chromatin in cells lacking lamin A/C have perturbed chromatin viscoelasticity with a 
decrease in local harmonic force (how much force is generated by the movement of 
chromatin) (Vivante et al., 2020). Two recent studies have looked at how the nuclear 
lamina and the chromatin respond to mechanical force of different types. They find 
that short extensions (following nuclear stretching) result in chromatin responding 
while longer extensions (>3µm) result in a response from the nuclear lamina 
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(Stephens et al., 2017). This observation was also confirmed using combined AFM 
and light sheet imaging to observe the chromatin and nuclear lamina. This study also 
found that chromatin responded to short extensions (indentations) while the nuclear 
lamina responded to longer extensions (Hobson et al., 2020). Ultimately, all these 
studies show that the mechanical properties of cells are regulated by an intricate 
balance between the cytoskeleton, nuclear lamina and chromatin. 
 
4.1.2 Hypothesis and Aims 
 
Previously published data discussed in section 1.2.3 suggests that disruption of DG 
results in a reduction of nuclear lamin proteins lamin A/C and B1 as well as 
mislocalisation of lamin B1 in mouse C2C12 cells. Both lamin A/C and lamin B1 have 
been reported to influence the mechanical properties of cells and nuclei. Therefore, 
the hypothesis is that perturbation of DG and subsequently the nuclear lamina would 
result in a decrease in nuclear stiffness. Despite the fact we do not see any observable 
effect on the nuclear lamina following DAG1 KO in human myoblast cells it is 
important to investigate any difference in mechanical properties of control and KO 
cell lines.  
 
The aims of the experiments presented in this chapter were to measure the Young’s 
modulus of control and DAG1 KO cell lines and directly compare these. Additionally, 
cells were treated with CytoD and TSA to determine the contribution of chromatin 
and the cytoskeleton. Further, isolated nuclei were measured to determine the 








The advantages of using a spherical tipped cantilever over sharp tips for mechanical 
measurements of cells has been well established (Zemła et al., 2020). One advantage 
is the more uniform distribution of applied force across the cell or organelle. This is 
not the case when a sharp tip is used as it results in localised force application and 
therefore a measurement of a smaller area of the cell. This localised application also 
increases the chance of damaging the sample. 
 
The rectangular MLCT-O10 probe was used for cell and nuclear measurements 
discussed in this chapter as it had a low spring constant (nominally 0.02N/m) 
comparable to the stiffness expected for cells and nuclei (Zemła et al., 2020). The 
MLCT-O10 cantilevers are tipless (Figure 4.1a) and required functionalising with a 
polystyrene bead that had a 5µm diameter. 5µm beads were chosen as that is the 
approximate size of the nuclei in KM155 human myoblasts. Multiple attempts were 
required to generate a procedure that could reliably produce functionalised 
cantilevers that were suitable for use. The first attempts involved using microscope 
slides cleaned with isopropanol and air dried, the adhesive and the beads stored in 
water were added to the slide. When the beads had dried the cantilever was dipped 
in the adhesive and then approached the surface over a single bead to pick it up. This 
method did not result in picking up the bead as it remained on the surface of the 
slide. The second method involved cleaning the slide with Piranha solution to reduce 
adhesion between the bead and the slide which would allow the bead to be picked 
up by the adhesive coated cantilever, but this was also unsuccessful. The third 
method was the same as the second, except the beads were washed extensively in 
ethanol before adding them to the slide. This was also unsuccessful. The following 
method was the same except the ethanol cleaned beads were allowed to air dry 
before adding to the slide. This was successful in terms of the cantilever coated in 
adhesive was able to pick up the bead from the slide. Despite the bead being stuck 
to the cantilever there was an excess of adhesive that resulted in adhesive covering 
most of the bead which is unsuitable for measurements as the spherical geometry is 
lost (Figure 4.1b). The final and successful method involved cleaning the slides with 
Piranha solution and washing the beads in ethanol and allowing the ethanol to 
evaporate before adding them to the slide. The cantilever then approached and 
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contacted the adhesive and contacted the surface of the slide twice following contact 
with the adhesive to remove any excess and leaving just a thin layer on the cantilever. 
This left just enough adhesive to pick up and maintain the bead in place but not 
enough to run over the sides of the bead (Figure 4.1c). 
 
 
Figure 4.1 SEM of MLCT-O10 cantilevers. (a) MLCT-O10 cantilever prior to functionalisation with 5µm bead. (b) 
MLCT-O10 cantilever functionalised with 5µm bead with excess glue. (c) MLCT-O10 cantilever successfully 








4.2.2 Force mapping of a single control cell in order to determine height and 
stiffness of different cellular regions 
 
Force mapping of an entire cell allows determination of multiple parameters across 
the whole cell; it provides information on height/topography and a corresponding 
map of Young’s moduli (E). Generating a force map of a control cell indicates the 
highest point of the cell is ~4.2µm and this corresponds to the nucleus (Figure 4.2). 
Based on this height analysis the lowest cytoplasmic hight is ~2µm with it increasing 
moving towards the nucleus. This is important information as it means indentation 




Figure 4.2 Topographical height map of gRNA control cell. (a) Map of cell height measured using a cantilever 
with 5µm bead. Measured with a setpoint of 3nN and a loading rate of 7µm/s. (b) 3D projection of the height 





From these measurements a map of Young’s modulus across the whole cell was also 
generated (Figure 4.3). The stiffest areas are at the cellular periphery as this is likely 
to include, in part, the stiffness of the underlying substrate (Figure 4.3a). When the 
Young’s moduli is thresholded to <12kPa and <6kPa the main body of the cell is within 
this range, with the nucleus being the softest region and the stiffness increasing 
moving further towards the cell periphery (Figure 4.3b,c).  
 
 
Figure 4.3 Modulus maps of a gRNA control cell. Modulus map of an entire cell measured using a cantilever with 
a 5µm bead. Measured with a setpoint of 3nN and a loading rate of 7µm/s. Force map thresholded at (a) 19.4kPa, 





4.2.3 Investigating the mechanical properties of asynchronous populations of 
control and DAG1 KO cells 
 
Following cell seeding the cells were incubated at 37°C for at least 24 hours to ensure 
secure attachment to the plastic petri dish. Measurements were taken in cell growth 
media at 37°C to keep the cells as close to physiological conditions as possible. Each 
cell was identified using the optical microscope associated with the AFM and 10 
measurements were taken either directly above the centre of the nucleus or away 
from the nucleus to measure the cytoplasmic stiffness (Figure 4.4a). The 
measurements produce a force-indentation curve (Figure 4.4b) from which the 
Young’s modulus can be calculated following the fitting of the Hertz model. To 
determine whether taking the average of 10 measurements resulted in a change in 
stiffness between the first and final measurements the E was determined following 
one approach and retraction cycle of the cantilever and then again using the 50th 
approach and retraction cycle (Figure 4.4c). The first measurement was normalised 
to 1 and the 50th measurement was normalised accordingly with no significant 
difference between the value determined after 1 cycle and the value determined 
after the 50th cycle which confirms the stability of the E after 10 measurements. 
Additionally, the extent to which the nuclear stiffness was affected by cell contacts 
was also determined. In order to test this, control cells that were either isolated from 
all other cells or in contact with at least one other cell, were measured (Figure 4.4d). 
The average E for cells with no contacts and those with contacts did not differ 
significantly. This data indicates it is not essential to only measure cells that are 
isolated from contact.  
 
In the case of the nuclear measurements, the average Young’s modulus of 
asynchronous control cells was slightly lower than that of all the KO clones (Figure 
4.5).  However, none of these differences were statistically significant as determined 
by a one-way ANOVA test. The fact that the Young’s modulus of all three DAG1 clones 
were not significantly different from the control indicates b-DG, and DG more 
broadly, does not influence the nuclear stiffness of an asynchronous population of 




Figure 4.4 Measurements of whole cells using AFM. (a) Example brightfield images demonstrating the optical 
view using the AFM. In each image the cantilever is at the bottom. The nuclear regions measured are indicated 
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control cells, the black curve indicates the approach while the grey curve indicates the retract. (c) Nuclear stiffness 
of gRNA control cells measured using the first measurement and the 50th measurement with each value for the 
50th measurement being normalized to the first measurement. n = 6, no significant difference using students t-
test, p = 0.2991. (d) Nuclear stiffness of gRNA control cells either in contact or isolated from other cells. 0 contacts 
n = 70, >1 contact n = 83, no significant difference using students t-test, p = 0.3998. 
 
Figure 4.5 No difference in average nuclear Young’s modulus between control and DAG1 KO cell lines in 
asynchronous populations. Nuclei were measured using a functionalised cantilever. Small black points indicate 
values from individual cells while larger coloured points indicate the average for each independent experiment. 
5 independent experiments were carried out with 125 nuclei measured per sample. Graph shows mean and 
standard deviation. A significant difference was not found between any of the samples as determined by one-
way ANOVA test p = 0.4372. p values for multiple comparisons using Dunnett’s multiple comparisons test are in 
the table. 





Control 2.4068 0.4726 N/A N/A
DAG1 KO C 2.6484 0.4565 0.7672 ns
DAG1 KO D 2.8256 0.2605 0.3661 ns
DAG1 KO E 2.7752 0.4812 0.4724 ns
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Results from the measurements of the cytoplasmic regions of control and DAG1 KO 
cells are similar to the nuclear region measurements. Control cells have an average 
cytoplasmic Young’s modulus slightly lower than the DAG1 KO cells (Figure 4.6) but 
as observed with nuclear stiffness, the difference was not statistically significant. 
These data show that the perturbation of DG has no effect on the cytoplasmic 
stiffness in asynchronous myoblasts.  
 
 
Figure 4.6 No difference in average cytoplasmic Young’s modulus between control and DAG1 KO cell lines in 
asynchronous populations. Cells were measured using a functionalised cantilever. Small black points indicate 
values from individual cells while larger coloured points indicate the average for each independent experiment. 
5 independent experiments were carried out with 125 cells measured per sample. Graph shows mean and 
standard deviation. A significant difference was not found between any of the samples as determined by one-
way ANOVA test p = 0.8078. p values for multiple comparisons using Dunnett’s multiple comparisons test are in 
the table. 
 





Control 2.7134 0.5498 N/A N/A
DAG1 KO C 2.7656 0.6224 0.9992 ns
DAG1 KO D 2.8728 0.3399 0.9777 ns
DAG1 KO E 3.1078 0.4812 0.759 ns
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The nuclear and cytoplasmic data was then combined to determine whether there is 
a difference between the nuclear stiffness and the cytoplasmic stiffness within each 
cell line (Figure 4.7). Generally, the average cytoplasmic stiffness is greater than that 
of the nucleus but there is no statistically significant difference between these values. 
This is in agreement with previously reported data in human fibroblasts (Apte et al., 
2017). Overall, these data indicate no difference between cytoplasmic or nuclear 
stiffness in asynchronous control or DAG1 KO cells. 
 
 
Figure 4.7 Comparison between nuclear and cytoplasmic Young’s modulus of asynchronous control and DAG1 
KO cell lines. This data is a combination of the data from figures 5 and 6. A significant difference was not found 
between any of the samples as determined by one-way ANOVA test p = 0.7009. p values for multiple comparisons 
using Šídák's multiple comparisons test are in the graph. 
 
4.2.4 Investigating the mechanical properties of synchronised control and DAG1 KO 
cells 
 
As there appeared to be a slightly higher, although non-significant, average stiffness 
for both nucleus and cytoplasm in the DAG1 KO cells compared with the control in 
an asynchronous population, the effect of synchronising the cells prior to AFM 
measurements was determined. Cell synchronisation was initially attempted using 
double thymidine block, however, this did not result in the synchronisation of control 
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cells (Figure 4.8a). Cells were then synchronised using serum starvation which 
prevents progression from G1 phase of the cell cycle ensuring the population is 
almost entirely in G1 phase (Figure 4.8b). Prior to serum starvation 63% of cells were 
in G1 phase, 15% in G2, and 22% in S phase while release from serum starvation 
resulted in >95% of cells being in G1 phase even 6 hours post-release (Figure 4.8b). 
 
 
Figure 4.8 Cell cycle synchronisation of control cells using double thymidine block and serum starvation. (a) 
Synchronisation using double thymidine block did not result in cells synchronised in G1 phase as expected. (b) 
Synchronisation using serum starvation successfully synchronised cells in the G1 phase and >95% remained in G1 
phase for the full 6 hours following release from serum starvation.   
 
Following serum starvation cells were again measured either directly over the 
nucleus or adjacent to the nucleus to generate a measure of nuclear and cytoplasmic 
stiffness. Using the functionalised cantilever discussed in section 4.2.1, control cells 
and the DAG1 KO clones A and B were measured. The results are similar to those 
observed in asynchronous cells whereby the KO clones had slightly stiffer nuclei 
compared with the controls (Figure 4.9), however, only clone A is significantly stiffer 
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Figure 4.9 Average nuclear Young’s modulus of control and DAG1 KO cell lines in G1 synchronised populations 
using functionalised cantilevers. Nuclei were measured using a functionalised cantilever. Small black points 
indicate values from individual cells while larger coloured points indicate the average for each independent 
experiment. 7 independent experiments were carried out with 181 nuclei measured per sample (except KO A 
where n = 173). Graph shows mean and standard deviation. A significant difference was not found between any 
of the samples as determined by one-way ANOVA test p = 0.0517. p values for multiple comparisons using 
Dunnett’s multiple comparisons test are in the graph, this suggests the difference between control and DAG1 KO 
clone A is significantly different but not the difference between control and clone B. 
 
Given that only one of the two DAG1 KO clones was significantly stiffer than the 
control further validation was required in order to understand if it is a genuine 
phenotype of knocking out DAG1. To this end a commercial cantilever with a rounded 
tip (Figure 4.10;inset) was used to repeat the measurements on all DAG1 KO clones. 
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The measurements obtained with this cantilever are more reliable than the 
functionalised ones as it is possible to be certain prior to measurements that the 
probe is located at the centre of the cantilever allowing precise orientation of the 
probe directly above the nucleus. The resultant stiffness of the nuclear regions of all 
KO clones does not maintain the slightly stiffer phenotype observed using the 
functionalised cantilever. The resultant nuclear stiffness of control cells is lower than 
that determined using the functionalised cantilevers. The DAG1 KO clones also had 
lower average Young’s moduli compared with the functionalised cantilever (Figure 
4.10). None of the average moduli for DAG1 KO clones are significantly different from 
the average of the control cells which confirms the conclusion that perturbing DG 
does not affect the nuclear mechanical properties of G1 synchronised myoblasts.  
 
In addition to the nuclear mechanical properties of G1 synchronised myoblasts the 
cytoplasmic mechanical properties were also investigated. When using the 
functionalised cantilever the average modulus of clone A is slightly higher than the 
control while clone B is slightly lower than the control however, neither of these are 
significantly different from the control (Figure 4.11). This was also confirmed using 
all available DAG1 KO clones and using the commercial cantilever (Figure 4.12). Only 
the difference between the control and DAG1 KO clone B was significant but given 
the evidence from the functionalised cantilever experiment this is very likely to be 
an artefactual outlier. These data strongly suggests that disruption of the DAG1 gene 





Figure 4.10 Average nuclear Young’s modulus of control and DAG1 KO cell lines in G1 synchronised populations 
using commercial cantilevers. Nuclei were measured using a commercial cantilever (inset). Small black points 
indicate values from individual cells while larger coloured points indicate the average for each independent 
experiment. 6 independent experiments were carried out with 90 individual nuclei measured per sample. Graph 
shows mean and standard deviation. A significant difference was not found between any of the samples as 
determined by one-way ANOVA test p = 0.6389. p values for multiple comparisons using Dunnett’s multiple 
comparisons test are in the table. 





Control 2.440 0.686 N/A N/A
DAG1 KO A 2.141 0.257 0.9715 ns
DAG1 KO B 2.449 0.699 >0.9999 ns
DAG1 KO C 2.608 1.115 0.9965 ns
DAG1 KO D 2.207 0.240 0.9905 ns
DAG1 KO E 1.879 0.153 0.7127 ns
Performance Summary of Large Radius MLCT
Wafer A000-03
**Lever A is non-functional
Die # F (kHz) k (N/m) F (kHz) k (N/m) F (kHz) k (N/m) F (kHz) k (N/m) F (kHz) k (N/m) Averages
01-16 9.47 0.029 5.99 0.017 11.29 0.058 24.20 0.169 62.56 0.982 Tip Radius 4.4 um
05-11 9.44 0.031 5.96 0.018 11.26 0.036 23.85 0.179 61.71 0.920 Tip Setback 14 um
05-22 9.50 0.029 6.02 0.018 11.34 0.052 24.03 0.164 61.54 0.937 Tip Height 10.2 um
08-02 9.79 0.036 6.14 0.019 11.41 0.047 23.41 0.201 59.24 0.791 Lever Thickness 571 nm
08-17 9.91 0.039 6.20 0.020 11.74 0.055 25.46 0.194 67.00 1.114
08-31 10.73 0.039 6.19 0.021 11.57 0.054 24.54 0.198 62.94 1.335
11-11 10.23 0.048 6.41 0.023 12.18 0.056 26.21 0.235 68.04 1.281
11-22 9.92 0.035 6.25 0.021 11.83 0.060 25.53 0.187 66.73 1.125
14-22 9.13 0.026 6.00 0.016 11.47 0.052 24.33 0.207 62.94 1.071
Avg 9.79 0.035 6.13 0.019 11.57 0.052 24.62 0.193 63.63 1.062
Min 9.13 0.026 5.96 0.016 11.26 0.036 23.41 0.164 59.24 0.791
Max 10.73 0.048 6.41 0.023 12.18 0.060 26.21 0.235 68.04 1.335
St Dev 0.48 0.007 0.15 0.002 0.30 0.007 0.92 0.022 2.95 0.175
Lever B Lever C Lever D Lever E Lever F
- Bruker Confidential -
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The nuclear and cytoplasmic data were combined, as previously, to determine the 
relationship between the nuclear and cytoplasmic stiffness within each cell line. As 
seen with unsynchronised cells the average cytoplasmic stiffness of synchronised 
cells is greater than that of the nucleus but not significantly so in most cases. In the 
case of the control, KO A and KO B cell lines measured with the functionalised 
cantilever the difference between the nuclear and cytoplasmic stiffness is 
significantly different in the control and DAG1 KO A cells (Figure 4.13). However, 
when we use the commercial cantilever there is no difference between the 
cytoplasmic and nuclear stiffness in control cells (Figure 4.14). The only difference 
that is significant in this data set is between the nuclear and cytoplasmic stiffness of 
the DAG1 KO B cell line. Taken together this data suggest that there is no real 
difference between the nuclear and cytoplasmic stiffness of control or KO cell lines 
following G1 phase cell synchronisation.  
 
 
Figure 4.11 Average cytoplasmic Young’s modulus of control and DAG1 KO cell lines in G1 synchronised 
populations using functionalised cantilevers. Cells were measured using a functionalised cantilever. Small black 
points indicate values from individual cells while larger coloured points indicate the average for each independent 
experiment. 7 independent experiments were carried out with 35 cells measured per sample. Graph shows mean 
and standard deviation. A significant difference was not found between any of the samples as determined by 
one-way ANOVA test p = 0.0725. p values for multiple comparisons using Dunnett’s multiple comparisons test 
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Figure 4.12 Average cytoplasmic Young’s modulus of control and DAG1 KO cell lines in G1 synchronised 
populations using commercial cantilevers. Cells were measured using commercial cantilevers. Small black points 
indicate values from individual cells while larger coloured points indicate the average for each independent 
experiment. 6 independent experiments were carried out with 90 individual cells measured per sample. Graph 
shows mean and standard deviation. A significant difference was found between the samples as determined by 
one-way ANOVA test p = 0.0002. p values for multiple comparisons using Dunnett’s multiple comparisons test 
are in the table. 





Control 2.626 0.482 N/A N/A
DAG1 KO A 2.384 0.256 0.934 ns
DAG1 KO B 3.411 0.529 0.0318 *
DAG1 KO C 3.114 0.555 0.3256 ns
DAG1 KO D 2.325 0.426 0.8509 ns
DAG1 KO E 1.834 0.219 0.0624 ns
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Figure 4.13 Comparison between nuclear and cytoplasmic Young’s modulus of G1 synchronised control and 
DAG1 KO cell lines measured with functionalised cantilevers. This data is a combination of the data from figures 
9 and 11. A significant difference was found between the samples as determined by one-way ANOVA test p = 
0.0051. p values for multiple comparisons using Šídák's multiple comparisons test are in the graph. 
 
 
Figure 4.14 Comparison between nuclear and cytoplasmic Young’s modulus of G1 synchronised control and 
DAG1 KO cell lines measured with commercial cantilevers. This data is a combination of the data from figures 
10 and 12. A significant difference was found between the samples as determined by one-way ANOVA test p = 
0.0030. p values for multiple comparisons using Šídák's multiple comparisons test are in the graph. 





Nuclear and Cytoplasmic Young’s
 Modulus of synchronised DAG1 































Nuclear and Cytoplasmic Young’s Modulus 
of synchronised DAG1 KO 
























0.9949 0.9928 0.9999 >0.9999
0.59730.0381
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4.2.5 Investigating the mechanical properties of synchronised control and DAG1 KO 
cells following trichostatin A treatment 
 
TSA inhibits histone deacetylases, this results in an increase in DNA acetylation and 
ultimately a decondensing of the chromatin. The decondensed chromatin results in 
an increased nuclear size and a reduction in nuclear stiffness. Treating with TSA prior 
to AFM experiments provides information on the effects of condensed 
heterochromatin on the inherent mechanical properties of the nucleus. In order to 
determine the concentration to use for AFM experiments, TSA was added to control 
cells at concentrations ranging from 5nM to 300nM and incubated for 24 hours. The 
nuclei were then stained with DAPI and the nuclear size was determined (Figure 
4.15). The average nuclear area increases for all treatments with those at 100nM, 
200nM and 300nM being significantly greater than the DMSO treated controls. Based 
on this, 300nM TSA was used for subsequent AFM experiments.  
 
 
Figure 4.15 Treatment with Trichostatin A results in an increase in nuclear area. Nuclear area for each treatment 
was normalised to the DMSO treated control. n = 3 independent experiments measuring 77 DMSO, 75 5nM, 83 
50nM, 74 100nM, 79 200nM and 83 300nM treated cells. A significant difference was found between the samples 
as determined by one-way ANOVA test p = 0.0315. p values for multiple comparisons using Dunnett’s multiple 
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DAG1 KO clones A and B were used as representatives for the KO cell lines and 
compared with control cells. The measurements were carried out using the 
functionalised cantilevers. As with untreated cells there is no difference in the 
nuclear stiffness of control and KO cell lines (Figure 4.16). This suggests TSA 
treatment does not affect the mechanical properties of control and DAG1 KO cells 
differently. However, when we look at the nuclear stiffness of untreated and TSA 
treated cells there is a clear and significant decrease in the TSA treated cells as 
expected (Figure 4.17). Again, when the nuclear and cytoplasmic stiffness of the 
three cell lines were compared the cytoplasmic average stiffness is slightly greater 
than the nuclear average stiffness, this difference is not significant for control or 
DAG1 KO A cells but the difference between nuclear and cytoplasmic stiffness in 
DAG1 KO B cells is statistically significant (Figure 4.18).  
 
 
Figure 4.16 Average nuclear Young’s modulus of control and DAG1 KO cell lines following 300nM Trichostatin 
A treatment using functionalised cantilevers. Nuclei were measured using a functionalised cantilever. Small 
black points indicate values from individual cells while larger coloured points indicate the average for each 
independent experiment. 5 independent experiments were carried out with 100 individual nuclei measured per 
sample. Graph shows mean and standard deviation. A significant difference was not found between any of the 
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samples as determined by one-way ANOVA test p = 0.9764. p values for multiple comparisons using Dunnett’s 
multiple comparisons test are in the graph. 
 
Figure 4.17 Treatment of 300nM Trichostatin A for 24 hours results in a decrease in nuclear Young’s modulus 
in control and DAG1 KO cell lines. This data is a combination of the data from figures 9 and 16. A significant 
difference was found between the samples as determined by one-way ANOVA test p = <0.0001. p values for 
multiple comparisons using Šídák's multiple comparisons test are in the graph. 
 
Figure 4.18 Comparison between nuclear and cytoplasmic Young’s modulus of control and DAG1 KO cell lines 
following 300nM Trichostatin A treatment using functionalised cantilevers. A significant difference was found 
between the samples as determined by one-way ANOVA test p = 0.0132. p values for multiple comparisons using 
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4.2.6 Investigating the mechanical properties of synchronised control and DAG1 KO 
cells following Cytochalasin D treatment 
 
CytoD is used to perturb the actin cytoskeleton, it prevents association and 
dissociation of actin monomers from the actin filament. Disrupting the actin 
cytoskeleton prior to AFM measurements enables the determination of the nuclear 
stiffness without the contribution of the actin cytoskeleton. A range of 
concentrations of CytoD were tested from 50nM to 1000nM and cells were incubated 
for 24 hours. Cells were then stained with phalloidin to determine the extent of actin 
perturbation (Figure 4.19). The actin cable staining was lost following all CytoD 
treatments and the phalloidin staining became more diffuse as the concentration of 
CytoD increased. At 1000nM the phalloidin staining is very diffuse but this 
concentration was not used as almost all cells had multiple nuclei, at 500nM only a 
few cells had multiple nuclei and there was no evidence of actin cables, this 
concentration was used for subsequent AFM experiments.  
 
As with TSA treatment, the CytoD experiments used DAG1 KO clones A and B as 
representative and were compared with the control cells. Measurements were 
carried out using the functionalised cantilever. Following CytoD treatment there is 
no statistically significant difference in the Young’s modulus of DAG1 KO nuclei 
compared with the controls (Figure 4.20). Similarly, when the cytoplasmic region of 
CytoD treated cells were measured, there was no statistically significant difference 
between the Young’s modulus of control and DAG1 KO cells (Figure 4.21). As 
expected, both the nuclear and cytoplasmic stiffness decreased significantly 
following CytoD treatment for both control and DAG1 KO clones (Figure 4.22). 
Additionally, the actin cytoskeleton perturbation does not affect the relationship 
between nuclear and cytoplasmic stiffness (Figure 4.23). In control and DAG1 KO cell 
lines the cytoplasmic stiffness is slightly greater than the nuclear stiffness but not 
significantly so, as seen for all other treatment conditions. Overall, this data suggests 
that cells lacking DAG1 do not have a significant change in nuclear or cytoplasmic 
stiffness following actin cytoskeleton perturbation compared with control cells.  
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Figure 4.19 Treatment with varying concentrations of cytochalasin D result in perturbation of actin filaments. 










filamentous actin. Representative images of each CytoD concentration taken from 3 independent experiments. 
Scale bar = 20µm. 
 
Figure 4.20 Average nuclear Young’s modulus of control and DAG1 KO cell lines following 500nM cytochalasin 
D treatment using functionalised cantilevers. Nuclei were measured using a functionalised cantilever. Small 
black points indicate values from individual cells while larger coloured points indicate the average for each 
independent experiment. 7 independent experiments were carried out with 140 individual cells measured per 
sample (except KO A where n = 138). Graph shows mean and standard deviation. A significant difference was not 
found between any of the samples as determined by one-way ANOVA test p = 0.0663. p values for multiple 
comparisons using Dunnett’s multiple comparisons test are in the graph. 
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Figure 4.21 Average cytoplasmic Young’s modulus of control and DAG1 KO cell lines following 500nM 
cytochalasin D treatment using functionalised cantilevers. Cells were measured using a functionalised 
cantilever. Small black points indicate values from individual cells while larger coloured points indicate the 
average for each independent experiment. 7 independent experiments were carried out with 35 individual cells 
measured per sample. Graph shows mean and standard deviation. A significant difference was not found 
between any of the samples as determined by one-way ANOVA test p = 0.4184. p values for multiple comparisons 
using Dunnett’s multiple comparisons test are in the graph. 
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Figure 4.22 Treatment with 500nM Cytochalasin D for 24 hours results in a decrease in nuclear and cytoplasmic 
Young’s modulus in control and DAG1 KO cell lines. (a) This data is a combination of the data from figures 9 and 
20. A significant difference was found between the samples as determined by one-way ANOVA test p = <0.0001. 
p values for multiple comparisons using Šídák's multiple comparisons test are in the graph. (b) This data is a 
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determined by one-way ANOVA test p = <0.0001. p values for multiple comparisons using Šídák's multiple 
comparisons test are in the graph. 
 
Figure 4.23 Comparison between nuclear and cytoplasmic Young’s modulus control and DAG1 KO cell lines 
following 500nM CytoD treatment using functionalised cantilevers. A significant difference was not found 
between the samples as determined by one-way ANOVA test p = 0.2071. p values for multiple comparisons using 
Šídák's multiple comparisons test are in the graph. 
 
4.2.7 Investigating the relationship between nuclear area and nuclear stiffness in 
control and DAG1 KO cells 
 
Given that almost all of the DAG1 KO cell lines have larger nuclei than the control 
cells (see section 3.2.4) it was useful to determine whether there was any correlation 
between nuclear area and the Young’s modulus of nuclei. The limitations associated 
with the optical microscope connected with the AFM means that the measurements 
of nuclear area are not as precise as those in chapter 3. However, all nuclei were 
measured in the same way so absolute values may not be accurate, but the values 
are all relative to each other making them valid for the investigation.  
 







Nuclear and Cytoplasmic Young’s Modulus of 


























When nuclear area is plotted against nuclear Young’s modulus of control cells there 
is no correlation between the two variables (Figure 4.24). The correlation coefficient, 
r, is negative, with a value of -0.092 and an r2 value of 0.00848. An r and r2 value this 
small would be indicative of a very weak correlation if there is any correlation at all. 
However, the p value is 0.2577 meaning this weak correlation is not statistically 
significant and it can only be concluded that there is no correlation between nuclear 
area and nuclear Young’s modulus in control cells.  
 
 
Figure 4.24 There is no correlation between nuclear size and nuclear Young’s modulus in control cells. Data 
from control cells using a commercial cantilever was pooled to determine any correlation between nuclear area 
and nuclear stiffness. n = 153, Pearson correlation r = -0.09206, r2 = 0.008475, p value = 0.2577. 
 
The range of the nuclear area in control cells is smaller than the range observed in 
the DAG1 KO cells – there are some DAG1 KO nuclei much larger than any seen in 
control cells. Based on this a correlation between nuclear area and nuclear Young’s 
modulus was carried out for all cell types combined (Figure 4.25). These data suggest 
a slight positive correlation with an r value of 0.086 and an r2 value of 0.00742. The 
p value for this correlation is 0.0236 indicating the slight positive correlation is 
statistically significant. However, given that the correlation coefficient is so small it is 
unlikely that this has any biological significance. Taken together these data would 
suggest there is no compelling evidence for a biologically relevent correlation 
between the nuclear area and nuclear Young’s modulus in human myoblast cell lines. 
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Figure 4.25 There is no correlation between nuclear size and nuclear Young’s modulus in control and DAG1 KO 
cells. Data from all cells (control and DAG1 KO) using a commercial cantilever was pooled to determine any 
correlation between nuclear area and nuclear stiffness. n = 691, Pearson correlation r = -0.08612, r2 = 0.007416, 
p value = 0.0236. 
 
4.2.8 Optimisation of nuclear isolation in order to measure mechanical properties 
of isolated nuclei  
 
In order to interrogate the mechanical properties of just the nuclei they need to be 
separated from all cytoplasmic and cytoskeletal contributions. A range of protocols 
were initially tested to determine a reliable and consistent method of producing 
isolated nuclei. Each of the protocols tested used slightly different methods. The first 
method relied on the use of a high salt buffer to osmotically lyse the cell membrane 
but leave the nuclear membrane intact (Ferrera et al., 2014). Following this method 
some lysis occurred but there was still membrane and cytoplasm associated with the 
nuclei (Figure 4.26a). The second method involved the mechanical rupture of the 
plasma membrane using a Dounce homogeniser, again the expected result of this is 
plasma membrane rupture but not nuclear membrane rupture (Guilluy et al., 2014). 
In order to optimise this, the number of strokes with the Dounce homogeniser was 
varied. However, in all the conditions (between 10 and 30 Dounce strokes) there 
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appeared to be some PM rupture but still cytoplasm, as determined by emerin 
staining, associated with all the nuclei (Figure 4.26b). The next method used a similar 
method involving the Dounce homogeniser to mechanically separate the cytoplasm 
and nucleus but this had the additional step of centrifuging the cells through a low 
concentration of sucrose in order to strip remaining cytoplasm from the nucleus 
(Dahl et al., 2005). This produced the most success with little intensity following 
phalloidin staining (Figure 4.26c) but there was clearly some cytoplasmic remains still 
associated with the nucleus when viewed with brightfield (Figure 4.26d).  
 
The final method used was an adaptation of the relatively successful method 
involving mechanical lysis and sucrose gradient. This method used the same system 
but with a higher sucrose concentration which results in a greater viscosity that helps 
to strip excess cytoplasm and cytoskeleton from the nuclei (Martínez-Vieyra et al., 
2013). Following nuclear isolation, the validity of the preparation was assessed by a 
combination of microscopy and western blotting analysis. Initially the quality was 
assessed by staining with DAPI and phalloidin to identify the nuclear and cytoplasmic 
components (Figure 4.27a). Based on this it is clear that the majority of the nuclei 
were lacking any surrounding phalloidin staining (white arrows) while there were still 
a few remaining nuclei that had at least some filamentous actin associated with the 
nuclei (grey arrows). Those cells that appeared to be F-actin free were also looked at 
using a brightfield microscope to determine if there was any associated cytoplasm 
that did not contain F-actin (Figure 4.27b). In addition to immunofluorescence and 
brightfield microscopy analysis, the purity was assessed using western blotting 
(Figure 4.28). In this assay GAPDH was used as a cytoplasmic marker, lamin A/C was 
used as a nuclear marker and calnexin was used as a marker of the ER. From this it is 
clear that the nuclear fraction only contains the nuclear proteins lamin A/C and 
neither the cytoplasmic nor ER markers were present in this fraction. Conversely, the 
cytoplasm contains the cytoplasmic marker protein GAPDH and the ER protein 
calnexin with no signal for the nuclear marker lamin A/C. This confirms the purity of 
the whole preparation suggesting that even the ER has been removed from the NE. 
Based on all these data combined, the protocol produces sufficiently clean nuclei to 
be used to measure isolated nuclei with AFM.  
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Figure 4.26 Nuclear isolation methods. (a) Representative brightfield microscopy of nuclear isolation following 
osmotic lysis, left image is untreated cell, right image is lysed cells where a large amount of cytoplasm is still 
present. Scale bar = 20µm. (b) Representative immunofluorescence images stained with DAPI and emerin 
following mechanical lysis using a Dounce homogenizer for varying numbers of strokes. (c) Representative 
immunofluorescence images stained with DAPI and calnexin following mechanical lysis followed by low-molarity 
sucrose gradient. Scale bar = 5µm. (d) Representative brightfield microscopy images of nuclei following 
















Figure 4.27 Refined method of nuclear isolation involved mechanical lysis followed by high-molar sucrose 
gradient evaluated by microscopy. (a) Representative nuclear isolation preparation stained with DAPI and 
phalloidin to identify the nucleus and any surrounding actin filaments indicative of cytoplasmic contamination. 
Cells lacking any phalloidin staining are indicated with white arrows while cells with some phalloidin staining 
remaining are indicated with grey arrows. Scale bar = 10µm. (b) Representative brightfield microscopy images of 








Figure 4.28 Refined method of nuclear isolation involved mechanical lysis followed by high-molar sucrose 
gradient evaluated by western blotting. Western blot analysis of nuclear and cytoplasmic fractions following 
mechanical lysis. GAPDH was used as the resident cytoplasmic protein marker, lamin A/C was used as the resident 
nuclear protein marker and calnexin was used as the resident ER marker protein. This representative blot 
indicates that the nuclear fraction did not contain the cytoplasmic or ER marker proteins. 
 
4.2.9 Investigating the mechanical properties of nuclei isolated from control and 
DAG1 KO myoblast cells 
 
In order to measure the mechanical properties of the isolated nuclei, the nuclei need 
to be harvested just before AFM measurements with as little time between isolation 
and measurement as possible to prevent nuclear deterioration over time. To this 
end, following isolation, nuclei were allowed to settle and attached to the poly-L-
lysine coated dish for 30 minutes. The dish was then washed twice to removed 
unattached nuclei or cell debris. Each nuclear sample was then measured for no 
longer than one hour before a new sample was prepared.  
 
Preliminary AFM data was generated using the commercial MLCT pyramidal tip 
rather than the functionalised or commercial cantilevers discussed above. This 
preliminary data was generated to give an idea of nuclear mechanical properties 
prior to cantilever functionalisation. The data from 5 control cells and 5 DAG1 KO B 
cells suggested the KO cells were significantly softer than the control (Figure 4.29a). 
The average stiffness of control nuclei was 372±95 Pa while the average KO nuclei 
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was 116±68 Pa. These data suggest there may be a difference between the two 
samples with additional experiments and repeats required to validate the 
preliminary finding. 
 
Mechanical measurements of control nuclei in addition to DAG1 KO A and B nuclei 
were carried out using functionalised cantilevers. As with the preliminary data the 
KO nuclei were significantly softer than the control nuclei (Figure 4.29b). The average 
nuclear stiffness for the control sample was 318±60 Pa while DAG1 KO A and B nuclei 
were 151±24 Pa and 152±37 Pa respectively. The two data sets are in good 
agreement despite the preliminary data only including a total of 5 nuclei per sample. 
Taken together these data strongly suggest that isolated nuclei from DAG1 KO cells 
are significantly softer than the control nuclei.  
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Figure 4.29 Isolated nuclei from DAG1 KO cells are less stiff than isolated nuclei from control cells. (a) 
Mechanical properties of isolated nuclei from control and DAG1 KO B as measured by a pyramidal MLCT 
cantilever. n = 5 nuclei, p = 0.0012, students t-test. (b) Mechanical properties of isolated nuclei from control and 
DAG1 KO A and B as measured by a functionalised MLCT cantilever. Small black points indicate individual nuclei 
while larger coloured points indicate the average of each experiment. Two individual outlier points from the 
control column were excluded to enable better visualisation, these values were 1121 Pa and 2553 Pa.  n = 3 
independent experiments with 35 individual cells measured per sample (except control where n = 36). Statistical 
analysis using one-way ANOVA test p = 0.0047. p values for multiple comparisons using Dunnett’s multiple 
comparisons test are in the graph. 
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The results described in this section were aimed at answering the question of 
whether a lack of DG results in a difference in mechanical properties of myoblasts 
when compared with appropriate controls. There has been some data presented in 
the literature which suggests the knock down of b-DG or the complete KO of the 
DAG1 gene in mouse C2C12 myoblasts results in reduction or aberrant localisation 
of the key structural nuclear proteins lamin B1 and emerin (Jimenez-Gutierrez et al., 
2020; Martínez-Vieyra et al., 2013). Given that these proteins contribute to the 
mechanical properties of the nucleus it would be expected that disruption of DG 
would result in a reduced nuclear Young’s modulus.  
 
This previously published data was the reason for carrying out these AFM 
measurements on DAG1 KO human myoblasts. However, these cells do not exhibit 
the same lamin B1 or emerin phenotype which is discussed in detail in chapter 3. The 
results described in this chapter, demonstrate no clear difference in the Young’s 
modulus of control and DAG1 KO cells. These data fit with the data described in 
chapter 3 suggesting perturbation of DG does not affect the levels or structural 
organisation of the lamins in human myoblasts. 
 
4.3.1 Comparison of Young’s moduli 
 
AFM has many advantages for measuring mechanical properties of cells however, it 
is very difficult to compare moduli between different studies as there are many 
factors that influence the final value (such as type of cantilever used, loading rate 
used, sample preparation, type of atomic force microscope and model used to 
determine the Young’s modulus) (Caluori et al., 2018; Schillers et al., 2017; Weber et 
al., 2020). Despite the difficulties in comparing results across different studies, AFM 
is extremely useful for producing an apparent Young’s modulus which can be 
compared across samples that have been handled and measured consistently (Zemła 
et al., 2020). Therefore, the values that other studies have determined for similar or 
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the same cell types may vary drastically depending on the parameters used. 
However, comparing these can give an indication of whether the measured data in 
this study is within the right range.  
 
There have been no studies measuring the mechanical properties of the human 
myoblast cells used in this study, however, there are some data for mouse myoblasts. 
Mouse C2C12 myoblasts and myotubes were measured using a triangular tip, this 
study presented a Young’s modulus of 3.15±0.24 kPa for myoblasts and 6.06±0.57 
kPa for myotubes while myoblasts treated with blebistatin had a modulus of 
2.37±0.30kPa (Streppa et al., 2018). This data is in good agreement with that 
presented here despite the difference in tip used. However, another earlier study 
using a cone shaped tip suggests the Young’s modulus is between 11-45 kPa 
(Collinsworth et al., 2002). These two studies demonstrate the range in values that 
can be determined from different studies.  
 
4.3.2 Reasons for variations in measurements 
 
Throughout these data sets there are occasional occurrences of differences being 
statistically significant in one of the KO cell lines. There are three examples of this: 
(1) The nuclear measurements from the synchronised sample measured with the 
functionalised cantilever, DAG1 KO A is significantly different from the control; (2) 
the cytoplasmic measurements from the synchronised sample measured with the 
commercial cantilever, DAG1 KO B is significantly different from the control and (3) 
the nuclear measurements from the CytoD treated sample measured with the 
functionalised cantilever, DAG1 KO B is significantly different from the control.  
 
The most likely explanation for the differences between the two nuclear samples (1 
and 3) is due to the use of the functionalised cantilever. The main problem with the 
functionalised cantilevers is a lack of consistency between cantilevers as the bead is 
unlikely to be stuck in the same position for each cantilever. Additionally, the 
functionalised cantilevers appeared to accumulate cell debris from the sample more 
readily than the commercial cantilever. This meant that each cantilever could only 
 178 
be used once on one sample (or sometimes less). Conversely, the commercial 
cantilever was generally used for all samples within each repeat which allowed a 
more accurate comparison. Additionally, if only one of the KO samples demonstrated 
this difference this was generally regarded as a clonal artefact, but additional 
experiments with the commercial cantilever were carried out where possible to 
confirm this. It was only when both KO samples differed significantly from the 
control, as with the isolated nuclei experiments, that this was considered as a 
genuine difference.  
 
The other variable result observed was using the commercial cantilever to measure 
the cytoplasmic stiffness of synchronised cells and DAG1 KO B appeared to be 
significantly different than the control. This was not observed in any of the other cell 
lines, nor was it observed in the same cell line when measured with the 
functionalised cantilever. This combined evidence suggests this result was due to 
experimental variation rather than a clonal artifact. The most likely explanation for 
this is measuring an area of the cytoplasm that was too close the cell periphery 
resulting in the measurement including the contribution of the underlying substrate. 
It is also possible that simply by chance a stiffer subset of the KO cells was measured.  
 
4.3.3 Differences in Young’s modulus of isolated nuclei 
 
Measuring the Young’s modulus of isolated nuclei from control and DAG1 KO clones 
A-B resulted in a significantly lower moduli for both DAG1 KO clones when compared 
with the control nuclei. Here, it is clear from both the preliminary data and the follow 
up data using two DAG1 KO cell lines that the KO isolated nuclei are softer than the 
control nuclei. It is possible that the two larger outlier values in the control sample 
resulted in skewed averages. However, when these outlier values are removed the 
difference between the control and DAG1 KO samples was still significantly different. 
Ideally a rescue experiment where full-length b-DG or a mutant b-DG lacking the 
nuclear localisation signal would be used to confirm that the finding is due to b-DG 
and not either a-DG or an off-target effect of the CRISPR knockout. Unfortunately, 
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due to time and technical limitations this has not been possible. Additionally, 
confirmation with the commercial cantilevers was not possible due to the probe size 
being greater than that of the isolated nuclei. Based on the data presented in chapter 
3 demonstrating that the structural nuclear proteins are not affected by knocking out 
DAG1 the observed difference in nuclear Young’s modulus is not easily explained. 
Additionally, the relative levels of heterochromatin and euchromatin are unaffected 
in DAG1 KO cells compared with controls which means this is not the reason for the 
differences observed in the isolated nuclei experiments.  
 
It would be possible to attempt to measure the relative contributions of the nuclear 
lamina or chromatin by varying the osmolarity of the buffer as has been done 
previously (Dahl et al., 2005). By subjecting the nuclei to a hypotonic solution, the 
nuclei swell and the contribution of the chromatin is reduced however, the 
contribution of the increased water pressure would need to be considered. 
Alternatively, it would be possible to treat the nuclei with DNase in order to remove 
the DNA and reduce the chromatin contribution. It is harder to remove the lamina 
while leaving the chromatin intact but nucleoli have been isolated for AFM 
measurements (Louvet et al., 2014). However, this additional information is unlikely 
to provide any clear answers given that no difference in the levels or localisation of 
any nuclear lamina proteins has been detected.  
 
One explanation could be down to the sensitivity of the different experiments used. 
It may be that the levels of lamin B1 are slightly reduced in DAG1 KO cell lines but 
this difference is too small to be detected by fluorescence microscopy or western 
blotting (chapter 3). Whereas the sensitivity of the AFM may be detecting these 
minute differences. These differences are lost in the whole cell measurements 
because cells have a Young’s modulus in kPa range while the isolated nuclei are 
measured in Pa. Thus, the difference of 200 Pa between control and KO isolated 
nuclei is lost in the background of whole cells which are much stiffer.    
 
Although there might not be an obvious explanation for the differences observed at 
the isolated nuclei level it is important to consider what the physiological 
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implications may be. As myoblasts differentiate into myotubes to form muscle fibres 
they are put under large amounts of mechanical pressure. Maintaining nuclear shape 
is required for correct cellular function (Mandigo et al., 2019) so maintaining a stiffer 
nucleus may be required for retaining correct nuclear shape. In the following chapter 
the response to a range of mechanical stressors will be investigated in order to 
determine whether a lower nuclear stiffness plays any role in resisting or responding 
to mechanical stress.     
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5 Investigating the role of DG in maintaining nuclear 




Mammalian cells are capable of adapting to varying types of mechanical stimulus and 
there are many mechanisms involved in converting mechanical stimulus into a 
biochemical signal that cells can respond to. The external mechanical environment 
can be sensed through membrane proteins which result in downstream signalling 
through pathways such as the Hippo pathway which results in the regulation of cell 
proliferation and cell survival (Zou et al., 2020). Additionally, direct mechanical force 
can be transmitted through focal adhesions, through the cytoskeleton and directly 
to the chromatin within the nucleus via the LINC complex and nuclear lamina (Crisp 
et al., 2006). The nucleus plays a central role in the response to mechanical cues and 
the response to excessive mechanical stress. The nuclear response produced differs 
depending on the type of mechanical stress and the relative intensity or persistence 
of that stress (Gilbert et al., 2019; Nava et al., 2020; Raab et al., 2016). In order to 
test the effect of mechanical stress, there are three major types of mechanical stress 
that mammalian cells can easily be subjected to in vivo; (1) cell/nuclear 
compression/deformation, (2) cell stretching and (3) being subjected to sheer forces. 
Compression occurs during development but also commonly in migrating cells that 
have to negotiate through narrow gaps in ECM, this is particularly relevant for 
metastatic cancer cells (Denais et al., 2016). Stretching occurs in many tissues but is 
extreme and consistent in muscle and skin tissue. This means cells require 
mechanisms in order to cope with the constant strain. Sheer stress is common in 
endothelial cells lining the blood vessels. It is important that cells are able to detect 
and respond to these mechanical stressors to maintain tissue homeostasis.  
 
5.1.1 Extreme cell/ nuclear compression results in an accumulation of DNA damage 
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Investigating the effects of compression on cells can be carried out in either an active 
or a passive manner. Active compression involves cells moving through 
gaps/pores/channels that are significantly smaller than the nucleus. The nucleus is 
the stiffest and largest organelle and represents the rate limiting component in 
migration through confined spaces (Mukherjee et al., 2020). The alternative, passive 
compression, simply involves cells growing in situ while a compressional force is 
applied on top of the cells. This allows a better understanding of the effects of the 
mechanical stress in isolation without additional variables such as migration.  
 
Cell migration through a confining environment has generally made use of the 
Transwell migration assay. This involves seeding cells onto a membrane with pores 
of a defined size. The cells then migrate through these pores, and it is possible to fix 
and stain either the top (unmigrated cells) or the bottom (migrated cells) of the 
membrane and image these as with normal immunofluorescence techniques. These 
types of experiments have been done extensively in many cell types with the majority 
responding in the same way. When mammalian cells migrate through 3µm pores the 
nuclei are constricted and result in aberrant nuclear morphology including decreases 
in nuclear area (Patteson et al., 2019a), changes in nuclear aspect ratio (Irianto et al., 
2017; Patteson et al., 2019a) and an increase in nuclear blebs (Irianto et al., 2017; 
Mukherjee et al., 2020; Patteson et al., 2019a; Pfeifer et al., 2018; Xia et al., 2019). 
The nuclear blebs are lamin A/C positive but lamin B1 negative as seen in nuclear 
blebs that have not resulted from mechanical stress (Pfeifer et al., 2018). In addition 
to nuclear morphology changes following migration through 3µm pores, there are 
also direct effects on the DNA and chromatin. There is an increase in DNA damage as 
determined by gH2AX intensity in migrated cells compared with non-migrated cells, 
while there is also mislocalisation of key repair protein Ku80. The DNA damage is not 
due to replication stress and is replication independent (Irianto et al., 2017; 
Mukherjee et al., 2020; Patteson et al., 2019a; Pfeifer et al., 2018; Xia et al., 2019). 
Additionally, there are gross chromosome changes including changes in chromosome 
copy number and changes in transcription profiles (Irianto et al., 2017; Xia et al., 
2019). The increased DNA damage and transcriptional changes are not permanent 
and generally recover back to baseline levels within 24 hours post migration. 
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However, when key DNA double strand break repair proteins are knocked down 
there are increased levels of DNA damage following migration and this damage is 
persistent (Irianto et al., 2017; Pfeifer et al., 2018). Finally, there are changes in the 
cell-cycle following migration through 3µm pores. The cell-cycle is arrested following 
migration however, this is reversable as the cell-cycle is reinitiated following DNA 
damage repair (Pfeifer et al., 2018; Xia et al., 2019). The cell-cycle arrest is also 
partially alleviated by addition of an antioxidant suggesting accumulation of ROS 
contributes to the DNA damage response (Xia et al., 2019). In all of these experiments 
an appropriate control was used, cells migrated through 8µm pores which does not 
result in nuclear compression. In these control experiments none of the nuclear 
abnormalities, increases in DNA damage or arrested cell-cycles were observed 
indicating these responses are specific to confined migration (Irianto et al., 2017; 
Patteson et al., 2019a; Pfeifer et al., 2018; Xia et al., 2019).  
 
One limitation of using the transwell migration assays discussed above is that it is not 
possible to visualise the cells as they migrate through the constricting pores. An 
alternative method for investigating migration through narrow pores is the use of 
microfluidic devices that allow real-time video microscopy to monitor progression 
through the pores (Keys et al., 2018). Using this method it was also found that nuclear 
morphology was affected and the levels of DNA damage increased following 
migration through constricting pores (Raab et al., 2016; Shah et al., 2020). 
Additionally, it is possible to obtain a greater depth of information on how these 
responses occur compared with the transwell assays. Shah and colleagues tested 
multiple cell lines and found two different mechanisms of DNA damage accumulation 
and each of these was found exclusively with none of the tested cell lines 
demonstrating both mechanisms. The first mechanism involved replication stress 
and replication fork failure which resulted in an accumulation of the DNA damage 
marker gH2AX following migration. The second mechanism involved nuclear rupture 
resulting in exchange of nuclear and cytoplasmic proteins, resulting in a loss of DNA 
repair factors in the nucleus and an increase in damaging cytoplasmic components 
such as nucleases (Shah et al., 2020). Pfeifer et al. (2018) found no evidence of 
replication stress, but they were using a breast cancer cell line that demonstrated 
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the nuclear rupture mechanism described by Shah et al. (2020). Additional studies 
using the microfluidic migration devices identified ESCRT III complex as a key 
component of nuclear envelope repair following a nuclear rupture event (Raab et al., 
2016). 
 
All of these migrational compression studies confirm that extreme compression of 
the relatively large nucleus results in an accumulation of DNA damage and this can 
occur either by exchange of nuclear/cytoplasmic components or by replication 
stress. However, the cells are able to deal with these DNA breaks by inhibiting the 
cell-cycle while DNA repair proteins repair the damage, and the cells are then 
released back into the cell-cycle. This mechanism allows cells to continue migrating 
through narrow gaps and also helps to explain some of  the increase in genetic 
variation in metastatic cancer cells (Denais et al., 2016; Irianto et al., 2017). 
 
These studies described above have all investigated the effects of cell/nuclear 
compression during active migration. When compression of cells grown in situ was 
investigated the results are similar. Using a custom-built device which compresses 
cells between two pieces of PDMS, the distance between the two PDMS plates was 
determined by the addition of glass beads with a well-defined height. It was found 
that compressed cells accumulated DNA damage within 30 minutes and the amount 
of damage increased as the compression height was decreased. There was some 
evidence of nuclear envelope rupture, but the majority of cells had increased levels 
of DNA damage without evidence of nuclear rupture. This was also observed using 
AFM combined with light-sheet microscopy, nuclei were compressed to a height of 
~2µm and DNA damage accumulated without the need for nuclear rupture (Shah et 
al., 2020). This approach was also used in another study where AFM was used to 
compress the nucleus and they found increased levels of cGAS which binds to 
cytoplasmic DNA suggesting nuclear rupture resulting in DNA leakage (Cho et al., 
2019). Additional studies find increased levels of cell death as levels of compression 
are increased. The levels of DNA damage were not investigated but it is likely that 
cell death increased as levels of DNA damage passed a threshold level (Patteson et 
 185 
al., 2019a). Together these studies suggest that compression of cells/nuclei whether 
it is active or passive results in an increase in DNA damage. 
 
5.1.2 Cyclic cell stretching results in cyto- and nucleoskeleton reorganisation in 
order to minimise DNA damage 
 
Cyclic cell stretching results in a cellular response that aims to decouple the nucleus 
from the recurrent stress, but the types of response differ depending on the 
frequency of stretching. Following cyclic stretch at both high and low frequencies 
nuclear morphology of human epidermal stem cells is affected whereby the nucleus 
becomes more wrinkled and has a decrease in nuclear envelope tension (Nava et al., 
2020). However, unlike with cell compression there is little evidence of nuclear 
envelope rupture in healthy cells. However, when lamin A/C is knocked down there 
is increased nuclear rupture during cyclic stretching (Cho et al., 2019). Nuclear size is 
also affected; at low-frequency cyclic stretching the cell size increases but the nuclear 
size does not, whereas at high-frequency stretching, the cell size remains the same 
but the nuclear size decreases (Gilbert et al., 2019). It has been shown that this 
change in nuclear size but not cell size is the result of nuclear decoupling, there is a 
decrease in levels of SUN2, a component of the LINC complex which links the nucleus 
to the cytoskeleton, thus preventing the force from being transmitted to the nucleus, 
especially at high-frequency stretching (Gilbert et al., 2019). This nuclear decoupling 
results in changes in transcription profiles resulting in increased levels of cytoskeletal 
proteins and decoupling also prevents the accumulation of DNA damage. Cyclic 
stretching results in a slight decrease in levels of DNA damage, however, 
overexpression of SUN2 which results in the nucleus being recoupled to the cell and 
subjected to the stretching forces results in an increase in DNA damage above basal 
levels (Gilbert et al., 2019; Heo et al., 2015). Based on this evidence it would suggest 
that the nuclear decoupling prevents stretching forces being transmitted to the 
nucleus and maintains DNA integrity.   
 
In addition to nuclear decoupling the cells are also able to realign the cytoskeleton in 
the direction of low-frequency stretching which reduces the strain transmitted to the 
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nucleus (Nava et al., 2020), similar to what is seen in response to sheer stress. 
Importantly, the chromatin state also responds to the cyclic stretching by becoming 
less condensed. At low-frequency stretching the chromatin becomes less condensed 
and remains this way until the stretching has stopped. However, at high-frequency 
stretching the levels of heterochromatin decrease initially and then return to 
baseline levels during prolonged stretching (Nava et al., 2020). These 
heterochromatin changes allow the nucleus to disperse the force thus preventing 
excessive DNA damage. The chromatin decondensing is controlled by Ca2+ signalling 
(Heo et al., 2015) that enters through the Peizo1 ion channel. Preventing Ca2+ 
signalling or knockdown of Peizo1 prevents the chromatin from decondensing and 
results in an increase in DNA damage during cyclic stretching (Nava et al., 2020). The 
data from these studies would suggest that cells have the ability to respond to cyclic 
stretching and prevent DNA damage occurring.  
 
5.1.3 Sheer stress results in changes in nuclear architecture 
 
Biological sheer stress is most commonly associated with fluid flow, such as blood, 
lymph, urine and synovial fluid for example. Endothelia are the cells most commonly 
exposed to constant mechanical forces in the form of sheer stress due to blood flow. 
The sheer stress experienced can be classed as laminar or disturbed. Laminar flow 
results in consistent flow rate in a single direction. Disturbed or oscillatory flow is any 
flow that is not laminar, it is often changing direction and rate of flow, this occurs 
around branches or obstructions in the blood vessels (Ji, 2018; Zhu et al., 2020). The 
type of sheer stress has been shown to result in changes in transcription and this is 
regulated by the JAK/STAT pathway (Mahmoud et al., 2017; Zhu et al., 2020).  
 
As with other forms of mechanical stress, sheer stress results in changes in nuclear 
morphology which is controlled by sheer stress-induced changes to the nuclear 
lamina. In MDCK epithelial cells subjected to sheer stress there was a decrease in 
both nuclear area and volume, this was controlled by the mechanosensitive channel 
Piezo1 (Jetta et al., 2019). In addition to changes in nuclear area and volume, nuclear 
shape was also affected by sheer stress. Nuclei had a decrease in nuclear circularity 
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following shear stress. The longer the cells were subjected to sheer stress the lower 
the value for nuclear circularity, the opposite was reported for elongation factor 
suggesting the nuclei become more elongated following sheer stress (Jiang and Ji, 
2018; Philip and Dahl, 2008). These observed changes in nuclear shape were 
accompanied by changes in levels and localisation of lamin A/C. Following sheer 
stress, lamin A/C staining became more intense at the NE compared with unstressed 
controls (Philip and Dahl, 2008). Additionally, the total levels of lamin A/C increased 
following 6 hours of sheer stress (Jiang and Ji, 2018). These studies suggest that sheer 
stress results in changes in nuclear morphology and changes in localisation and levels 
of lamin A/C. 
 
There have been a limited number of investigations into the effects of sheer stress 
on levels of DNA damage and how cells might adapt to minimise levels of DNA 
damage. However, it has been found that following sheer stress there is an increase 
in the percentage of apoptotic cells. The percentage of apoptotic cells also increases 
with the amount of time cells are subjected to sheer stress (Pan et al., 2017). 
Additionally, the levels of DNA fragmentation were investigated following sheer 
stress. The percentage of DNA fragmentation increased both with sheer level and 
with time (Triyoso and Good, 1999). Taken together these studies suggest that sheer 
stress results in nucleoskeletal reorganisation, changes in nuclear morphology and 
increased levels of apoptosis and DNA damage. 
 
5.1.4 Hypothesis and aims 
 
Data described in previous chapters suggests there is no difference in levels of 
nucleoskeletal proteins in DAG1 KO cells compared with controls and this is also 
confirmed in the data that suggests the stiffness of DAG1 KO nuclei within whole cells 
does not differ from that of the controls. However, it was found that when the nuclei 
are separated from all cytoskeletal influence the DAG1 KO nuclei were significantly 
softer than the control nuclei. This then leads to the question of whether the 
difference in nuclear stiffness has any physiological relevance.  
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The aim of this chapter is to investigate the response of DAG1 KO cells to mechanical 
compression and to determine whether the response differs from that of control 
cells. Cells have been subjected to active compression as they migrate through 3µm 
transwell pores in addition to passive compression with the addition of weighted 
inserts. Following these experiments the nuclear morphology was assessed in 




5.2.1 Determining baseline levels of DNA damage and nuclear morphology prior to 
mechanical and chemical stress 
 
Before conducting experiments to determine the effects mechanical or chemical 
stress has on DAG1 KO and control cells it is important to understand the baseline 
levels of DNA damage. The levels of gH2AX were therefore determined using 
immunofluorescence microscopy (Figure 5.1a,b) as were the values for nuclear area 
(Figure 5.1c), nuclear circularity (Figure 5.1d) and nuclear aspect ratio (Figure 5.1e). 
Although these experiments were carried out in chapter 3 it was important to ensure 
the results were consistent before starting this set of experiments.  
 
In the case of levels of DNA damage as indicated by gH2AX staining the nuclear 
intensity appeared to be slightly lower in DAG1 KO clones A and B compared with 
control cells. The difference between control and DAG1 KO A was insignificant 
however, the difference between the control and DAG1 KO B was just below the 
significance cut off of p = 0.05. The difference between the control and KO B was 




Figure 5.1  Baseline averages for nuclear morphology and levels of gH2AX in control and DAG1 KO clones A and 
B without additional cell stress. (a) Representative images of cells grown for 24 hours before fixing and staining 
with DAPI (blue) and gH2AX (red) to identify nuclear morphology and levels of DNA damage. Cells were imaged 
using the Leica fluorescence microscope. Scale bar = 20µm. (b) Nuclear levels of gH2AX without additional cell 
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experiments were carried out with 392 control, 401 KO A and 377 KO B cells measured. Graph shows mean and 
standard deviation. The one-way ANOVA test returned a p value of 0.0575 which is not below the significance 
threshold of 0.05. Using a Dunnett’s multiple comparison test the difference between control and DAG1 KO clone 
B was significant with a p value of 0.0495. (c) Nuclear area without additional cell stress. As before. The one-way 
ANOVA test returned a p value of 0.0061 which is below the significance threshold of 0.05. Using a Dunnett’s 
multiple comparison test the difference between control and DAG1 KO B was significant with a p value of 0.0031 
while the difference between control and DAG1 KO A was not significant (p = 0.2939). (d) Nuclear circularity 
without additional cell stress. As before. The one-way ANOVA test returned a p value of 0.7156 which is below 
the significance threshold of 0.05. Dunnett’s multiple comparison test was also carried out, p values are on the 
graph. (e) Nuclear aspect ratio without additional cell stress. As before. The one-way ANOVA test returned a p 
value of 0.3871 which is below the significance threshold of 0.05. Dunnett’s multiple comparison test was also 
carried out, p values are on the graph.  
 
When nuclear morphology was compared between control and DAG1 KO clones A 
and B the results were as observed in chapter 3. In the case of nuclear area, both 
DAG1 KO clones had a larger average nuclear area than the control but this difference 
was only significantly different between control and DAG1 KO B (Figure 5.1c). The 
nuclear shape parameters circularity and aspect ratio were investigated and as with 
chapter 3 there was no significant difference in the circularity or aspect ratio of 
control cells compared with DAG1 KO clones A and B (Figure 5.1d,e). Despite the 
differences not being significant the average nuclear circularity is slightly higher for 
DAG1 KO clones than for control and the average nuclear aspect ratio is slightly lower 
for DAG1 KO clones compared with controls.  
 
Given that there are differences (even if not statistically significant) between control 
and DAG1 KO cells, the values for all mechanical and chemical stress experiments 
have been normalised to the untreated value for each cell line. This will allow the 
identification of relative changes between the cell lines rather than absolute 
changes.  
 
5.2.2 Investigating the response of control and DAG1 KO cells to oxidative stress 
following treatment with H2O2 
 
In order to determine if DAG1 KO cells respond to mechanical stress differently to 
control cells, it is important to understand if the two cell types respond differently to 
non-mechanical stress. Oxidative stress as induced by treatment with H2O2 was used 
to investigate any differences in response between control and DAG1 KO clones. In 
 191 
order to determine the most appropriate concentration of H2O2 to use, control and 
DAG1 KO A cells were subjected to a range of concentrations and cell viability was 
crudely assessed by calculating the percentage of trypan blue negative cells following 
treatment (Figure 5.2). Untreated cells had almost 100% viability as did those cells 
treated with 0.1mM H2O2, following treatments with 1mM and 2mM cell viability 
dropped to just above 50% and the percentage of viable cells continued to drop for 
3mM, 4mM and 5mM. Based on this, 2mM was chosen as it is clearly sufficient to 
induce a response and there was still >50% cell viability.  
 
 
Figure 5.2 Optimisation of H2O2 concentration. Control and DAG1 KO A cells were treated with varying 
concentrations of H2O2 and percentage of cell viability was assessed. 2 independent experiments were carried 
out with at least 100 cells counted per sample per experiment. Graph shows mean and actual range. The 
differences between control and DAG1 KO A were tested using multiple t tests with none of the p values being 
<0.05. 
 
Control cells and DAG1 KO clones A and B were either untreated (0mM) or H2O2 
treated (2mM) for 1 hour. Cells were then fixed and stained for gH2AX as a read out 
of DNA damage and nuclear morphology was assessed (Figure 5.3a). As expected, 
the intensity of gH2AX staining increased significantly following H2O2 treatment in all 
cell types (Figure 5.3b). When comparing the relative levels of gH2AX following H2O2 
treatment in control and DAG1 KO A cells there is no significant difference. However, 
the difference between control and DAG1 KO B was significant as tested by one-way 
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ANOVA (p = 0.0381). This difference is possibly due to clonal variation however, if the 
difference in response is not present in both DAG1 KO clones then it is not considered 
a genuine consequence of knocking out the DAG1 gene.  
 
 
Figure 5.3 Average nuclear levels of gH2AX in control and DAG1 KO clones A and B with and without H2O2 
treatment. (a) Representative images of cells grown for 24 hours before treating with 0mM or 2mM H2O2 and 
then fixing and staining with DAPI and gH2AX to identify nuclear morphology and levels of DNA damage with and 
without H2O2 treatment. Cells were imaged using the Leica fluorescence microscope. Scale bar = 20µm (b) 
Normalised nuclear levels of gH2AX following treatment with 0mM or 2mM H2O2. 4 independent experiments 
were carried out. Control 0mM n = 102, 2mM n = 107. KO A 0mM n = 110, 2mM n = 123. KO B 0mM n = 117, 
2mM n = 104. Graph shows mean and standard deviation. The one-way ANOVA test returned a p value of 0.0004 
which is below the significance threshold of 0.05. for multiple comparisons, a Šídák's multiple comparisons test 
was used and the p values can be seen on the graph. 
 
In addition to gH2AX levels, the nuclear area, circularity and aspect ratio were 
assessed in treated and untreated cells (Figure 5.4). Nuclear area was consistently 
0mM
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lower in treated cells compared with untreated for control and DAG1 KO cells alike. 
This difference was significant in both control and DAG1 KO A but not in DAG1 KO B 
(Figure 5.4a), this could be due to clonal variation or the fact that DAG1 KO B nuclei 
are significantly larger to start with. Relative nuclear area of treated cells was also 
compared between control and DAG1 KO cells. The difference between control and 
DAG1 KO A was significant while the difference between control and DAG1 KO B was 
not. Again, only significant differences observed between control and both KO clones 
were considered to be different due to a lack of DG.  
 
 
Figure 5.4 Nuclear morphology of control and DAG1 KO clones A and B with and without H2O2 treatment. (a) 
Normalised nuclear area with and without treatment with 2mM H2O2. 4 independent experiments were carried 
out. Control 0mM n = 102, 2mM n = 107. KO A 0mM n = 110, 2mM n = 123. KO B 0mM n = 117, 2mM n = 104. 
Graph shows mean and standard deviation. The one-way ANOVA test returned a p value of 0.0468 which is below 
the significance threshold of 0.05. For multiple comparisons, a Šídák's multiple comparisons test was used and 
the p values can be seen on the graph. (b) Normalised nuclear circularity with and without treatment with 2mM 
H2O2. As before. The one-way ANOVA test returned a p value of 0.2766 which is not below the significance 
threshold of 0.05. For multiple comparisons, a Šídák's multiple comparisons test was used and the p values can 
be seen on the graph. (c) Normalised nuclear aspect ratio with and without treatment with 2mM H2O2. As before. 
The one-way ANOVA test returned a p value of 0.3131 which is not below the significance threshold of 0.05. For 
multiple comparisons, a Šídák's multiple comparisons test was used and the p values can be seen on the graph. 
 
When testing the effect of H2O2 treatment on nuclear shape it was found that neither 
nuclear circularity nor nuclear aspect ratio was different in treated or untreated cells 
in any of the cell lines (Figure 5.4b,c). Additionally, when comparing H2O2 treated 
control with DAG1 KO clones there was no significant difference in either nuclear 
circularity or nuclear aspect ratio.  
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Taken together these data suggest that following H2O2 treatment there is no clear 
difference in how DAG1 KO clones respond compared with control cells when 
assessing levels of gH2AX staining and nuclear morphology.  
 
5.2.3 Investigating the response of control and DAG1 KO cells to osmotic stress 
following treatment with NaCl and PEG 
 
In addition to treating cells with H2O2 in order to subject them to oxidative stress, 
cells were also subjected to two forms of osmotic stress. The addition of NaCl results 
in the hyperosmotic stress of the cells and therefore nuclei too as they lose water, 
resulting in a reduction in volume and a crinkled nuclear morphology. Additionally, if 
cells are treated with polyethylene glycol (PEG) with a molecular mass of 4000 Da 
then cells are also hyperosmotically stressed but they also experience compressional 
forces. It is suggested that this osmotic pressure is similar to the forces exerted by 
cytoskeletal contractility (Damodaran et al., 2018; Khavari and Ehrlicher, 2019). It is 
also suggested that osmotically stressing cells and nuclei with PEG allows cell 
compression to be investigated without the need for complex technical set ups and 
direct contact with the cells (Zhou et al., 2009). Furthermore, this system can be used 
to determine the relationship between compression and volume in order to observe 
and track force changes in 3D cell systems (Khavari and Ehrlicher, 2019).  
 
In order to determine an appropriate concentration of NaCl to use, control cells were 
treated with a range of concentrations between 0mM and 500mM and the nuclear 
area was measured (Figure 5.5). There were slight decreases in the average nuclear 
area when between 20mM and 100mM was used. The clearest reduction in nuclear 
area was following addition of 500mM NaCl as expected, however, there was a 
decrease in the number of viable cells in this condition. Therefore, it was decided 
that cells would be treated with both 200mM and 500mM as both conditions 




Figure 5.5 Optimisation of NaCl concentration based on nuclear area of control cells. Control cells were treated 
with varying concentrations of NaCl and nuclear area was assessed. 2 independent experiments were carried out 
with 110 0mM, 118 20mM, 100 50mM, 123 100mM, 104 200mM and 102 500mM treated cells. Graph shows 
mean and standard deviation. The one-way ANOVA test returned a p value of <0.0001 which is below the 
significance threshold of 0.05. For multiple comparisons, a Dunnett's multiple comparisons test was used, p 
values; * = <0.0332, ** = <0.0021, *** = <0.0002 and **** = <0.0001. 
 
In order to determine if control cells respond to osmotic stress any differently to 
DAG1 KO cells, control and both DAG1 KO clones A and B were subjected to 0mM, 
200mM or 500mM NaCl and the levels of gH2AX were determined (Figure 5.6). When 
the total nuclear levels of gH2AX were assessed, it was clear that the lower NaCl 
concentration did not affect the relative levels, however the higher concentration 
did. This was consistent across control and DAG1 KO cell lines (Figure 5.6b). When 
relative levels of gH2AX in control and DAG1 KO cells subjected to osmotic stress 
were compared there was no significant difference between the control and either 
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Figure 5.6 Average nuclear levels of gH2AX in control and DAG1 KO clones A and B following 0mM, 200mM or 
500mM NaCl treatment. (a) Representative images of cells grown for 24 hours before treating with NaCl for 1 
hour followed by fixing and staining with DAPI and gH2AX to identify levels of DNA damage at varying NaCl 
treatments. Cells were imaged using the Leica fluorescence microscope. Scale bar = 20µm. (b) Normalised nuclear 
levels of gH2AX following 0mM, 200mM or 500mM NaCl treatment. 4 independent experiments were carried 
out. Control 0mM n = 111, 200mM n = 115 and 500mM n = 103. KO A 0mM n = 126, 200mM n = 119 and 500mM 
n = 121. KO B 0mM n = 105, 200mM n = 131 and 500mM n = 109. Graph shows mean and standard deviation. 
Following a two-way ANOVA test a Dunnett’s multiple comparison test was used to determine the difference 
between 0mM, 200mM and 500mM treatment in each cell line (p value; * = <0.0332, ** = <0.0021). A Turkey’s 
multiple comparison test was used to determine the difference between cell lines in each treatment condition – 
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In addition to levels of gH2AX, changes in nuclear morphology were also investigated 
in all three cells lines subjected to 0mM, 200mM or 500mM NaCl. As previously, 
nuclear morphology was assessed using the parameters nuclear area, nuclear 
circularity and nuclear aspect ratio. The nuclear area significantly decreased in all cell 
lines when either 200mM or 500mM NaCl was added to the culture medium, except 
in the control cells treated with 500mM (Figure 5.7a). In the control sample treated 
with 500mM NaCl there was a decrease in nuclear area however, this decrease was 
not statistically significant. Importantly, there was no difference in the relative 
nuclear area between control and DAG1 KO clones when treated with either 200mM 
or 500mM NaCl. A similar trend is observed in the nuclear circularity experiment. The 
nuclear circularity is significantly lower in all cell lines following treatment with 
200mM or 500mM NaCl while there is no significant difference between the control 
and either DAG1 KO clone following 200mM or 500mM NaCl treatment (Figure 5.7b). 
When nuclear aspect ratio was compared following NaCl treatment there was no 
difference between the untreated and the 200mM treated conditions for either 
control or DAG1 KO B however, there was a significant difference between untreated 
and 200mM treated DAG1 KO A cells (Figure 5.7c). When cells were treated with 
500mM NaCl there was a significant increase in nuclear aspect ratio compared with 
untreated cells and this was the case for control and DAG1 KO cells alike. When the 
200mM condition was compared, there was a significant difference between control 
and DAG1 KO A but not DAG1 KO B suggesting this was not a DG specific difference 
and likely due to clonal variation. For the 500mM condition there is no significant 
difference between the control and either DAG1 KO. Overall, these data suggest that 
DAG1 KO cells respond to osmotic stress caused by an increase in NaCl concentration 
in the same way as control cells.  
 
As with NaCl the appropriate concentration of PEG4000 was assessed by treating 
control cells with a range of concentrations and measuring the nuclear area (Figure 
5.8). Interestingly, treating with 5% had no effect on cell area whereas treating with 
10% and 20% resulted in a significant decrease in cell area in a dose dependent 
manner. However, treatment with 30% resulted in no significant decrease in nuclear 
area while 40% resulted in a slight but significant decrease in nuclear area. Based on 
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this, 20% and 40% PEG4000 was used as both resulted in a decrease in nuclear area 
but interestingly, not in a concentration dependent manner.  
 
 
Figure 5.7 Nuclear morphology of control and DAG1 KO clones A and B following 0mM, 200mM or 500mM NaCl 
treatment. (a) Normalised nuclear area (b) normalised nuclear circularity and (c) normalised nuclear aspect ratio 
following 0mM, 200mM or 500mM NaCl treatment. 4 independent experiments were carried out. Control 0mM 
n = 111, 200mM n = 115 and 500mM n = 103. KO A 0mM n = 126, 200mM n = 119 and 500mM n = 121. KO B 
0mM n = 105, 200mM n = 131 and 500mM n = 109. Graph shows mean and standard deviation. Following a two-
way ANOVA test a Dunnett’s multiple comparison test was used to determine the difference between 0mM, 
200mM and 500mM treatment in each cell line (p value; * = <0.0332, ** = <0.0021, *** = <0.0002). A Turkey’s 
multiple comparison test was used to determine the difference between cell lines in each treatment condition – 
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In order to determine if there is a difference in response between control and DAG1 
KO cells following osmotic and slight compressional stress by PEG4000 treatment, 
cells were subjected to either 0%, 20% or 40% PEG4000 for 30 minutes. Cells were 
then fixed and stained for gH2AX in order to determine levels of DNA damage and 
assess changes in nuclear morphology (Figure 5.9a). Treating all cell lines with 20% 
PEG4000 had no effect on the levels of gH2AX as these did not differ significantly 
from the untreated cells (Figure 5.9b). Additionally, there was no difference in the 
levels between control and DAG1 KO clones following treatment with 20% PEG4000. 
Somewhat surprisingly, following treatment with 40% PEG4000 there was a decrease 
in the average gH2AX intensity in all conditions, this decrease was significant for 
control and DAG1 KO clone B but not statistically significant for DAG1 KO clone A. 
When the difference between control and DAG1 KO clones was investigated, there 
was no significant difference in the relative gH2AX levels between control and KO 
clones (Figure 5.9b).  
 
 
Figure 5.8 Optimisation of PEG4000 concentration based on nuclear area of control cells. Control cells were 
treated with varying concentrations of PEG4000 and nuclear area was assessed. 2 independent experiments were 
carried out with 109 0%, 114 5%, 106 10%, 111 20%, 136 30% and 113 40% treated cells. Graph shows mean and 
actual range. The one-way ANOVA test returned a p value of <0.0001 which is below the significance threshold 
of 0.05. For multiple comparisons, a Dunnett's multiple comparisons test was used,  p values; * = <0.0332, ** = 



























Nuclear Area of control cells 
following treatment with varying





In addition to measuring DNA damage levels in cells treated with PEG4000, the 
nuclear morphology was also assessed. In the case of nuclear area there was a 
decrease in nuclear area for all cell lines following treatment with 20% PEG4000. 
However, this decrease was not statistically significant for control cells but was for 
both DAG1 KO cell lines (Figure 5.10a). Importantly, there was no statistical 
difference in the nuclear area of control and DAG1 KO clones following treatment 
with 20% PEG4000. Surprisingly, following treatment with 40% PEG4000 there was 
no decrease in nuclear area for any cell line and there was no difference in the area 
of control or DAG1 KO cells (Figure 5.10a). In regard to nuclear circularity and nuclear 
aspect ratio there was no change in shape in any cell lines following treatment with 
either 20% or 40% PEG4000. There were also no differences in the nuclear circularity 




Figure 5.9 Average nuclear levels of gH2AX in control and DAG1 KO clones A and B following 0%, 20% or 40% 
PEG4000 treatment. (a) Representative images of cells grown for 24 hours before treating with PEG4000 for 30 
minutes followed by fixing and staining with DAPI and gH2AX to identify levels of DNA damage at varying PEG4000 
treatments. Cells were imaged using the Leica fluorescence microscope. Scale bar = 20µm. (b) Normalised nuclear 
levels of gH2AX following 0%, 20% or 40% PEG4000 treatment. 4 independent experiments were carried out. 
Control 0% n = 115, 20% n = 117 and 40% n = 124. KO A 0% n = 100, 20% n = 107 and 40% n = 102. KO B 0% n = 
137, 20% n = 127 and 40% n = 113. Graph shows mean and standard deviation. Following a two-way ANOVA test 
a Dunnett’s multiple comparison test was used to determine the difference between 0%, 20% and 40% treatment 
in each cell line (p value; * = <0.0332, ** = <0.0021, *** = <0.0002). A Turkey’s multiple comparison test was used 
to determine the difference between cell lines in each treatment condition – p values are on the graph. 
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Figure 5.10 Nuclear morphology of control and DAG1 KO clones A and B following 0%, 20% and 40% PEG4000 
treatment. (a) Normalised nuclear area (b) normalised nuclear circularity and (c) normalised nuclear aspect ratio 
following 0%, 20% or 40% PEG4000 treatment. 4 independent experiments were carried out. Control 0% n = 115, 
20% n = 117 and 40% n = 124. KO A 0% n = 100, 20% n = 107 and 40% n = 102. KO B 0% n = 137, 20% n = 127 and 
40% n = 113.  Graph shows mean and standard deviation. Following a two-way ANOVA test a Dunnett’s multiple 
comparison test was used to determine the difference between 0%, 20% and 40% treatment in each cell line (p 
value; * = <0.0332, ** = <0.0021, *** = <0.0002). A Turkey’s multiple comparison test was used to determine the 
difference between cell lines in each treatment condition – p values are on the graph. 
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In order to investigate how control and DAG1 KO cells respond to migration through 
restricting spaces, it is important to first understand the migration capabilities of 
these cell types. It has been demonstrated previously that reduced levels of b-DG in 
myoblasts result in reduced migration velocity while overexpressing b-DG increases 
migration velocity (Thompson et al., 2010b). The effect of disrupting the DAG1 gene 
on cell migration has been investigated in this study. Control and DAG1 KO cells were 
plated in the same glass bottom dish following treatment with CellTracker in order 
to identify the two cell lines. The cells were then imaged every 10 minutes for 15 
hours in order to track the cell movement in normal cell culture conditions. Following 
analysis of this data it was found that DAG1 KO did indeed have impaired cellular 
migration (Figure 5.11). Migration velocity was significantly reduced in both DAG1 
KO clones A and B when compared with control cells (Figure 5.11a). As would be 
expected from cells that migrate more slowly, DAG1 KO cells also migrated a shorter 
total distance than the controls (Figure 5.11b). Anecdotally, the control cells still 
migrated the greatest distance despite 58% migrating out of the frame of view within 
the 15 hours, while only 16% and 23% of DAG1 KO clones A and B respectively 
migrated out of the frame of view within 15 hours.  
 
Given that DAG1 KO cells migrate more slowly, it is not possible to determine how 
well KO cells migrate through narrow pores compared with control cells using a 
transwell migration assay. However, it is possible to determine how the cells respond 
to constricted migration by assessing levels of DNA damage and quantifying the 
nuclear morphology. Cell migration through pores was initially carried out using 
transwell membranes containing 8µm pores (Figure 5.12a). 8µm pores are large 
enough that even the larger DAG1 KO B nuclei are not compressed during migration. 
This experiment was used as a control to ensure that any differences observed when 
cells migrated through narrow 3µm pores is due to the constriction and not due to 
the process of migration. Following migration through 8µm pores, control and DAG1 
KO clones were fixed and stained for gH2AX (Figure 5.12). When comparing the 
relative levels of gH2AX between cells at the bottom (migrated) or the top 
(unmigrated) of the membrane there was no significant difference in any of the cell 
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lines (Figure 5.12b). Additionally, there was no difference in the relative levels of 
gH2AX when either DAG1 KO clone was compared with the control (Figure 5.12b).  
 
 
Figure 5.11 Migration velocity and distance in control and DAG1 KO clones A and B. (a) Cell velocity. (b) Total 
migration distance in 16 hours. Each coloured point indicates an individual cell. 2 independent experiments were 
carried out with 160 control, 150 KO A and 143 KO B cells. Graph shows mean and standard deviation. The one-
way ANOVA test returned a p value of <0.0001 which is below the significance threshold of 0.05. Dunnett’s 
multiple comparison test was also carried out, p values are on the graph. 
 
The nuclear morphology of cells at the top or the bottom of the membrane were also 
quantified. The nuclear area of all cell lines was lower in the migrated cells compared 
with the unmigrated cells. However, this difference was only statistically significant 
for control and DAG1 KO clone A (Figure 5.13a). There was also no difference in the 
nuclear area when control and DAG1 KO clone A were compared but there was a 
significant difference between control and DAG1 KO clone B (Figure 5.13a). When 
nuclear circularity was compared there was no statistically significant difference 
between migrated and unmigrated cells and there was also no difference between 
control and DAG1 KO clones following migration (Figure 5.13b). There is no 
difference in the nuclear aspect ratio when comparing cells at the top and bottom of 
the membrane for control and DAG1 KO clone B however, there is a small but 
significant decrease in DAG1 KO clone A cells following migration (Figure 5.13c). 
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control and DAG1 KO B but there is a small but significant difference between control 
and DAG1 KO clone A (Figure 5.13a). 
 
 
Figure 5.12 Average nuclear levels of gH2AX in control and DAG1 KO clones A and B before and after migration 
through 8µm pores. (a) Representative images of cells on either the top (unmigrated cells) or bottom (migrated 
cells) of the Transwell membrane. Cells were stained with DAPI and gH2AX to determine nuclear morphology and 
levels of DNA damage. Cells were imaged using a Leica DMIRE2 fluorescence microscope. Scale bar = 20µm. (b) 
Normalised nuclear levels of gH2AX in migrated or non-migrated cells. 6 independent experiments were carried 
out. Control top n = 159, bottom n = 162. KO A top n = 172, bottom n = 154. KO B top n = 166, bottom n = 182.  
Graph shows mean and standard deviation. The one-way ANOVA test returned a p value of 0.4686 which is not 
below the significance threshold of 0.05. For multiple comparisons, a Šídák's multiple comparisons test was used 
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Figure 5.13 Nuclear morphology of control and DAG1 KO clones A and B before and after migration through 
8µm pores. (a) Normalised nuclear area in migrated or non-migrated cells. 6 independent experiments were 
carried out. Control top n = 159, bottom n = 162. KO A top n = 172, bottom n = 154. KO B top n = 166, bottom n 
= 182. Graph shows mean and standard deviation. The one-way ANOVA test returned a p value of 0.0005 which 
is below the significance threshold of 0.05. For multiple comparisons, a Šídák's multiple comparisons test was 
used and the p values can be seen on the graph. (b) Normalised nuclear circularity in migrated or non-migrated 
cells. As above. The one-way ANOVA test returned a p value of 0.2884 which is not below the significance 
threshold of 0.05. For multiple comparisons, a Šídák's multiple comparisons test was used and the p values can 
be seen on the graph. (c) Normalised nuclear aspect ratio in migrated or non-migrated cells. As above. The one-
way ANOVA test returned a p value of 0.1287 which is not below the significance threshold of 0.05. For multiple 
comparisons, a Šídák's multiple comparisons test was used and the p values can be seen on the graph. 
 
Given that there are no consistent differences in how control and DAG1 KO cells 
respond to migration through 8µm non-constrictive pores, these cells were then 
subjected to migration through 3µm constrictive pores (Figure 5.14a). Contrary to 
what was expected, cells on the bottom of the membrane (therefore had migrated 
through the pores) did not appear to have increased levels of DNA damage (Figure 
5.14b). There was no significant difference in gH2AX intensity between the top and 
bottom cells in any of the cell lines but there was a large amount of variation between 
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Figure 5.14 Average nuclear levels of gH2AX in control and DAG1 KO clones A and B before and after migration 
through 3µm pores. (a) Representative images of cells on either the top (unmigrated cells) or bottom (migrated 
cells) of the Transwell membrane. Cells were stained with DAPI and gH2AX to determine nuclear morphology and 
levels of DNA damage. Cells were imaged using a Leica DMIRE2 fluorescence microscope. Scale bar = 20µm (b) 
Normalised nuclear levels of gH2AX in migrated or non-migrated cells. 6 independent experiments were carried 
out. Control top n = 174, bottom n = 182. KO A top n = 173, bottom n = 168. KO B top n = 154, bottom n = 147.   
Graph shows mean and standard deviation. The one-way ANOVA test returned a p value of 0.4153 which is not 
below the significance threshold of 0.05. For multiple comparisons, a Šídák's multiple comparisons test was used 
and the p values can be seen on the graph. 
 
As with migration through 8µm pores, nuclear area and nuclear shape were 
quantified following migration. Interestingly, there was no reduction in nuclear area 
for control or DAG1 KO clone A following migration as observed in the 8µm pore 
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reduced nuclear area compared with unmigrated cells (Figure 5.15a). When 
comparing nuclear area of migrated cells there was no difference in the relative area 
between control and DAG1 KO A but there was a significant difference between 
control and DAG1 KO B (Figure 5.15a). When nuclear circularity was quantified, there 
was a clear significant difference between cells on the top and the bottom of the 
membrane for all cell types (Figure 5.15b). The significant reduction in nuclear 
circularity indicates that migration results in a loss of nuclear shape. However, the 
extent of nuclear circularity change between control and DAG1 KO clones following 
migration is not significantly different. A similar trend was observed when nuclear 
aspect ratio was measured (Figure 5.15c). A consistent increase in nuclear aspect 
ratio was measured in migrated cells compared with non-migrated cells for both 
control and DAG1 KO cells. There is also no statistically significant difference between 
the relative aspect ratios of control or DAG1 KO A migrated cells. However, there is 
a significant difference between the control and DAG1 KO B migrated cells, but this 
difference is very small (Figure 5.15c). 
 
 
Figure 5.15 Nuclear morphology of control and DAG1 KO clones A and B before and after migration through 
3µm pores. (a) Normalised nuclear area in migrated or non-migrated cells. 6 independent experiments were 
carried out. Control top n = 174, bottom n = 182. KO A top n = 173, bottom n = 168. KO B top n = 154, bottom n 
= 147. Graph shows mean and standard deviation. The one-way ANOVA test returned a p value of 0.0029 which 
is below the significance threshold of 0.05. For multiple comparisons, a Šídák's multiple comparisons test was 
used and the p values can be seen on the graph. (b) Normalised nuclear circularity and (c) normalised nuclear 
aspect ratio in migrated or non-migrated cells. As before. The one-way ANOVA test returned a p value of <0.0001 
which is below the significance threshold of 0.05. For multiple comparisons, a Šídák's multiple comparisons test 
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Taken together, the data from migration through 8µm pores suggest that migrating 
through a non-constricting environment results in a small reduction in nuclear area 
but has no effect on levels of gH2AX or nuclear shape. While migration through the 
constricting 3µm environment does not result in a reduction in nuclear area and does 
not affect the levels of gH2AX but does result in large and significant changes in 
nuclear shape. Importantly, this data demonstrates that DAG1 KO cells do not 
respond differently than control cells to confined migration when DNA damage and 
nuclear morphology are measured.  
 
5.2.5 Investigating the response of control and DAG1 KO cells to nuclear 
compression in situ 
 
In addition to investigating the response to active compression as cells migrate 
through narrow pores, passive compression was also tested by placing a weighted 
insert on top of growing cells in situ. The weighted inserts had a mass of ~14g which 
equates to ~800 Pa of compressive force. Due to the technical limitations, it is not 
possible to fix and stain cells following cell compression, so cells were imaged live 
after 1 hour of compression (Figure 5.16a). Therefore, it was only possible to assess 
nuclear morphology in this assay while levels of DNA damage were not determined. 
Following 1 hour of compression the relative nuclear area was reduced significantly 
in compressed cells compared with non-compressed cells, this was true for control 
and both DAG1 KO clones (Figure 5.16b). Additionally, there was a significant 
difference between compressed control cells and compressed DAG1 KO A cells 
however, there was no difference between control and DAG1 KO B cells. In regard to 
nuclear circularity there was a significant decrease in compressed compared with 
non-compressed cells for both control and DAG1 KO A samples however, no 
difference between the two DAG1 KO B conditions (Figure 5.16c). The difference in 
circularity between compressed control and DAG1 KO A samples was not significant 
whereas the control and DAG1 KO B samples differed significantly. Overall, this data 
suggests that there are nuclear morphology changes following passive compression, 
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as with active compression, but there is no consistent difference in the response 
between control cells and DAG1 KO cells.  
 
 
Figure 5.16 Nuclear morphology of control and DAG1 KO clones A and B subjected to passive compressional 
stress. (a) Representative images of either compressed or uncompressed cells. Cells were stained with Hoechst 
33342 to determine nuclear morphology of live cells. Cells were imaged using a Leica DMIRE2 fluorescence 
microscope. Scale bar = 20µm. (b) Normalised nuclear area of compressed or uncompressed cells. 4 independent 
experiments were carried out. Control uncompressed n = 119, compressed n = 123. KO A uncompressed n = 133, 
compressed n = 107. KO B uncompressed n = 127, compressed n = 102. Graph shows mean and standard 
deviation. The one-way ANOVA test returned a p value of <0.0001 which is below the significance threshold of 
0.05. For multiple comparisons, a Šídák's multiple comparisons test was used and the p values can be seen on 
the graph. (c) Normalised nuclear circularity of compressed or uncompressed cells. As before. The one-way 
ANOVA test returned a p value of 0.0005 which is below the significance threshold of 0.05. For multiple 
comparisons, a Šídák's multiple comparisons test was used and the p values can be seen on the graph. 
 
It is possible to use AFM to subject cells/nuclei to compressive forces. This is generally 
used in concert with high-resolution imaging to study biochemical responses to 
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compression (Cho et al., 2019). Additionally, it has been suggested that mechanical 
stress in the form of cell stretching may result in changes to nuclear stiffness (Ahrens 
et al., 2019). Therefore, in this study AFM was used to compress the cells over the 
nuclear region with a force of ~1 kPa and then the change in nuclear stiffness was 
measured over a period of 30 minutes. A preliminary assessment using a single 
control cell suggested that there was an initial increase in nuclear stiffness following 
compression followed by a decrease to a lower stiffness than the starting value 
(Figure 5.17a). The next question following this is whether this was a consistent trend 
for all control cells and then further, is it consistent in DAG1 KO clones as well. This 
was tested with at least 12 cells for each sample. This initial trend noticed in a lone 
control cell was not consistently the case when multiple cells were measured 
resulting in an almost consistent normalised value of 1 throughout the full 30 
minutes (Figure 5.17b). The same results were observed for DAG1 KO clones A and 
B, the normalised value remained at ~1 during the 30-minute time period (Figure 
5.17b). No statistical test was carried out as there was so much overlap between 
values. These data suggest that there is no clear trend in mechanical response to low-




Figure 5.17 Mechanical response to cell compression. (a) Preliminary test of a single control cell. The cell was 
compressed over the nuclear region and the nuclear stiffness was measured every 5 minutes for 30 minutes. (b) 
Mechanical response to nuclear compression of control and DAG1 KO clones A and B were measured using AFM. 
The nuclear stiffness was measured every 5 minutes for a total of 30 minutes. 
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The work presented in this chapter has aimed to determine if the response to 
mechanical stress differs in DAG1 KO cells when compared with control. On the 
whole, the data presented here would suggest that this is not the case, the DAG1 KO 
cells appear to respond to chemical, osmotic and compressional stress in a broadly 
similar way as controls. There are multiple examples throughout this chapter where 
one of the DAG1 KO clones responds differently to the control, however it is only 
those differences that are consistent across both KO clones that would be considered 
a genuine difference. This was not the case for any experiments described in this 
chapter and any differences observed could be due to clonal variation or other 
artefactual variation.  
 
5.3.1 Discrepancies from PEG4000 treatment 
 
PEG has been used previously to osmotically stress mammalian cells and in these 
studies an increase in PEG concentration results in an increase in osmotic pressure 
and ultimately a decrease in nuclear volume (Khavari and Ehrlicher, 2019; Zhou et 
al., 2009). There is no evidence of a bimodal response where nuclear size decrease 
with concentration up to a point where it then increases again as observed in this 
study (shown in Figure 5.8). The observation of a bimodal response was further 
confirmed following treatment with 20% and 40% PEG4000 where not all cell types 
had a significantly reduced nuclear area following 20% treatment and none of the 
cell types had a significantly reduced area following the 40% treatment. One 
explanation for the disparity between these results and those previously published 
is that lower molecular weight PEG was used for the two studies mentioned 
previously. Zhou et al. (2009) used 400 Da PEG while Khavari and Ehrlicher (2019) 
used 1500 Da PEG. However, this is unlikely to be the reason as in both these cases 
the range of concentrations used result in pressures between 0.5 MPa and 5 MPa 
(Cohen et al., 2009) and these all resulted in a decrease in nuclear volume. The 
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concentrations of 20% and 40% of PEG4000 result in pressures of 0.72 MPa and 4.3 
MPa respectively (Cohen et al., 2009). These values sit between the values tested in 
the previous studies. Therefore, it is unlikely that the molecular weight of the PEG 
used would explain this discrepancy. An alternative explanation is that the cells did 
not have long enough to equilibrate in the PEG containing media, however, this again 
is unlikely to be the reason as Khavari and Ehrlicher (2019) observe their results 
within 20 minutes of incubation while cells in this study were incubated for 30 
minutes prior to staining and imaging. The only other difference between the 
experiments carried out here and those described previously is that at least one of 
the studies used detached cells that were imaged on a thin layer of agar (Khavari and 
Ehrlicher, 2019) while in this study cells were attached to stiff glass coverslips. This 
could explain the discrepancy in these results as it has been shown that both cell and 
nuclear size decreases on softer matrix (Swift et al., 2013a), so this could potentially 
exacerbate the nuclear size differences. Ultimately, it is unclear why the nuclear area 
in this study doesn’t follow a dose dependent regime as PEG concentration increases.       
 
Unlike nuclear area, following treatment with PEG, there is no previous evidence to 
indicate how DNA damage is affected by PEG. Therefore, it is unknown whether the 
result suggesting the levels of DNA damage decreased in cells treated with 40% PEG 
are consistent across other cell types. However, one would expect that following 
osmotic stress and possible low levels of compressive stress there would be an 
increase in levels of gH2AX as observed in NaCl osmotic stress experiments (shown 
in Figure 5.6). Conversely, in cells treated with 40% PEG there is a decrease in levels 
of gH2AX in both control and DAG1 KO clone B cells (shown in Figure 5.9). As 
mentioned before, this has not been investigated in mammalian cells, however it has 
been studied in plants. PEG is used in plants to better understand growing conditions 
and it has been found that levels of antioxidant proteins increase following treatment 
with PEG, however, this is at much lower concentrations than those used in this study 
and plants likely have very different mechanisms for dealing with osmotic stress 
(Jamshidi Goharrizi et al., 2020; Sahoo et al., 2020). One explanation is that the 
increase in osmotic pressure results in loss of nuclear water and therefore results in 
macromolecular crowding (Finan et al., 2009) and this may reduce the mobility of 
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DNA damage response factors resulting in a reduction in gH2AX. However, this is 
unlikely for two reasons; (1) an increase in gH2AX is observed in cells treated with 
500mM NaCl which results in extreme osmotic stress and (2) there is no decrease in 
nuclear area when cells are treated with 40% PEG suggesting the nuclei are not 
osmotically stressed to the point of extreme macromolecular crowding. As with the 
unexpected nuclear area results there is no clear explanation for the observed 
decrease in gH2AX following treatment with 40% PEG.  
 
5.3.2 Observations from Transwell migration experiments 
 
It is clear from the data presented in this chapter that DAG1 KO cells do not respond 
to migrating through narrow pores any differently than control cells when DNA 
damage and nuclear morphology is assessed. However, there are two results from 
these experiments that were not as expected. The first is that nuclear area decreased 
in control and DAG1 KO A cells but not DAG1 KO B cells following migration through 
8µm pores but following migration through 3µm pores conversely only DAG1 KO B 
cells had a decreased area (as shown in Figure 5.13a and Figure 5.15a). The second 
unexpected result is that following migration through 3µm pores there was no 
increase in levels of gH2AX which has been observed across many previous studies 
(Irianto et al., 2017; Mukherjee et al., 2020; Patteson et al., 2019a; Pfeifer et al., 2018; 
Xia et al., 2019), but there was evidence of abnormal nuclear morphology. 
 
One possible explanation for why there is a decrease in nuclear area following 
migration through 8µm pores but not 3µm pores is due to cell density. Cell density is 
one of the key regulators of cell and nuclear size as it is regulated by YAP (Mugahid 
et al., 2020). High cell density results in a decrease in nuclear size. Cells were seeded 
at an extremely high cell density at the start of the experiment and then allowed to 
grow and migrate freely for 48 hours. In the 8µm experiment cells are able to migrate 
through the pores with relative ease which results in a large number migrating 
through the pores. This could result in a high cell density at the bottom and a lower 
cell density at the top. The high cell density at the bottom would result in a reduction 
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in nuclear size at the bottom and less so at the top which would explain the results 
in Figure 5.13a. On the other hand, it is difficult and requires a lot more time for cells 
to migrate through the 3µm pores which could mean there is a higher cell density at 
the top and a lower cell density at the bottom or at least a more equal density 
distribution. This would either result in the cells at the top being slightly smaller due 
to high cell density or neither top nor bottom having sufficiently high cell density to 
affect nuclear size, resulting in the more equal values observed in Figure 5.15a. This 
does not explain the difference seen in DAG1 KO clone B but any differences here 
could be due to the fact the nuclei and cells were larger to start with or could simply 
be down to clonal variation.  
 
An alternative explanation for the nuclear area differences above and below the 
filter, could be due to selectivity. In the relatively large population of cells there will 
be some smaller and some larger cells, some of these larger cells may be larger than 
the pore size and therefore do not migrate through while smaller cells migrate 
through quickly, resulting in an accumulation of the smaller cells on the bottom of 
the 8µm pore membrane. In the case of the 3µm pores, all cells are too large for the 
pores, so this selection pressure is reduced. The fact that DAG1 KO clone B doesn’t 
fit the trend for either 3µm or 8µm pores provides support for this suggestion. This 
clone is, on average, significantly larger than the other two cells. It is possible that 
there are far fewer smaller cells, making the selection pressure less of a factor. 
Ultimately, it is not possible to determine the reason behind this observation using 
Transwell migration assays, it would require live visualisation of the cells migrating 
through channels in order to answer this question.  
 
The question of why the levels of gH2AX did not increase following migration through 
3µm pores is more perplexing. It is clear from previous reports that DNA damage 
increases following constricting migration and that this damage can accumulate 
through multiple rounds of migration (Pfeifer et al., 2018) or it can be repaired and 
returned to baseline levels (Irianto et al., 2017). Given that there is an obvious 
difference in the nuclear shape between the top and the bottom as described in 
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other studies (Irianto et al., 2017; Patteson et al., 2019a; Pfeifer et al., 2018; Xia et 
al., 2019), it is clear that the correct side of the membrane is being imaged and that 
the cells on the bottom of the membrane have indeed migrated through the pores. 
Two possible explanations for this difference are (1) the increased level of 
background intensity has resulted in a large amount of variation between 
independent experiments and (2) cells may have repaired the DNA damage prior to 
cell fixing and staining.  
 
Six independent experiments were carried out for the 3µm Transwell migration assay 
and for all three cell lines at least 4 of the 6 values indicated an increase in levels of 
gH2AX compared with the unmigrated cells. However, some of these experiments 
resulted in a value <1 indicating there was less gH2AX in the migrated nuclei 
compared with the unmigrated. This suggests that there is a general trend for an 
increase in levels of gH2AX but this was not consistently the case. It is possible that 
this discrepancy is due to increased background intensity on both the top and the 
bottom of the membrane as the membrane appeared to retain more antibodies and 
therefore more fluorophore than would normally be seen on glass coverslips.  
 
The other possible explanation for the lack of difference in DNA damage between 
migrated and unmigrated cells is the amount of time that cells were allowed to 
migrate. Cells were seeded and then incubated for 48 hours before fixing and 
staining. This time frame was chosen as after 24 hours there were almost no cells on 
the bottom of the membrane in any condition, this would not give a sufficient 
number of cells for any meaningful statistical analysis. Previous reports using this 
assay have only allowed cells to migrated for 24 hours (Irianto et al., 2017; Pfeifer et 
al., 2018; Xia et al., 2019), however, they have used cancer cell lines which are both 
far softer than myoblasts and more migratory (Efremov et al., 2014; Krause et al., 
2013; Lekka and Pabijan, 2019). Importantly, it has been shown that DNA repair 
following migration through narrow pores/channels occurs within 24 hours and can 
occur even more rapidly than that (Raab et al., 2016; Shah et al., 2020). This means 
that the methodology used in this study is not capable of identifying differences in 
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levels of DNA damage due to the longer time scale it takes for cells to migrate but 
the relatively quick time scale in which cells can repair DNA damage following 
constricted migration.  
 
The transwell migration assay provides a good starting point for investigating cell 
migration through narrow channels however, the main limitation is the inability to 
track the migration in real time. In an ideal situation it would be possible to observe 
the migration of control and DAG1 KO cells live using a microfluidic device with 
defined pore sizes as described in section 5.1.1. However, due to the technical and 
financial requirements to establish these devices it was not possible within the 
bounds and timescale of this project. If this had been achievable it would have been 
used to observe cell migration directly and it would be possible to track levels of DNA 
damage as they occur.  
 
5.3.3 Limitations of passive cell compression assay 
 
As with active cell compression the ideal set up for carrying out passive cell 
compression assays is to use a specifically designed device like that described by Shah 
et al. (2020). This allows the specific adjustment for compression to a pre-determined 
height, it allows removal and reapplication of compressional stress and it allows cells 
to be fixed and stained which allows additional information to be obtained (Shah et 
al., 2020). Similar to the migration microfluidic device, the technical, financial and 
time requirements to establish this process was not possible for this project. Despite 
this the methodology used was sufficient to provide information on nuclear 
morphology and this was in general agreement with the constricted migration data. 
In both cases compression resulted in a reduction in nuclear circularity for both 
control and DAG1 KO A cells. There was also a significant reduction in nuclear area 
when cells were passively compressed which may indicate this might be the case as 
cells migrate through constricted environments, however, nuclear area recovers 
more rapidly than nuclear circularity when the cells have finished migrating.   
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The other limitation with the passive compression assays is the AFM method used. 
Ideally, the AFM would have the capabilities to carry out high-resolution fluorescence 
imaging with either an associated light sheet or confocal microscope. This would 
allow the tracking of key cytoskeletal/nucleoskeletal proteins and levels of DNA 
damage as the cells respond to nuclear compression. The other limitation, 
particularly with the experiment outlined here, is the flexibility of the cantilever. The 
most accurate way to carry out this experiment would be to use a very stiff cantilever 
to compress the cells to ensure all compressional forces was imparted on the cell and 
not dissipated through the cantilever. However, the cantilever needs to be soft in 
order to accurately measure the mechanical properties of the soft cell and it is not 
possible to easily switch between cantilevers in a relevant time frame to carry out 
this experiment. Therefore, these limitations may have had tangible impacts on the 
results observed.  
 
5.3.4 Other forms of mechanical stress that were investigated 
 
In addition to cell compression there are other forms of mechanical stress that can 
be applied to cells. Cell stretching is a popular form of generating cell stress and this 
can be applied either as a single stretching event or applied as cyclic stretching. 
Additionally, cells can be stretched uniaxially or biaxially. An attempt to establish a 
cell stretching set up for this study was made, however, this was unfortunately 
unsuccessful due to time constraints. If these attempts had been successful, this 
would have been the preferred method of mechanical stress applied to myoblasts as 
this is closest to the type of stresses they would be subjected to in vivo. Myoblasts 
are subjected to passive stretching as they migrate along muscle filaments which are 
contracting and relaxing. Additionally, they have the potential to differentiate into 
myotubes which are subjected to constant stretching and relaxation cycles during 
muscle contraction (Chen et al., 2020; Soltow et al., 2013).  
 
An alternative form of mechanical stress is shear stress – this can be most easily 
applied by simply pumping media over cultured cells and this can replicate shear 
stress forces exerted on endothelial cells during blood flow (Deguchi et al., 2005; 
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Jetta et al., 2019). In this study a set up for applying shear stress was established, 
however, actual experiments were not carried out. There are two main reasons for 
this; (1) there is very little physiological relevance as myoblasts are unlikely to be 
subjected to forms of shear stress and (2) this was only going to be investigated if 
DAG1 KO cells responded differently to control cells following compressional forces 
in order to determine if the response was specific to compression or was universal 
for multiple forms of mechanical stress.  
 
Compressional stress was used as the form of mechanical stress applied in this study 
because it was an affordable, commercially available way of investigating mechanical 
properties that has been reported extensively in the literature. Therefore, there was 
no requirement to design a new technically demanding protocol. Additionally, cell 
compression, particularly through confined migration, may be physiologically 
relevant. Myoblasts are involved in migration through basement membrane during 
embryogenesis and there is eclectic research implicating DG in cancer and cancer 
progression as discussed in section 1.1.5.2. In the context of cancer, confined 
migration is extremely important in transformation from non-malignant to malignant 
forms. 
 
In summary, the results presented in this chapter suggest that cells lacking DG do not 
respond differently to cells expressing DG when subjected to chemical, osmotic or 
mechanical stress. These data, along with data presented in chapter 4, suggest that 
DG has minimal effects on nuclear mechanics and nuclear response to mechanical 






There has been fairly extensive research into the nuclear role of b-DG, however, the 
majority of this research has been conducted by a single group. The published articles 
investigating nuclear b-DG vary in quality with some being rigorous and very 
convincing while others lack appropriate controls to draw any genuine conclusions. 
This range of quality makes it difficult to comprehensively understand the role b-DG 
has in the nucleus. In addition to the varying quality of published literature, this 
present study and Matt Cook’s study (Cook, 2021) directly contradict many of the 
findings in the literature. This further complicates the overall understanding of a role 
for b-DG in the nucleus.  
 
Based on all the available evidence it is probable that b-DG is found in the nucleus, 
however, whether it resides at the NE or if it is present transiently is not immediately 
clear. Additionally, the role of b-DG at the nucleus is not conclusive and it is possible 
that we, as investigators, have not yet asked the right questions to allow us to fully 
dissect the nuclear function.  
 
6.1 Role of DG in the nucleus  
 
6.1.1 Nuclear localisation of b-DG 
 
b-DG has been frequently reported to localise to the nucleus in a range of cell lines 
from multiple organisms including human and mouse  (Fuentes-Mera et al., 2006; 
Gonzalez-Ramirez et al., 2008; Mathew et al., 2013; Rodríguez-Munoz et al., 2015; 
Villarreal-Silva et al., 2010). Further, in this study b-DG has been shown to be present 
in the nucleus of KM155 human myoblast cells as shown by immunofluorescence 
staining and western blotting of nuclear and cytoplasmic cell fractions (chapter 3, 
Figure 3.1 and Figure 3.2). However, when a range of full-length tagged DG constructs 
were used to better identify subcellular localisation without the use of b-DG 
antibodies, there appeared to be little nuclear localisation (Cook, 2021; Leocadio-
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Victoria, 2015). This lack of nuclear localisation could be due to incorrect processing 
due to the addition of tags, but processing was investigated and fragment sizes were 
as expected, however, it is possible the tags altered or affected other forms of post-
translational modifications.  These results call into question the validity of b-DG 
antibodies when trying to determine nuclear localisation. GFP tagged b-DG has also 
been used previously, this comes with its own processing caveats but there is 
compelling evidence that mutating the nuclear exit signal in a b-DG-GFP construct 
results in consistent nuclear accumulation. These results also indicated that the 
mutant b-DG-GFP construct accumulated in the nucleoplasm and was not restricted 
to any particular nuclear compartment (NE or nucleoli) (Vélez-Aguilera et al., 2018).     
 
Mass spectrometry has been used abundantly to identify interacting proteins or 
proteins that reside in specific cellular compartments. Looking at available mass 
spectrometry data it is possible to probe for the presence of b-DG at the nucleus. In 
multiple studies when either the nucleus or just NE fractions from a range of cell 
types including muscle were subjected to mass spectrometry analysis there was no 
evidence of DG (Buchwalter et al., 2019; Korfali et al., 2012; Schirmer et al., 2003; 
Swift et al., 2013b; Wilkie et al., 2011). Additionally, when the interactomes of 
nuclear envelope proteins LEM2, MAN1 and emerin were assessed DG was not 
associated with any of these proteins (Moser et al., 2020). Further, a BioID 
experiment using ONM protein Nesprin-1a was carried out, DG was not identified 
(Gimpel et al., 2017). However, this would be expected if b-DG localises to the INM. 
VAPB, which is a membrane protein that localises to both the ER and the INM, was 
used to identify proteins at the INM and DG was not identified, but interestingly 
dystrophin was (James et al., 2019). This is in agreement with earlier studies 
investigating the nuclear localisation of the short dystrophin isoform Dp71 (Fuentes-
Mera et al., 2006; González et al., 2000; Marquez et al., 2003; Oppizzi et al., 2008). 
Despite the lack of evidence of nuclear DG in mammalian cell lines investigated using 
mass spectrometry data there is some evidence of nuclear DG from Drosophila when 
studied with mass spectrometry. In this study the DG interactome was investigated 
and identified multiple nuclear proteins. A number of histones were associated with 
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DG as were two NE proteins; baf and msp300 - equivalent to mammalian nesprins 
(Yatsenko et al., 2020). However, one issue with this particular study is they did not 
look at the nuclear fraction specifically, these interactions were determined from 
whole cell lysates which means the interactions could occur in other organelles such 
as the ER during processing, or they could occur following nuclear/cell rupture. Thus, 
these interactions are not necessarily indicative of nuclear localisation of DG. 
 
In addition to localisation studies by either visualisation or mass spectrometry 
analysis the functional nuclear data must also be considered. There have been 
reports of increased nuclear-centrosome distance in b-DG knockdown cells 
(Martínez-Vieyra et al., 2013), DAG1 KO mouse cells (Gómez-Monsiváis et al., 2020) 
and cells subjected to nuclear accumulation of b-DG (Vélez-Aguilera et al., 2018). 
Additionally, increased nuclear-centrosome distance has also been observed in the 
DAG1 KO human myoblasts used in this study (Cook, 2021). Emerin is thought to play 
a key role in regulating nuclear-centrosome distance (Salpingidou et al., 2007), 
however, it has been shown both in this study and by Matt Cook (Cook, 2021) that 
the level and localisation of emerin is not changed in DAG1 disrupted cells. This 
change in nuclear-centrosome distance had been previously attributed to a 
mislocalisation of emerin (Gómez-Monsiváis et al., 2020; Martínez-Vieyra et al., 
2013; Vélez-Aguilera et al., 2018), however, the same observation in KM155 human 
myoblasts where localisation of emerin is not affected suggests this is not the case. 
This leads to the question that if b-DG is not localised to the nucleus and is not 
involved in regulating emerin localisation how does a lack of, or accumulation of, b-
DG result in this increased distance. This question requires further study as DG may 
be involved in regulating the levels or localisation of an as yet unidentified protein 
involved in regulating nuclear-centrosome distance.  
 
In addition to nuclear-centrosome distance, nuclear stiffness is also different in DAG1 
KO cells compared with control. This is not the case when the nuclei are measured 
within the whole cell environment, but isolation of the nuclei allowed small 
differences to be measured (chapter 4, Figure 4.29). As these nuclei are separated 
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from all cytoplasmic and cytoskeletal influence the observed differences must come 
from a difference in the nucleus itself. There are a limited number of studies that 
investigate isolated nuclei stiffness and even fewer that look at the influence of 
different nuclear proteins. However, one study does suggest that reduced levels of 
lamin B1 result in a decrease in isolated nuclear stiffness and an increase in lamin B1 
results in increased stiffness (Ferrera et al., 2014). However, the levels of lamin B1 in 
DAG1 KO cells used in this study do not differ significantly from the control so this is 
unlikely to be the explanation. It is possible that this small difference in nuclear 
stiffness is related to the difference in nuclear size, however, it is not possible to 
conclude that from this study. Further experiments are required to gain a better 
understanding of the impact DG has on isolated nuclear stiffness. 
 
Based on the data presented in this study and that of studies published previously it 
is difficult to convincingly conclude either way whether under normal wild type 
conditions b-DG is localised to the nucleus or not. There is certainly strong evidence 
for nuclear localisation however, it is difficult to understand why b-DG is not detected 
in any mass spec experiments. Despite this there are sparse but clear phenotypic 
differences (nuclear stiffness, nucleus-centrosome distance) between the nuclei of 
cells lacking b-DG and cells expressing it. This therefore suggests that b-DG does 
localise to the nucleus, however, its exact function is still yet to be identified.  
 
6.1.2 Regulation of the levels and localisation of lamin B1 and emerin 
 
As mentioned above it has been frequently reported that both lamin B1 and emerin 
are mislocalised and total levels reduced in cells with perturbed levels of DG (Gómez-
Monsiváis et al., 2020; Jimenez-Gutierrez et al., 2020; Martínez-Vieyra et al., 2013; 
Vélez-Aguilera et al., 2018). The perturbations involved in these studies include b-DG 
knockdown, DAG1 KO or nuclear accumulation of b-DG and each of these result in a 
reduction and mislocalisation of lamin B1 and emerin. However, all of these 
experiments have been carried out in mouse C2C12 myoblasts and has not been 
tested in other cell lines. In this present study the levels and localisation of emerin 
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and lamin B1 appear unaffected by DAG1 KO in human myoblasts (chapter 3, figure 
3.22-3.28). This would suggest that these observations in C2C12 cells are not 
necessarily consistent across cell types or different organisms. Both levels and post-
translational modifications of DG vary between cell types so it is possible that 
differences in levels and post-translational modifications may result in different 
phenotypes. In order to further elucidate the role of b-DG in the regulation of lamin 
B1 and emerin it would be sensible to knock down b-DG in a range of cell types from 
a range of different organisms in order to understand the prevalence of this 
phenotype in multiple cell types. It would also be useful to carry out mutagenesis 
studies in order to determine which parts of DG are required for this regulation, 
phosphorylation states can also be investigated with the use of phosphomimetic 
mutants. An investigation into which cell types b-DG is required for correct 
localisation of emerin and lamin B1 is an important question to answer for the field.   
 
6.1.3 Contribution to mechanical properties of myoblast nuclei 
  
This study is the first to investigate the potential role DG has on the mechanical 
properties of the nucleus. This study was prompted by the available evidence 
suggesting that a lack or reduction of DG resulted in abnormally shaped nuclei 
(Jacobs, 2017), reduced levels of lamin B1 and emerin and potential interactions 
between b-DG and lamin A/C, B1 and emerin (Gómez-Monsiváis et al., 2020; 
Jimenez-Gutierrez et al., 2020; Martínez-Vieyra et al., 2013; Vélez-Aguilera et al., 
2018). Lamin A/C, B1 and emerin play key structural roles in the NE and are largely 
responsible for the mechanical properties of nuclei (Ferrera et al., 2014; Lammerding 
et al., 2006; Rowat et al., 2006), based on this previous evidence it was hypothesised 
that cells/nuclei lacking DG would have altered nuclear mechanical properties.  
 
There are multiple techniques that can be used for assessing mechanical properties 
of cells such as optical stretching (Guck et al., 2001), magnetic twisting cytometry 
(Tajik et al., 2016), micropipette aspiration (Dahl et al., 2005; Davidson et al., 2019) 
and more recently the contact-free imaging method Brillouin microscopy (Zhang et 
 225 
al., 2020). However, AFM was used due to the medium throughput (greater than 
micropipette aspiration but lower than magnetic twisting cytometry, optical 
stretching and Brillouin microscopy), the ability to measure cells in their usual culture 
conditions (which isn’t possible using optical stretching) and the availability of 
specialist equipment (Brillouin microscopy is still in its infancy and being developed). 
The other advantage of using AFM is the well-defined and well-established 
mathematical models which are used to calculate mechanical properties, such as 
Young’s modulus, from force indentation curves (Bouchonville and Nicolas, 2019).   
 
Using AFM, the mechanical properties of myoblast nuclei, either with or without 
functional DG, were investigated extensively (chapter 4). The results suggest that the 
mechanical properties of nuclei without DG did not differ significantly from the 
control nuclei when tested with two types of cantilevers and following treatments 
including cell synchronisation, chromatin decondensation and actin cytoskeleton 
perturbation. There are no published data to compare these results to, as nuclei of 
KM155 human myoblasts have not been measured previously and there has been no 
comparison of nuclei with or without DG in any cell lines. The results from this study 
allow the conclusion that DG does not influence the mechanical properties of nuclei 
when in a whole cell environment. These data fit with data presented in chapter 3 
suggesting that levels of key structural proteins lamin A/C, B1 and emerin are also 
unaffected by disruption of DG. However, when nuclei were isolated from the 
surrounding cytoplasm and cytoskeleton there was a small but significant decrease 
in Young’s modulus for both DAG1 KO cells measured. This suggest that DG may 
indeed play a role in the mechanical properties of myoblast nuclei, but the 
contribution is so small that it becomes insignificant in the background of a whole 
cell.  
 
As the impact of DG on the mechanical properties of the nucleus appeared so small 
it was important to investigate whether it plays any part in responding to mechanical 
stimuli. Following compression, cells lacking DG did not respond any differently to 
cells expressing DG. This suggests that the small difference in nuclear mechanical 
properties does not make a functional difference when cell compression was 
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assessed. Ideally, cells would have been subjected to mechanical stretching, but it 
was not possible to establish this technique despite extensive efforts.  
 
6.2 Conclusions and future work 
 
In summary, the work presented in this thesis aimed to understand the functional 
relevance of b-DG in the nucleus and determine whether it played a role in 
determining the mechanical properties of human myoblast nuclei. Based on the 
detailed analysis it is possible to conclude that disruption of DG in these cells results 
in an increase in nuclear and cell area that can be rescued by the addition of 
exogenous DG. It is also possible to conclude that DG may contribute to the 
mechanical properties of nuclei, however, the magnitude of this contribution is small 
and is not relevant at a whole cell level using the testing regimes employed here. It 
is also possible to conclude from this study that, at least in human myoblasts, DG is 
not involved in maintaining nuclear shape, regulating levels or localisation of lamin 
A/C, B1 or emerin or responding to mechanical compression. 
 
The evidence presented in this work provides no compelling reason to continue 
investigating a mechanical role for DG in the nucleus. However, there are other 
avenues that can be investigated in terms of the role of DG. The most interesting of 
these is the consistent observation that cells where DG is disrupted are larger, as is 
the nucleus. Jimenez-Gutierrez et al., (2020) suggest this difference in size is due to 
cellular senescence however, there are some methodological issues with this 
investigation. Additionally, the results presented in this present study suggest that 
cellular senescence is not consistently observed in cells lacking DG and that this 
phenotype can be rescued by the addition of exogenous DG. Further investigations 
could involve rescue experiments with a range of DG constructs such as one lacking 
the NLS to determine whether nuclear localisation of DG is involved. Additionally, it 
is important to get a handle on the extent of nuclear localisation of b-DG across a 
range of cell types and organisms, this will be required in the attempt to better 
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